β-Lactam antibiotics

ABSTRACT

Antibacterially active and animal feedstuff supplement β-lactam antibiotics of the formula ##STR1## in which R is H or --UR&#39;, 
     U is O or S, 
     R&#39; is optionally substituted alkyl, alkenyl, alkinyl, aralkyl, aryl or cycloalkyl, ##STR2## R 1  and R 2  individually are hydrogen or, individually or together with the carbon atom to which they are bonded, are any of various radicals, 
     A is --CH 2  --CH 2  --, --CH 2  --CH 2  --CH 2  -- or ##STR3## B is optionally substituted phenyl or is cyclohexenyl or cyclohexadienyl; X is S, O, SO, SO 2  or --CH 2  --; and 
     Y is a group of the formula ##STR4## T is hydrogen, alkyl-CO-O-, pyridinium, aminopyridinium, carbamoyloxy, azido, cyano, hydroxyl or optionally substituted -S-phenyl, or is -S-Het, 
     in which 
     Het is an optionally substituted heterocyclic 5-membered or 6-membered ring; 
     and wherein 
     E is hydrogen, a radical forming, with the carboxyl group to which it is attached, a carboxy ester group, a cation of a salt, or a protective group, 
     or a hydrate thereof. A process is also given for converting R directly from H to UR&#39; employing a base, a halogenating agent and R&#39;UH.

This is a division of application Ser. No. 862,466, filed Dec. 20, 1977,now U.S. Pat. No. 4,200,576.

The present invention relates to certain new β-lactam compounds to aprocess for their preparation and to their use as medicaments, inparticular as antibacterial agents and as agents for promoting thegrowth and for improving feedstuff utilisation in animals.

It has already been disclosed that certainα-(imidazolidin-2-oxo-1-yl-carbonylamino)-benzylpenicillins have anantibacterial action (compare Belgian patent specifications Nos. 767,647and 767,648 as well as Netherlands patent specification No. 7,114,254and German Offenlegungsschrift (German Published Specification) No.2,152,968).

The new β-lactam antibiotics according to the invention differchemically from the known compounds of the state of the art, above all,in that the N₃ of the imidazolidinone radical is bonded to the N atom ofan imino group.

The present invention provides as new compounds β-lactams of formula I##STR5## in which

R is hydrogen or a group --UR', in which

U is oxygen or sulphur and

R' is optionally substituted alkyl, alkenyl, alkinyl, aralkyl, aryl orcycloalkyl

Z is a group of the formula ##STR6## wherein

R¹ and R² are the same or different and each is hydrogen, optionallysubstituted alkyl or alkenyl, optionally substituted cycloalkyl,cycloalkenyl or cycloalkadienyl, optionally substituted aralkyl,optionally substituted aryl, optionally substituted heterocyclyl,carboxyl, methoxycarbonyl, ethoxycarbonyl, cyano, nitro, loweralkylcarbonyl, --CONH₂, --CONHCH₃, --CON(CH₃)₂, --SO₂ NH₂, --SO₂ --NHCH₃or --SO₂ N(CH₃)₂, or R¹ and R², together with the carbon atom to whichthey are bonded, represent an optionally substituted 3-membered to7-membered saturated or unsaturated carbocyclic or heterocyclic ring;

A is --CH₂ --CH₂ --, --CH₂ --CH₂ --CH₂ -- or ##STR7##

B is optionally substituted phenyl or is cyclohexenyl orcyclohexadienyl;

X is S, O, SO, SO₂ or --CH₂ --; and

Y is a group of the formula ##STR8## in which

the carbon atom which carries the carboxyl group is bonded to thenitrogen atom of the β-lactam ring and T is hydrogen, alkyl--CO--O--,pyridinium, aminopyridinium, carbamoyloxy, azido, cyano, hydroxyl oroptionally substituted -S-phenyl, or is -S-Het,

in which

Het is an optionally substituted heterocyclic 5-membered or 6-memberedring;

and wherein

E is hydrogen, a radical forming, with the carboxyl group to which it isattached, a carboxy ester group such as, for example, the pivaloylgroup, a cation of a salt or is a suitable protective group; saidβ-lactams of formula I being optionally in either of the two possible R-and S-configurations, with respect to the chirality centre C, and in theform of mixtures of the diastereomers resulting therefrom, and, when Zis a group of formula ##STR9## in which R¹ and R² are different, theβ-lactams of formula I also being optionally in the syn form and/or inthe anti form, with respect to the imino group, said β-lactams offormula I also being optionally in the form of one or more hydrate formsthereof.

Among the new β-lactam salts and esters of the invention, those saltsand esters that are pharmaceutically acceptable are particularlyimportant and are preferred.

Furthermore, it has been found that the compounds of the invention maybe prepared by a process (process A), comprising reaction of a compoundof formula II. ##STR10## in which

R, B, C, X and Y have the same meaning as defined hereinbefore informula I, with a compound of the formula III ##STR11## in which

Z and A have the same meaning as defined hereinbefore in formula I, and

W is halogen, azide or another nucleofugic leaving group, usually in thepresence of a solvent, and optionally in the presence of an acid-bindingagent, preferably at a temperature of from about -20° C. to about +50°C., and optionally converting the resulting β-lactam of formula I whenin the form of a salt or ester into the free acid form or when in theform of an acid into a salt or ester.

The new β-lactam free acid and salt and ester forms of the generalformula I can be interconverted in any suitable manner or method forsuch interconversion, known in the art.

In a further aspect the present invention provides a process (Process B)for the preparation of compounds of the general formula I in which Z, A,B, X and Y have the same meaning as first defined hereinbefore informula I and R is a group --UR' in which U and R' have the same meaningas defined hereinbefore in formula I comprising treatment of acorresponding compound of the general formula I in which Z, A, B, X andY have the same meaning as defined hereinbefore and R is H, and E is Hor a cation, namely an organic or inorganic cation, with an excess of abase, preferably from 2 to 10 equivalents of base in the presence of 1to 8 equivalents of a halogenating agent in an inert organic, preferablyanhydrous, solvent and an excess of a compound of formula RH in which Ris a group --UR' as defined hereinbefore preferably at a temperaturebelow -10° C.

In this form, the process differs significantly from the processesdisclosed previously for the preparation of compounds of analogousstructure, in which exclusively compounds with a protected carboxylgroup were methoxylated.

It is to be regarded as decidedly surprising that virtually no sidereactions, and only the stereospecific replacement at C₆ or C₇, occurs,even with sensitive penicillins and cephalosporins which containunprotected functional groups.

The present state of the art regards protection of the carboxyl group asan essential prerequisite. Groups additionally present in the molecule(such as OH, NH and a further carboxyl group), which according toexisting knowledge also had to be protected, likewise do not interferewith the reaction. The process according to the invention is withoutdoubt unrivalled in its advantage of being a one-stage process and inits stereoselectivity and its high yields and is thus an importantcontribution to the art.

Surprisingly, the compounds of the invention exhibit a considerablyhigher and, above all, broader spectrum antibacterial action, effectiveagainst several families of bacteria in the Gram-negative range, than,for example, the β-lactam antibiotics known from the state of the art.Because of their powerful antibacterial properties and because of theirability to improve the growth of and feedstuff utilisation by animals,the compounds according to the invention are an important contributionto the art.

If, for example, D-β-aminobenzylpenicillin and1-chlorocarbonyl-3-benzylideneimino-imidazolidin-2-one are used as thestarting materials, the course of the reaction can be represented by thefollowing equation: ##STR12##

The equation which follows can be indicated as an example of thepreparation of the substances according to the invention by the directintroduction of a group --UR' as first defined hereinbefore in formula I(R is not H), onto C₆ (or C₇ as appropriate) (Process B): ##STR13##

R' preferably is alkyl which is substituted by halogen, preferablychlorine and bromine, amino, monoalkylamino, dialkylamino, the alkylsubstituents on the N atom of the amino group preferably each having 1to 6 C atoms, or alkoxy having 1 to 6 C atoms; alkenyl having 3 to 6 Catoms, alkinyl having 3 to 6 C atoms, cycloalkyl having 3 to 7 C atomsor benzyl, phenyl or naphthyl.

However, the compounds in which R' is an unsubstituted alkyl radicalhaving 1 to 4 C atoms, such as methyl, ethyl, n-propyl, i-propyl,n-butyl, i-butyl or --CH₂ CH₂ N(CH₃)₂ and U is oxygen are particularlypreferred, and those in which --UR' is methoxy are especially preferred.

In the general formulae, R¹ and/or R² may each be an optionallysubstituted, straight-chain or branched, alkyl, having preferably 1 to6, most preferably 1 to 4, carbon atoms. Examples which may be mentionedare optionally substituted methyl, ethyl, n- and i-propyl, and n-, i-and t-butyl.

R¹ and/or R² may also each be an optionally substituted straight-chainor branched, alkenyl having preferably 2 to 6, most preferably 2 to 4,carbon atoms. Examples which may be mentioned are optionally substitutedethenyl, propen-1-yl, propen-2-yl, buten-3-yl and buten-2-yl-.

R¹ and/or R² may also each be an optionally substituted, monocyclic,bicyclic or tricyclic, cycloalky, cycloalkenyl or cycloalkadienyl,preferably containing 3 to 10, most preferably 3, 5 or 6 carbon atoms.Examples which may be mentioned are optionally substituted cyclopropyl,cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl,cyclohexadienyl, cycloheptyl, bicyclo-[2,2,1]-heptyl,bicyclo-[2,2,2]-octyl and adamantyl.

R¹ and/or R² may also each be optionally substituted aryl havingpreferably from 6 to 10 carbon atoms in the aryl moiety. Examples whichmay be mentioned are optionally substituted phenyl or naphthyl.Substituents in the phenyl ring may be in the o-position, m-position orp-position. The radicals ##STR14## may also be mentioned as furtherexamples of R¹ and R².

R¹ and/or R² may also each be aralkyl, optionally substituted in thearyl moiety and/or alkyl moiety, having preferably 6 or 10, mostpreferably 6, carbon atoms in the aryl moiety and preferably from 1 to4, most preferably 1 or 2, carbon atoms in the alkyl part, the alkylmoiety being straight-chain or branched. Examples which may be mentionedare optionally substituted benzyl and phenylethyl.

R¹ and/or R² may also each be optionally substituted, hetero-paraffinic,hetero-aromatic or hetero-olefinic, 5-membered to 7-membered, preferably5-membered or 6-membered, rings having preferably from 1 to 3, mostpreferably 1 or 2 identical or different, hetero-atoms. Thehetero-atom(s) may each be oxygen, sulphur or nitrogen. Examples of theheterocyclic groups which may be mentioned are optionally substitutedthienyl, furyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrrolyl,imidazolyl, pyrazolyl, oxdiazolyl, thiadiazolyl, triazolyl, oxtriazolyl,thiatriazolyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidinyl,tetrahydrofuranyl, dioxanyl, pyrrolidinyl, piperidinyl, morpholinyl,pyronyl-2 and pyronyl-4.

When R¹ and/or R² is/are alkyl, alkenyl, cycloalkyl, cycloalkenyl,cycloalkadienyl, aryl and aralkyl, the R¹ and/or R² group(s) can haveone or more, preferably 1 to 3, most preferably 1 or 2, identical ordifferent substituents R³ as defined hereinbelow. Most preferably, thesaid radicals R¹ and R² are unsubstituted or contain one saidsubstituent R³.

When R¹ and/or R² is/are heterocyclyl, the R¹ and/or R² group(s) canhave one or more, preferably 1 to 3, most preferably 1 or 2, identicalor different substituents R⁴ as defined hereinbelow. Most preferably aheterocyclyl R¹ or R² radical is unsubstituted or contains onesubstituent R⁴, as defined hereinbelow.

In the following statements, the expression "lower alkyl" wherever itoccurs, including when bonded to other atoms or groups (as for examplein lower alkoxy, ##STR15## and the like), denotes straight-chain orbranched alkyl having preferably 1 to 6 most preferably 1 to 4, carbonatoms. Examples which may be mentioned are optionally substitutedmethyl, ethyl, n- and i-propyl and n-, i- and t-butyl. "Lower alkyl" canbe substituted by 1 to 5, in particular 1 to 3, identical or differenthalogen atoms, halogen atoms being preferably fluorine, chlorine andbromine, especially fluorine and chlorine. Examples which may bementioned are trifluoromethyl, chloro-di-fluoromethyl, bromomethyl,2,2,2-tri-fluoroethyl and pentafluoroethyl.

R³ may be an atom or a group and preferably is halogen, most preferablyfluorine, chlorine, bromine or iodine, most desirably fluorine, chlorineor bromine; amino; mono-lower arkylamino, most preferably methylamino orethylamino, most desirably methylamino; di-lower alkylamino, mostpreferably dimethylamino or diethylamino, most desirably dimethylamino;pyrrolidyl; piperidyl; HCO--NH--; lower alkyl---CO--NH--, mostpreferably CH₃ --CO--NH--; H--CO--N (lower alkyl)-, most preferablyH--CO--N(CH₃)-- or H--CO--N(C₂ H₅)--; lower alkyl --CO--N(lower alkyl)-,most preferably CH₃ --CO--N(CH₃)--; (lower alkyl)₂ C═N--; loweralkyl--SO₂ --NH--, most preferably CH₃ --SO₂ --NH-- or C₂ H₅ --SO₂--NH--, most desirably CH₃ --SO₂ --NH--; lower alkyl --SO₂ --N(loweralkyl)-, most preferably CH₃ --SO₂ --N(CH₃)--; HO--SO₂ --NH--; HO-SO₂--N(lower alkyl)--, most preferably HO--SO₂ --N(CH₃)-- or HO--SO₂ --N(C₂H₅ )--; amidino; (lower alkyl)₂ --N--CH═N--, especially (CH₃)₂N--CH═N--; ##STR16## guanido, nitro, azido or hydroxyl, or loweralkyl-oxy-, most preferably CH₃ --O-- and C₂ H₅ --O--, most desirablyCH₃ --O--; H--CO--O--, or lower alkyl --CO--O--, most preferably CH₃--CO--O, C₂ H₅ --CO--O-- or (CH₃)₃ C--CO--O--; lower alkyl --O--CO--O--,most preferably CH₃ --O--CO--O--, C₂ H₅ --O--CO--O-- or (CH₃)₃C--O--CO--O--; H₂ N--CO--O--; lower alkyl--NH--CO--O--, most preferablyCH₃ --NH--CO--O-- or C₂ H₅ --NH--CO--O--; (lower alkyl)₂ N--CO--O--,most preferably (CH₃)₂ N--CO--O-- or (C₂ H₅)₂ N--CO--O--, ##STR17## orH₂ N--SO₂ --O--; lower alkyl --NH--SO₂ --O--, most preferably CH₃--NH--SO₂ --O-- or C₂ H₅ --NH--SO₂ --O--; (lower alkyl)₂ N--SO₂ --O--,most preferably (CH₃)₂ N--SO₂ ----O-- or (C₂ H₅)₂ N--SO₂ --O--; HOOC--or H₂ N--CO--; (lower alkyl)₂ N--CO--, most preferably (CH₃)₂ N--CO-- or(C₂ H₅)₂ N--CO--; OHC-, HO--SO₂ --O-- or HS--; lower alkyl--S--, mostpreferably CH₃ --S--, CF₃ --S--, C₂ H₅ --S-- or (CH₃)₂ CH--S--;##STR18## HO₃ S--; lower alkyl--SO₂ --, most preferably CH₃ --SO₂ --,CF₃ SO₂ -- and C₂ H₅ --SO₂ --; the group H₂ N--SO₂ --; lower alkyl--NH--SO₂ --, most preferably CH₃ --NH--SO₂ -- or C₂ H₅ --NH--SO₂ --;(lower alkyl)₂ N--SO₂ --, most preferably (CH₃)₂ N--SO₂ -- or (C₂ H₅)₂N--SO₂ --; ##STR19## the group HO--SO₂ --S--; straight-chain or branchedalkyl having 1 to 6 carbon atoms, especially methyl, ethyl, propyl,isopropyl, n-butyl, sec.butyl or tert.-butyl, most preferably methyl; orphenyl or phenoxy.

Each substituent R⁴ may be an atom or group and preferably is loweralkyl, most preferably methyl, ethyl and isopropyl, especially methyl;trifluoromethyl; halogen, most preferably fluorine, chlorine or bromine;amino; lower alkylamino, most preferably CH₃ --NH-- or C₂ H₅ --NH--;di-lower alkylamino, most preferably (CH₃)₂ N-- or (C₂ H₅)₂ N--;formylamino; acetylamino; CH₃ --O--CO--NH-- or C₂ H₅ O--CO--NH--; CH₃--SO₂ --NH--; hydroxyl; methoxy or ethoxy; methylthio or ethylthio; CH₃--SO₂ --; CH₃ --SO--; HOOC--; HO₃ S--; HCO--; lower alkyl--CO--, mostpreferably CH₃ --CO--; lower alkyl--O--CO--, most preferably CH₃--O--CO-- or C₂ H₅ O--CO--; or --CN.

When R¹ and R² together represent a nitrogen-containing heterocyclyl R⁴is a substituent on one or more nitrogen atoms of said heterocyclyl andpreferably is lower alkyl, most preferably methyl, ethyl, propyl orisopropyl, especially methyl or ethyl; --C.tbd.N; --CHO; --COO--loweralkyl, most preferably --COO--CH₃, --COOC₂ H₅, --COOCH(CH₃)₂ or--COO--C(CH₃)₃ ; --CO--NH₂ ; --CO--NH--lower alkyl, most preferably--CO--NH--CH₃, --CO--NH--C₂ H₅ or --CO--NH--CH(CH₃)₂ ; or --CO-- loweralkyl, most preferably --CO--CH₃, --CO--C₂ H₅ or --CO--CH(CH₃)₂.

When R¹ and R², together with the carbon atom to which they are bonded,represent an unsaturated ring, said unsaturated ring preferably contains1 or 2 double bonds. The ring can also contain 1 or more, preferably 1or 2, in particular 1, hetero-atom or hetero-group. Hetero-atoms whichmay be mentioned are oxygen, sulphur and/or nitrogen. Examples ofhetero-groups which may be mentioned are the SO₂ group and the loweralkyl-N-group, one hetero-atom or one hetero-group preferably being inthe 4-position (relative to the carbon atom to which R¹ and R² arebonded) in the case of 6-membered rings. Particularly preferred ringswhich may be mentioned are: ##STR20##

When R¹ and R², together with the carbon atom to which they are bonded,represent a substituted ring, said ring can contain one or more,preferably 1 to 3, in particular 1 or 2, identical or differentsubstituents R⁵. R⁵ preferably denotes halogen, most preferablyfluorine, chlorine or bromine; hydroxyl; lower alkoxy, most preferablymethoxy or ethoxy; lower alkylthio, most preferably methylthio orethylthio; amino; lower alkylamino, most preferably CH₃ --NH-- or C₂ H₅--NH--; di-lower alkylamino, most preferably dimethylamino ordiethylamino; --CN; --COOH; --COOCH₃ or --COOC₂ H₅ ; or straight-chainor branched lower alkyl, most preferably methyl or ethyl.

At least one of the radicals R¹ and R², most preferably is hydrogen.

Z most preferably represents the group ##STR21##

Compounds which contain the radical ##STR22## are formed when thisradical is already present in the compounds of the formula III, or canbe formed when the reaction is carried out in water-containing solvents.

When B is phenyl it can carry one or more, preferably 1 to 3, inparticular 1 or 2, identical or different substituents. The substituentscan be in the o-position, m-position and/or p-position. Preferably, onesubstituent is in the p-position or m-position. Examples of substituentswhich may be mentioned are halogen, for example fluorine, chlorine,bromine or iodine, preferably fluorine, chlorine or bromine; alkylhaving 1 to 6, preferably 1 to 4, most preferably 1 or 2, carbon atoms;cyano and methylsulphonyl. Substituted phenyl radicals B which may bementioned are, in particular, the hydroxphenyl radical (preferablyp-hydroxyphenyl), the methylphenyl radical (preferably p-methylphenyl),the cyanophenyl radical (preferably m- and p-cyanophenyl), themethylsulphonyl radical (preferably p-methylsulphonylphenyl) and thefluorophenyl radical (preferably o-fluorophenyl and m-fluorophenyl).

In the definition of T, alkyl in alkyl--CO--O-- preferably is alkylhaving 1 to 4, most preferably 1 or 2, carbon atoms. Examples which maybe mentioned are methyl and ethyl, methyl being particularly preferred.

The heterocyclic ring Het in -S-Het (in the definition of T) consists of5 or 6 ring members and contains 1 to 4 preferably 1 to 3, identical ordifferent hetero-atoms, heterto-atoms being oxygen, sulphur andnitrogen. The heterocyclic ring is preferably unsaturated andparticularly preferably contains 2 double bonds. The heterocyclic ringcan contain one or more, preferably 1 or 2, in particular one,substituent. Examples of substituents which may be mentioned are:halogen, for example fluorine, chlorine, bromine or iodine, preferablychlorine or bromine, amino, lower alkylamino, di-lower alkylamino, loweralkyl, cycloalkyl(having 3 to 7, preferably 5 or 6, carbon atoms in thecycloalkyl moiety), lower alkyloxy (wherein the alkyl moiety has thesame meaning as that given for "lower alkyl" hereinbefore),trifluoromethyl, phenyl and benzyl, and acylamino with preferably 2 to5, most preferably 2 or 3, carbon atoms. Particularly preferred examplesof --S--Het which may be mentioned are: ##STR23##

The --S-- phenyl radical in the direction of T may be substituted by oneor more, preferably 1 to 3, most preferably 1 or 2, identical ordifferent substituents, substituents which are preferred being thosewhich are listed hereinbefore as examples of substituents of the radical--S--Het.

Compounds according to the invention in which C is present in theD-configuration are very particularly preferred.

All the crystals forms and hydrate forms of the compounds according tothe invention, of the general formula I, and their salts are believed tobe antibacterially active in the same way.

When the leaving group W is halogen it usually is fluorine, chlorine orbromine, preferably bromine or chlorine, most preferably chlorine.

Nucleofugic leaving groups in the definition of W are to be understoodas all the nucleofugic groups customarily used in organicchemistry, andabove all those which are described in Angewandte Chemie, 81 (1969),page 543.

Non-toxic, pharmaceutically acceptable salts of formula I are salts ofthe corresponding acid compounds with inorganic and organic bases, inparticular at the acid carboxyl group or the acid carboxyl and sulphonicacid groups of said acid compounds. All the bases customarily used inpharmaceutical chemistry, in particular in the chemistry of antibiotics,may be employed as bases here. Examples of inorganic bases which may bementioned are: alkali metal hydroxides and alkaline earth metalhydroxides, alkali metal carbonates and alkaline earth metal carbonatesand alkali metal bicarbonates, such as sodium hydroxide and potassiumhydroxide, calcium hydroxide and magnesium hydroxide, sodium carbonateand potassium carbonate, calcium carbonate and sodium bicarbonate andpotassium bicarbonate; aluminum hydroxide and ammonium hydroxide.Primary, secondary and tertiary aliphatic amines and heterocyclic aminescan be employed as organic amines. Examples which may be mentioned are:di-lower alkylamines and tri-lower alkylamines, for example diethylamineand triethylamine, tri-β-hydroxyethylamine, procaine, dibenzylamine,N,N'-dibenzylethylenediamine, N-benzyl-β-phenylethylamine, N-methyl- andN-ethyl-morpholine, 1-ephenamine, dehydroabiethylamine,N,N'-bis-dehydroabietylethylene-diamine and N-lower alkylpiperidine.So-called basic amino-acids, such as lysine or arginine, can also beadvantageously used as bases. Particularly preferred salts are thesodium salts. Preferred esters of formula I include those wherein E ispivaloyl.

Very particularly preferred compounds of the formula I are those inwhich:

R is hydrogen, alkoxy having 1 to 4 C atoms, preferably methoxy, or theradical --OCH₂ CH₂ N(CH₃)₂,

Z is a group of formula ##STR24## wherein

R¹ is hydrogen; and

R² is phenyl optionally substituted by halogen (preferably fluorine,chlorine and bromine), alkyl having 1 to 4 carbon atoms (preferablymethyl), alkoxy having 1 to 4 carbon atoms (preferably methoxy), nitro,cyano, alkylsulphonyl having 1 to 4 carbon atoms (preferablymethylsulphonyl) or CH₃ OOC--, or furyl or thienyl, optionallysubstituted, preferably in the 4-position or 5-position, by halogen(preferably chlorine or bromine), NO₂, alkyl or alkoxycarbonyl having 1to 4 carbon atoms or CH₃ COOCH₂ --, the furyl and thienyl ringspreferably being bonded in the 2-position or 3-position; or is pyridyl(preferably pyridyl-3); or is optionally substituted cyclic, alkyl oralkenyl having up to 7 carbon atoms, in particular cyclohexenyl, oralkyl or alkenyl having up to 4 carbon atoms, the said alkyl and alkenylgroups being optionally substituted, preferably by halogen and/or alkoxyhaving 1 to 4 carbon atoms, preferably methoxy; and

A is --CH₂ --CH₂ --; and

B is phenyl, hydroxyphenyl (preferably p-hydroxyphenyl) orcyclohexadienyl (preferably cyclohexa-1,4-dien-1-yl); and

Y is a group of the formula ##STR25## wherein

T is hydrogen, --O--CO--CH₃, hydroxyl or thiadiazolythio ortetrazolylthio optionally substituted by alkyl having 1 to 4 carbonatoms or CF₃ ; and

C is in the D-configuration as well as the sodium salts of thesecompounds.

The compounds of the general formula II used as starting materials arealready known, or can be obtained by known methods (compare DOS (GermanPublished Specification) No. 2,555,159).

All the crystal forms, hydrate forms and salts of the compounds of thegeneral formula II are suitable starting materials for the processaccording to the invention.

Examples which may be mentioned are: α-aminobenzylpenicillin,α-amino-p-hydroxybenzylpenicillin, α-amino-p-methylbenzylpenicillin,α-amino-p-chlorobenzylpenicillin,6-[2-amino-2-(1,4-cyclohexadien-1-yl)-acetamido]-penicillanic acid,7-(α-amino-phenylacetamido)-3-methyl-ceph-3-em-4-carboxylic acid7-(α-amino-phenylacetamido)-3-acetoxymethylceph-3-em-4-carboxylic acid,7-(2-amino-phenylacetamido)-7-methoxy-3-methyl-ceph-3-em-4-carboxylicacid and7-(2-aminophenylacetamido)-7-methoxy-3-acetoxymethyl-ceph-3-em-4-carboxylicacid or the corresponding trifluoroacetate.

Salts of the compounds of the formula II which can be employed arepreferably salts with bases which are listed as being suitable forsalt-formation with compounds of the formula I. The sodium salts areparticularly preferred.

The compounds of the general formula III used as starting materials canbe obtained by known methods. For example, they can be obtained by areaction route shown in the following reaction diagram (compare, alsoJ.A.C.S. 78 (1956) 5349): ##STR26##

It is also possible to carry out the phosgenation directly, withoutprior silylation, in an inert organic solvent in the presence of a base.

Examples which may be mentioned of starting compounds, according to theinvention, of the general formula III, are:1-chlorocarbonyl-2-oxo-3-benzalimino-imidazolidine,1-azidocarbonyl-2-oxo-3-benzalimino-imidazolidine,1-chlorocarbonyl-2-oxo-3-(4-chloro)-benzalimino-imidazolidine,1-chlorocarbonyl-2-oxo-3-(4-methoxy)-benzalmino-imidazolidine,1-chlorocarbonyl-2-oxo-3-(4 -nitro)-benzalimino-imidazolidine,1-chlorocarbonyl-2-oxo-3-(4-cyano)-benzalimino-imidazolidine,1-chlorocarbonyl-2-oxo-3-(4-methylsulphonyl)-benzalimino-imidazolidine,1-chlorocarbonyl-2-oxo-3-(thiophene-2-aldimino)-imidazolidine,1-azidocarbonyl-2-oxo-3-(thiophene-2-aldimino)-imidazolidine,1-chlorocarbonyl-2-oxo-3-(furane-2-aldimino)-imidazolidine,1-azidocarbonyl-2-oxo-3-(furane-2-aldimino)-imidazolidine and1-chlorocarbonyl-2-oxo-3-(but-2-enylideneamino)-imidazolidine.

Those compounds of the general formula III in which W is azide areobtained by known methods, for example from the corresponding compoundsof formula III, in which W is halogen, by reaction thereof, for example,with alkali metal azides.

Diluents which can be used in the process (A) according to the inventionare water and any inert organic solvent, preferably one which iswater-miscible. Examples include, most preferably, lower dialkylketones, for example acetone and methyl ethyl ketone, and cyclic ethers,for example tetrahydrofurane and dioxane; nitriles, for exampleacetonitrile; lower dialkylformamides, for example dimethylformamide;lower alkyl alcohols, for example ethanol and isopropanol, anddimethylsulphoxide. These solvents can also be used in mixtures with oneanother as well as in any desired mixture of one or more of thesesolvents with water. The process according to the invention can thus becarried out in solvents consisting of: (a) exclusively water, (b)exclusively one or more organic solvents or (c) water and one or moreorganic solvents. If, by virtue of the presence of water, it is possibleto measure the pH of the reaction medium during the course of thereaction according to the invention, the pH of the reaction mixture ispreferably kept at a pH of from 6.5 to 7.5 by adding base or by using abuffer. However, the process according to the invention can also besatisfactorily carried out at other pH values, for example at a pH from4.5 to 9.0, or at pH from 2.0 to 4.5. Furthermore, it is possible tocarry out said reaction in solvents which are not water-miscible, forexample halogenated hydrocarbons, such as chloroform or methylenechloride, with the addition of organic bases, preferably loweralkylamines, for example triethylamine and diethylamine, or cyclicbases, for example N-ethylpiperidine. Moreover, the reaction can becarried out in a mixture of water and a solvent which is notwater-miscible, such as, for example, a lower alkyl ether, such asdiethyl ether, a halogenated hydrocarbon, such as chloroform ormethylene chloride; carbon disulphide; isobutyl methyl ketone; an ester,such as ethyl acetate; or an aromatic hydrocarbon, such as benzene, itbeing appropriate to stir the mixture vigorously and to keep the pHvalue at from 4.5 to 9.0, or, from 2.0 to 4.5, by adding base or using aconventional buffer solution, for example, a phosphate buffer, acetatebuffer or citrate buffer. However, the reaction can also be carried outin water alone in the absence of an organic solvent in the presence ofan organic or inorganic base or with the addition of conventional bufferconstituents.

Acid-binding agents which can be employed include any acid-binding agentcustomarily used in the chemistry of antibiotics. These includeinorganic bases and organic bases which, for example because of sterichindrance, are difficult to acylate. Examples of inorganic bases whichmay be mentioned are sodium hydroxide and potassium hydroxide. Virtuallyall the open-chain or cyclic amines which cannot be acylated or aredifficult to acylate, and also heteroaromatic bases, can be used asorganic bases. Examples of bases which may be mentioned are tertiaryamines, preferably lower alkylamines, for example triethylamine, and/orcyclic bases, for example pyridine, and a secondary amine which may bementioned which is difficult to acylate is dicyclohexylamine.

The addition of a base is only necessary in the process according to theinvention when acid compounds are formed during the reaction, forexample in the case where W is halogen or azide.

The reaction temperature can be varied within a relatively wide range.In general, the reaction is carried out at from -20° C. to +50° C.,preferably from 0° and +20° C. However, as in most chemical reactions,in principle, higher or lower temperatures can also be used.

The reaction can be carried out under normal pressure, but also underreduced pressure or elevated pressure. In general, the reaction iscarried out under normal pressure.

In carrying out the process according to the invention, the proportionsof the reactants of the formulae II and III can be varied within widelimits without adversely influencing the result. For example, thestarting materials can be reacted with one another in equimolar amounts.However, it can be appropriate to use one of the two reactants inexcess, in order to make it easier to purify the desired penicillin orto prepare it in a pure state, and to increase the yield.

For the second process of the invention (process B) comprising directintroduction of a substituent --UR' into a compound of the generalformula I in which R is H and E is H or a cation, chemically inertcompounds, such as ether, hydrocarbons or halogenohydrocarbon,preferably tetrahydrofurane, are used as solvent.

As far as possible, the temperature are to be kept below -10° C., butpreferably between -40° and -90° C.

t-Butyl hypochlorite is preferably used as the N-chlorinating agent, butother compounds which contain positively charged chlorine, such asN-chloroacetamide, are also suitable.

The base can be, for example: LiH, NaH, BuLi, PhLi, PhMgBr, or alkylMgBr, or borax or sodium carbonate. LiH orBuLi is preferably used. Incarrying out the process, 1 molar equivalent of a starting compound ofthe formula I (wherein R is H, E is H or a cation) is reacted with a3-fold to 6-fold excess of the base, and usually an equimolar amount oft-butyl hypochlorite at a low temperature, an excess (2-100 molar) of acompound RH (wherein R is --UR' as defined hereinbefore) being initiallyintroduced together with the solvent at the same time. It is alsopossible to initially introduce the base, the solvent and said compoundRH, which is preferably an alcohol, such as methanol or ethanol, at alow temperature and then to add the compound of the formula I (wherein Ris H) and t-butyl hypochlorite in rapid succession.

The reaction time depends on the size of the group to be introduced. Ifa methoxy group is introduced, in the case of cephalosporin compounds offormula I 60 minutes are usually sufficient for the reaction to go tocompletion, and in the case of penicillin compounds of formula I 2 hoursare usually sufficient.

However, the rate of reaction can be beneficially shortened by using anexcess of t-butyl hypochlorite, but in this case side reactions canoccur to an increasing extent. If further functional groups such as OH,NH or COOH, are present in the starting compound an extra equivalent oft-butyl hypochlorite can be used for each further group present in themolecule. The addition of base can also be increased accordingly.

For example, it is possible to employ the reactants of the generalformula II in an excess of 0.1 to 0.3 molar equivalents and thereby toachieve a lower decomposition of the reactants of the general formulaIII in a water-containing solvent mixture. Because of their goodsolubility in aqueous mineral acids, the excess of the reactants of thegeneral formula II can be easily removed during working up of thereaction mixture.

On the other hand, however, the reactants of the general formula III canalso be advantageously employed in an excess of, for example, 0.1 to 1.0molar equivalents. The reactants of the general formula II are therebybetter utilised and the decomposition of the reactants of the generalformula III, which proceeds as a side reaction in water-containingsolvents, is compensated. Since the compounds of the general formulaIII, added in excess, are rapidly converted in water into neutralnitrogen-containing heterocyclic compounds, which can be easily removed,the purity of the antibiotics is scarcely impaired here.

The amount of the bases optionally used is determined, for example, bythe desire to maintain a particular pH value. Where a pH measurement andadjustment does not take place or, because of the lack of sufficientamounts of water in the diluent, is not possible or is not appropriate,2 molar equivalents of base are preferably added.

The working up of the reaction batches for the preparation of thecompounds according to the invention and their salts is withoutexception carried out in the manner known generally for these materials.The isolation and purification of the compounds according to theinvention and the liberation of the free acids from salts or theconversion of the free acids into salts are also carried out by methodsof organic chemistry which are generally customary and which arefamiliar to anyone skilled in the art.

The compounds of the general formula I in the form of the free acid areantibacterially active in the same way both in the crystalline form andthe amorphous form and both in the anhydrous form and in the varioushydrate forms. Likewise, the compounds of the general formula I in theform of their salts, for example the sodium salts, are antibacteriallyactive in the same way both in the crystalline form and in the amorphousform and both in the anhydrous form and in the watercontaining form, forexample in the hydrate form.

New active compounds which may be mentioned (formulae IV and V) are:

    __________________________________________________________________________     ##STR27##                              (IV)                                  (A) (1) R.sup.1 represents hydrogen                                           (A) (1a)                                                                      R.sup.2     B              R                                                  __________________________________________________________________________     ##STR28##                                                                                 ##STR29##                                                        R.sup.5     R.sup.6                                                           __________________________________________________________________________    H           H              H                                                  4-Cl        4-HO           H                                                  4-CH.sub.3 O                                                                              H              H                                                  4-NO.sub.2  H              H                                                  4-CN        H              H                                                  4-CH.sub.3 SO.sub.2                                                                       H              H                                                  4-CH.sub.3 SO.sub.2                                                                       4-HO           H                                                  __________________________________________________________________________    (A) (1b)                                                                      R.sup.2     B              R                                                  __________________________________________________________________________     ##STR30##                                                                                 ##STR31##                                                        R.sup.7     R.sup.8    R.sup.6                                                __________________________________________________________________________    H           H         H    H                                                  H           H         4-OH OCH.sub.3                                          H           CH.sub.3  H    H                                                  H           C.sub.2 H.sub.5                                                                         H    H                                                  H           i-C.sub.3 H.sub.7                                                                       H    H                                                               ##STR32##                                                                              H    H                                                  H           CH.sub.3 OCH.sub.2                                                                      H    H                                                  H           C.sub.2 H.sub.5 OCH.sub.2                                                               H    H                                                  H           (C.sub.2 H.sub.5 O).sub.2 CH                                                            H    H                                                  H           CH.sub.3 S                                                                              H    H                                                  H           CH.sub.3 O                                                                              H    H                                                  H           C.sub.2 H.sub.5 O                                                                       H    H                                                  H           OHC       H    H                                                  H           O.sub.2 N H    H                                                  H           CH.sub.3 SO.sub.2                                                                       H    H                                                  H           CH.sub.3 CO                                                                             H    H                                                  H           CH.sub.3 OCOCH.sub.2                                                                    H    H                                                  H           CH.sub.3 OCO                                                                            H    H                                                  H           C.sub.2 H.sub.5 OCO                                                                     H    H                                                  H           F         H    H                                                  H           Cl        H    H                                                  H           Br        H    H                                                  H           CH.sub.3 SO.sub.2 NH                                                                    H    H                                                  i-C.sub.3 H.sub.7                                                                         H         H    H                                                  H           HOCH.sub.2                                                                              H    H                                                  H           CH.sub.3 NHSO.sub.2                                                                     H    H                                                  H                                                                                          ##STR33##                                                                              H    H                                                  H                                                                                          ##STR34##                                                                              H    H                                                  H           H         H    OCH.sub.3                                          H           Cl        4-OH OCH.sub.3                                          H           H         H    OC.sub.2 H.sub.5                                   H           H         H    OCH.sub.2 CH.sub.2 CH.sub.3                        H           H         H    OCH(CH.sub.3).sub.2                                H           H         H    OCH.sub.2CH(CH.sub.3).sub.2                        H           H         H    OCH.sub.2CH.sub.2N(CH.sub.3).sub.2                 H           H         4-OH OC.sub.2 H.sub.5                                   H           H         4-OH OCH.sub.2 CH.sub.2 N(CH.sub.3).sub.2               H           H         4-OH OCH.sub.2 CH.sub.2 CH.sub.3                        __________________________________________________________________________    (A) (2) R and R.sup.1 represent hydrogen; B represents phenyl;                R.sup.2 represents:                                                            ##STR35##                                                                     ##STR36##                                                                     ##STR37##                                                                     ##STR38##                                                                     ##STR39##                                                                     ##STR40##                                                                    __________________________________________________________________________    (A) (3) B represents phenyl;                                                  R.sup.1              R.sup.2                                                  __________________________________________________________________________    CH.sub.3             CH.sub.3                                                 CH.sub.3                                                                                            ##STR41##                                                ##STR42##                                                                                          ##STR43##                                               CF.sub.3             C.sub.2 H.sub.5                                          cyclohexyl           H                                                         ##STR44##           H                                                        __________________________________________________________________________    (A) (4) B represents 2-furyl, R represents H                                  R.sup.1                   R.sup.2                                             __________________________________________________________________________                               ##STR45##                                          __________________________________________________________________________    (A) (5) B represents p-hydroxyphenyl, R represents H                          R'                    R.sup.2                                                 H                     (CH.sub.3).sub.3 C                                      H                     CH.sub.3                                                H                     CH.sub.3CHCH                                            __________________________________________________________________________    (A) (6) B represents cyclohexa-1,4-dien-1-yl; R represents H                  R.sup.1               R.sup.2                                                 __________________________________________________________________________    H                     C.sub.6 H.sub.5                                         H                     4-CH.sub.3 OC.sub.6 H.sub.4                             H                     4-CH.sub.3 SO.sub.2 C.sub.6 H.sub.4                     __________________________________________________________________________    (A) (7) B represents phenyl; R represents H and                                ##STR46##                                                                    __________________________________________________________________________     ##STR47##                                                                     ##STR48##                                                                    __________________________________________________________________________     ##STR49##                              (V)                                   (B) (1) R.sup.1 represents hydrogen; T represents OCOCH.sub.3 :               (B) (1a)                                                                      R.sup.2              B              R                                         __________________________________________________________________________     ##STR50##                                                                                          ##STR51##     H                                         R.sup.5              R.sup.6                                                  __________________________________________________________________________    H                    H                                                        4-Cl                 4-HO                                                     4-CH.sub.3 O         H                                                        4-NO.sub.2           H                                                        4-CN                 H                                                        4-CH.sub.3 SO.sub.2  H                                                        4-CH.sub.3 SO.sub.2  4-HO                                                     __________________________________________________________________________    (B) (1b)                                                                       ##STR52##                                                                                           ##STR53##                                              R.sup.7   R.sup.8     R.sup.6 R                                               __________________________________________________________________________    H         H           H       H                                               H         H           H       OCH.sub.3                                       H         H           4-OH    OCH.sub.3                                       H         CH.sub.3    H       H                                               H         C.sub.2 H.sub.5                                                                           H       OCH.sub.3                                       H         i-C.sub.3 H.sub.7                                                                         H       H                                                          ##STR54##  H       H                                               H         CH.sub.3 OCH.sub.2                                                                        H       H                                               H         C.sub.2 H.sub.5 OCH.sub.2                                                                 H       H                                               H         (C.sub.2 H.sub.5 O).sub.2 CH                                                              H       H                                               H         CH.sub.3 S  H       H                                               H         CH.sub.3 O  H       H                                               H         C.sub.2 H.sub.5 O                                                                         H       H                                               H         OHC         H       H                                               H         O.sub.2 N   H       H                                               H         CH.sub.3 SO.sub. 2                                                                        H       H                                                         "           H       OCH.sub. 3                                      H         CH.sub.3 CO H       H                                               H         CH.sub.3 OCOCH.sub.2                                                                      H       H                                               H         CH.sub.3 OCO                                                                              H       H                                               H         C.sub.2 H.sub.5 OCO                                                                       H       H                                               H         F           H       OCH.sub.3                                       H         H           4-OH    OC.sub.2 H.sub.5                                H         H           4-OH    OCH.sub.2 CH.sub.2 CH.sub.3                     H         H           4-OH    OCH.sub.2 CH.sub.2 N(CH.sub.3).sub.2            H         H           4-OH    OCH.sub.2 CH(CH.sub.3).sub.2                    H         H           H       OC.sub.2 H.sub.5                                H         H           H       OCH.sub.2 CH.sub.2 CH.sub.3                     H         H           H       OCH(CH.sub.3).sub.2                             H         H           H       OCH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3            H         H           H       OCH.sub.2 CH(CH.sub.3).sub.2                    H         H           H       OCH.sub.2 CH.sub.2 N(CH.sub.3).sub.2            H         Cl          H       H                                               H         Br          H       H                                               H         CH.sub.3 SO.sub.2 NH                                                                      H       H                                               i-C.sub.3 H.sub.7                                                                       H           H       H                                               H         HOCH.sub.2  H       H                                               H         CH.sub.3 NHSO.sub.2                                                                       H       H                                               H                                                                                        ##STR55##  H       H                                               H                                                                                        ##STR56##  H       H                                               __________________________________________________________________________    (B) (2) R.sup.1 represents hydrogen; B represents phenyl;                     T represents  OCOCH.sub.3 ; R.sup.2 represents (the meaning                   of R in brackets)                                                              ##STR57##                                                                     ##STR58##                                                                     ##STR59##                                                                     ##STR60##                                                                     ##STR61##                                                                     ##STR62##                                                                    __________________________________________________________________________    (B) (3) B represents phenyl; T represents OCOCH.sub.3 ; R = H                 R.sup.1              R.sup.2                                                  __________________________________________________________________________    CH.sub.3             CH.sub.3                                                 CH.sub.3                                                                                            ##STR63##                                                ##STR64##                                                                                          ##STR65##                                               CF.sub.3             C.sub.2 H.sub.5                                          cyclohexyl           H                                                         ##STR66##           H                                                        __________________________________________________________________________    (B) (4) B represents 2-furyl; T represents OCOCH.sub.3                        R.sup.1              R.sup.2      R                                           __________________________________________________________________________                          ##STR67##   H                                           H                                                                                                   ##STR68##   OCH.sub.3                                   __________________________________________________________________________    (B) (5) B represents cyclohexa-1,4-dien-1-yl; T represents                    OCOCH.sub.3, R = H                                                            R.sub.1              R.sub.2                                                  __________________________________________________________________________    H                    C.sub.6 H.sub.5                                          H                    4-CH.sub.3 OC.sub.6 H.sub.4                              H                    4-CH.sub.3 SO.sub.2 C.sub.6 H.sub.4                      __________________________________________________________________________    (B) (6) B represents phenyl; T represents OCOCH.sub.3, R                       ##STR69##                                                                     ##STR70##                                                                     ##STR71##                                                                    __________________________________________________________________________    (B) (7)                                                                       R.sup.1  R.sup.2   B        T     R                                           __________________________________________________________________________              ##STR72##                                                                              C.sub.6 H.sub.5                                                                        OH    H                                           H                                                                                       ##STR73##                                                                              C.sub.6 H.sub.5                                                                        OH    H                                           H                                                                                       ##STR74##                                                                              C.sub.6 H.sub.5                                                                        OH    H                                           H                                                                                       ##STR75##                                                                              cyclohexa- 1,4-dien- 1-yl                                                              H     OCH.sub.3                                   H                                                                                       ##STR76##                                                                              cyclohexa- 1,4-dien- 1-yl                                                              H     H                                           __________________________________________________________________________    (B) (8) B represents phenyl; R represents H                                            ##STR77##           T                                                __________________________________________________________________________             ##STR78##          OCOCH.sub.3                                                ##STR79##          OCOCH.sub.3                                                ##STR80##          OCOCH.sub.3                                                ##STR81##          OCOCH.sub.3                                                ##STR82##          OCOCH.sub.3                                                ##STR83##          OCOCH.sub.3                                       __________________________________________________________________________

The active compounds according to the invention display a powerful andbroad antimicrobial activity, coupled with low toxicity. Theseproperties enable them to be used as chemotherapeutic active compoundsin medicine and as substances for preserving inorganic and organicmaterials, especially organic materials of all kinds, for examplepolymers, lubricants, paints, fibres, leather, paper and timber, andfoodstuffs, and water.

The active compounds according to the invention are active against avery broad spectrum of micro-organisms. With their aid it is possible tocombat Gram-negative and Gram-positive bacteria and bacteria-likemicroorganisms and to prevent, alleviate and/or cure diseases caused bythese pathogens.

The active compounds according to the invention are particularly activeagainst bacteria and bacteria-like microorganisms. They are, therefore,particularly suitable for the prophylaxis and chemotherapy, in humanmedicine and veterinary medicine, of local and systemic infectionscaused by these pathogens.

For example, local and/or systemic diseases which are caused by thefollowing pathogens or by mixtures of the following pathogens can betreated and/or prevented;

Micrococcaceae, such as Staphylococci, for example Staphylococcusaureus, Staph. epidermidis and Staph. aerogenes, and Gaffkya tetragena(Staph.=Staphylococcus);

Lactobacteriaceae, such as Streptococci, for example Streptococcuspyogenes, α- and β-haemolysing Streptococci, non-(γ-)-haemolysingStreptococci, Str. viridans, Str. faecalis (Enterococci), Str.agalactiae, Str. lactis, Str. equi and Str. anaerobis, and Diplococcuspneumoniae (Pneumococci) (Str.=Streptococcus);

Neisseriaceae, such as Neisseriae, for example Neisseria gonorrhoeae(Gonococci), N. meningitidis (Meningococci), N. catarrhalis and N. flava(N.=Neisseria);

Corynebacteriaceae, such as Corynebacteria, for example Corynebacteriumdiphtheriae, C. pyogenes, C. diphtheroides, C. acnes, C. parvum, C.bovis, C. renale, C. ovis and murisepticum.

Mycobacteriaceae, such as pathogens of mycobacterioses, for exampleMycobacterium tuberculosis, M. bovis, M. avium, so-called atypicalmycobacteria of the Runyon groups I, II, III and IV and M. leprae(M.=Mycobacterium);

Enterobacteriaceae, such as Escherichiae bacteria of the Coli group:Escherichia bacteria, for example Escherichia coli, Enterobacterbacteria, for example E. aerogenes and E. cloacae, Klebsiella bacteria,for example K. pneumoniae, K. pneumoniae and K. ozaenae, Erwiniae, forexample Erwinia spec., and Serratia, for example Serratia marcescene,(E.=Enterobacter) (K.=Klebsiella), Proteae bacteria of the Proteusgroup: Proteus, for example Proteus vulgaris, Pr. morganii, Pr. rettgeriand Pr. mirabilis, and Providencia, for example Providencia sp.,(Pr.=Proteus), Salmonelleae: Salmonella bacteria, for example Salmonellaparatyphi A and B, S. typhi, S. enteritidis, S. cholerae suis and S.typhimurium (S.=Salmonella, and Shigella bacteria, for example Shigelladysenteriae, Sh. ambigua, Sh. flexneri, Sh. boydii and Sh. sonnei(Sh.=Shigella);

Pseudomonadaceae, such as Pseudomonas bacteria, for example Pseudomonasaeruginosa and Ps. pseudomallei (Ps.=Pseudomonas), and Aeromonasbacteria, for example Aeromonas liquefaciens and A. hydrophila(A.=Aeromonas);

Parvobacteriaceae, such as Pasteurella bacteria, for example Pasteurellamultocida, Past. pestis (Yersinia) and Past. pseudotuberculosis,Haemophilus bacteria, for example Haemophilus influenzae, H. ducreyi, H.suis, H. canis and H. aegypitcus (H.=Haemophilus) and Bordetellabacteria, for example B. bronchiseptica (B.=Bordetella);

Bacteroidaceae, such as Bacteroides bacteria, for example Bacteroidesfragilis and B. serpens (B.=Bacteroides), Fusiforme bacteria, forexample Fusobacterium fusiforme, and Sphaerophorus bacteria, for exampleSphaerophorus necrophorus, Sph. necroticus and Sph. pyrogenes(Sph.=Sphaerophorus)

Bacillaceae, such as aerobic spore-forming Bacillaceae, for exampleBacillus anthracis (B. subtilis and B. cereus) B.=Bacillus) andanaerobic spore-forming Chlostridia, for example Clostridiumperfringens, Cl. septicium, Cl. oedematien, Cl. histolyticum, Cl. tetaniand Cl. botulinum (Cl.=Clostridium).

The above list of pathogens is purely illustrative and is in no way tobe interpreted as restrictive.

Examples which may be mentioned of diseases which can be prevented,alleviated and/or cured by the active compounds according to theinvention are: diseases of the respiratory passages and of thepharyngeal cavity; otitis; pharyngitis; pneumonia; peritonitis;pyelonephritis; cystitis; endocarditis; systemic infections; bronchitis;arthritis and local infections.

As stated above, the invention also relates to the use in human andveterinary medicine of the compounds of the invention.

The present invention provides a pharmaceutical composition containingas active ingredient a compound of the invention in admixture with asolid or liquefied gaseous diluent, or in admixture with a liquiddiluent other than a solvent of a molecular weight less than 200(preferably less than 350) except in the presence of a surface activeagent.

The invention further provides a pharmaceutical composition containingas active ingredient a compound of the invention in the form of asterile and/or isotonic aqueous solution.

The invention also provides a medicament in dosage unit form comprisinga compound of the invention.

The invention also provides a medicament in the form of tablets(including lozenges and granules), dragees, capsules, pills, ampoules orsuppositories comprising a compound of the invention.

"Medicament" as used in this specification means physically discretecoherent portions suitable for medical administration. "Medicament indosage unit form" as used in this specification means physicallydiscrete coherent units suitable for medical administration eachcontaining a daily dose or a multiple (up to four times) or submultiple(down to a fortieth) of a daily dose of the compound of the invention inassociation with a carrier and/or enclosed within an envelope. Whetherthe medicament contains a daily dose or, for example, a half, a third,or a quarter of a daily dose will depend on whether the medicament is tobe administered once or, for example, twice, three times or four times aday respectively.

The pharmaceutical compositions according to the invention may, forexample, take the form of ointments, gels, pastes, creams, sprays(including aerosols), lotions, suspensions, solutions and emulsions ofthe active ingredient in aqueous or non-aqueous diluents, syrups,granulates or powders.

The diluents to be used in pharmaceutical compositions (e.g. granulates)adapted to be formed into tablets, dragees, capsules and pills includethe following:

(a) fillers and extenders, e.g. starch, sugars, mannitol, and silicicacid; (b) binding agents, e.g. carboxymethyl cellulose and othercellulose derivatives, alginates, gelatine and polyvinyl pyrrolidone;(c) moisturizing agents, e.g. glycerol; (d) disintegrating agents, e.g.agar-agar, calcium carbonate and sodium bicarbonate; (e) agents forretarding dissolution e.g. paraffin; (f) resorption accelerators, e.g.quaternary ammonium compounds; (g) surface active agents, e.g. cetylalcohol, glycerol monostearate; (h) adsorptive carriers, e.g. kaolin andbentonite; (i) lubricants, e.g. talc, calcium and magnesium stearate andsolid polyethylene glycols.

The tablets, dragees, capsules and pills formed from the pharmaceuticalcompositions of the invention can have the customary coatings, envelopesand protective matrices, which may contain opacifiers. They can be soconstituted that they release the active ingredient only or preferablyin a particular part of the intestinal tract, possibly over a period oftime. The coatings, envelopes and protective matrices may be made, forexample, of polymeric substances or waxes.

The ingredient can also be made up in microencapsulated form togetherwith one or several of the above mentioned diluents.

The diluents to be used in pharmaceutical compositions adapted to beformed into suppositories can, for example, be the usual water-solubleor water-insoluble diluents, such as polyethylene glycols and fats (e.g.cocoa oil and high esters [e.g. C₁₄ -alcohol with C₁₆ -fatty acid]) ormixtures of these diluents.

The pharmaceutical compositions which are ointments, pastes, creams andgels can, for example, contain the usual diluents, e.g. animal andvegetable fats, waxes, paraffins, starch, tragacanth, cellulosederivatives, polyethylene glycols, silicones, bentonites, silicic acid,talc and zinc oxide or mixtures of these substances.

The pharmaceutical compositions which are powders and sprays can, forexample, contain the usual diluents, e.g. lactose, talc, silicic acid,aluminium hydroxide, calcium silicate, and polyamide powder or mixturesof these substances. Aerosol sprays can, for example, contain the usualpropellants, e.g. chlorofluorohydrocarbons.

The pharmaceutical compositions which are solutions and emulsions can,for example, contain the customary diluents (with, of course, the abovementioned exclusion of solvents having a molecular weight below 200except in the presence of a surface-active agent), such as solvents,dissolving agents and emulsifiers; specific examples of such diluentsare water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethylacetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyleneglycol, dimethylformamide, oils [for example ground nut oil], glycerol,tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid estersof sorbitol or mixtures thereof.

For parenteral administration, solutions and emulsions should besterile, and, if appropriate, blood-isotonic.

The pharmaceutical compositions which are suspensions can contain theusual diluents, such as liquid diluents, e.g. water, ethyl alcohol,propylene glycol, surface-active agents (e.g. ethoxylated isostearylalcohols, polyoxyethylene sorbite and sorbitane esters),microcrystalline cellulose, aluminium metahydroxide, bentonite,agar-agar and tragacanth or mixtures thereof.

All the pharmaceutical compositions according to the invention can alsocontain colouring agents and preservatives as well as perfumes andflavouring additions (e.g. peppermint oil and eucalyptus oil) andsweetening agents (e.g. saccharin).

The pharmaceutical compositions according to the invention generallycontain from 0.1 to 99.5, usually from 0.5 to 95% of the activeingredient by weight of the total composition.

In addition to a compound of the invention, the pharmaceuticalcompositions and medicaments according to the invention can also containother pharmaceutically active compounds. They may also contain aplurality of compounds of the invention.

Any diluent in the medicaments of the present invention may be any ofthose mentioned above in relation to the pharmaceutical compositions ofthe present invention. Such medicaments may include solvents ofmolecular weight less than 200 as sole diluent.

The discrete coherent portions constituting the medicament according tothe invention will generally be adapted, by virtue of their shape orpackaging, for medical administration and may be, for example, any ofthe following: tablets, (including lozenges and granulates), pills,dragees, capsules, suppositories and ampoules. Some of these forms maybe made up for delayed release of the active ingredient. Some, such ascapsules, include a protective envelope which renders the portions ofthe medicament physically discrete and coherent.

The preferred daily dose for administration of the medicaments of theinvention is 0.25 to 50 g preferably 1 to 10 g of active ingredient.

The production of the above mentioned pharmaceutical compositions andmedicaments is carried out by any method known in the art, for example,by mixing the active ingredient(s) with the diluent(s) to form apharmaceutical composition (e.g. a granulate) and then forming thecomposition into the medicament (e.g. tablets).

This invention further provides a method of combating (includingprevention, relief and cure of) the above mentioned diseases in humanand non-human animals, which comprises administering to the animals acompound of the invention alone or in admixture with a diluent or in theform of a medicament according to the invention.

It is envisaged that these active compounds will be administeredperorally, parenterally (for example intramuscularly, intraperitoneallyor intravenously), rectally or locally, preferably orally orparenterally, most preferably intravenously or intramuscularly.Preferred pharmaceutical compositions and medicaments are thereforethose adapted for oral or parenteral, especially intravenous orintramuscular administration. Administration in the method of theinvention is preferably oral or parenteral; especially intravenous orintramuscular.

In general it has proved advantageous to administer amounts of from 5 to1000, preferably 20 to 200, mg/kg of body weight per day to achieveeffective results. Individual doses preferably contain from 1 to 250,most preferably 10 to 100, mg/kg of body weight. Nevertheless, it can attimes be necessary to deviate from those dosage rates, and in particularto do so as a function of the nature and body weight of the human oranimal subject to be treated, the individual reaction of this subject tothe treatment, the type of formulation in which the active ingredient isadministered and the mode in which the administration is carried out,and the point in the progress of the disease or interval at which it isto be administered. Thus it may in some case suffice to use less thanthe above mentioned minimum dosage rate, whilst other cases the upperlimit mentioned must be exceeded to achieve the desired results. Wherelarger amounts are administered it can be advisable to divide these intoseveral individual administrations over the course of the day.

In further respects the invention provides a preservative comprising acompound of the invention, and a method of preserving organic andinorganic materials which comprises administering to them a compound ofthe invention either alone or in admixture with a diluent or in the formof a said preservative.

When used as feedstuff additives, the new compounds can be administeredin the customary concentrations and formulations, together with thefeedstuff or with feedstuff formulations or with the drinking waterprovided. By this means it is possible to prevent, alleviate and/or cureinfections by Gram-negative or Gram-positive bacteria and also toachieve promotion of growth and better utilisation of the feedstuff.

The new penicillins and cephalosporins are distinguished by powerfulantibacterial actions, which have been tested in vivo and in vitro.

The penicillins and cephalosporins according to the invention can, inorder to broaden the spectrum of activity and to achieve a more powerfulaction, especially in the case of bacteria which form β-lactamase, becombined with other antimicrobial active compounds, for example withpenicillins which, in particular, are resistant to penicillinase. Such acombination would be, for example, that with oxacillin or dicloxacillin.

The pencillins and cephalosporins according to the invention can, inorder to broaden the spectrum of activity or to achieve a more powerfulaction, also be combined with aminoglycoside antibiotics, such as, forexample, gentamycin, kanamycin, sisomycin, amicacin or tobramycin.

The activity of the β-lactam antibiotics according to the invention canbe demonstrated, by way of example, by the following in vitro and invivo experiments:

1. In vitro experiments

Examples 1.3., 2.3. and 2.4., which can be regarded as typicalrepresentatives of the compounds according to the invention, werediluted to a content of 100 μg/ml with Muller-Hinton nutrient broth,with the addition of 0.1% of glucose. In each case, the nutrientsolution contained 1×10⁵ to 2×10⁵ bacteria per milliliter. The smalltubes containing this batch were in each case incubated for 24 hours andthe degree of turbidity was then determined. Freedom from turbidityindicates action. At a dosage of 100 μg/ml, the following bacterialcultures were free from turbidity (sp.=species):

Klebsiella pneumoniae; Enterobacter aerogenes sp.; Providencia; Serratiamarcescens; E. coli BE; Salmonella sp.; Shigella sp.; Proteus,indole-negative and indole-positive; Pasteurella pseudotuberculosis;Brucella sp.; Haemophilus influenzae; Bordetella bronchiseptica;Staphylococcus aureus 133; Neisseria catarrhalis sp.; Diplococcuspneumoniae sp.; Streptococcus pyogenes W.; Enterococcus sp.;Lactobacillus sp.; Corynebacterium diphteriae gravis; Corynebacteriumpyogenes M; Clostridium tetani and Pseudomonas aeruginosa sp.

2. In vivo experiments

Table 1 which follows shows the action of one of the compounds accordingto the invention against several bacteria in an animal experiment usingwhite mice. White mice of the CF₁ strain were infected intraperitoneallywith the particular strain of bacteria indicated.

                  TABLE 1                                                         ______________________________________                                        Animal experiments with white mice                                            Determination of the ED.sub.100 after 24 hours                                               Dose in mg of the β-lactam antibiotic                                    of Examples 1.3., 2.3 and 2.4 per                              Germ           kg/body weight (subcutaneously)                                ______________________________________                                        Escherichia coli C 165                                                                       2 × 150                                                  Klebsiella 63  2 × 150                                                  ______________________________________                                    

Therapy: 2 administrations: 30 minutes and 90 minutes after infection.The ED₁₀₀ is the dose at which 100% of the infected animals stillsurvive after 24 hours.

Examples 36 and 36.5 were also investigated in the in vitro testdescribed above. It is shown that all the abovementioned bacterialcultures also remain free from turbidity in this test.

In addition, the compound7-methoxy-7-[D-α-[(2-oxo-3-furfurylideneamino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido]-3-acetoxymethyl-ceph-3-em-4-carboxylicacid was compared with the commercial product Cefazolin in the agardilution test using OXOID DST agar as the growth medium. In thiscomparison, the substances were diluted in liquid agar in two steps;after the agar had solidified, the bacteria were applied to the agarsurface, using a multiple inoculation apparatus and the plates wereincubated at 37° C. for 24 hours. After 24 hours, the concentration atwhich no colony formation took place was read as the minimum inhibitoryconcentration (MIC).

The table which follows shows the results of this comparison.

    ______________________________________                                        MIC in mcg/ml                                                                                  Example                                                      Germ             No. 36.5    Cefazolin                                        ______________________________________                                        E. coli T 7      ≦0.25                                                                              16.0                                             E. coli A 261    ≦0.25                                                                              4.0                                              E. coli F 14     4.0         16.0                                             Klebsiella pneumoniae                                                         57 US            1.0         4.0                                              1852             1.0         16.0                                             Proteus vulgaris 1017                                                                          16.0        >256                                             ______________________________________                                    

The process according to the invention is illustrated by the exampleswhich follow:

The α-aminobenzylpenicillin used in the examples which follow containedabout 14% of water; however, anhydrous α-aminobenzylpencillin [compareU.S. Pat. No. 3,144,445] can also be equally well used.

The α-amino-p-hydroxybenzylpenicillin used in the examples containedabout 13% of water; however, anhydrous α-amino-p-hydroxybenzylpenicillincan also be equally well used.

The 6-[2-amino-2-(1,4-cyclohexadien-1-yl)-acetamido]penicillanic acidused in the examples was essentially anhydrous.

The 7-(α-amino-phenylacetamido)-3-methyl-ceph-3-em-4-carboxylic acidused in the examples contained about 5% of water; however, anhydrous7-(α-amino-phenylacetamido)-3-methyl-ceph-3-em-4-carboxylic acid canalso be equally well used.

The 7-(α-amino-phenylacetamido)-3-acethoxymethyl-ceph-3-em-4-carboxylicacid used in the examples contained 8% of water; however, anhydrous7-(α-amino-phenylacetamido)-3-acetoxymethyl-ceph-3-em-4-carboxylic acidcan also be equally well used.

The water content of the starting compounds is not important in carryingout the process according to the invention.

By "ampicillin" is meant that α-aminobenzylpenicillin with theD=R-configuration in the side chain, by "amoxicillin" is meant thatα-amino-p-hydroxy-benzylpencillin with the D=R-configuration in the sidechain and by "epicillin" is meant thatα-amino-α-(1,4-cyclohexadien-1-yl)-methylpencillin with theD=R-configuration in the side chain.

By "cefalexin" is meant that7-(α-amino-phenylacetamido)-3-methyl-ceph-3-em-4-carboxylic acid withthe D=R-configuration in the side chain and by "cephaloglycine" is meantthat 7-(α-amino-phenylacetamido)-3-acetoxymethyl-ceph-3-em-4-carboxylicacid with the D=R-configuration in the side chain.

Unless otherwise indicated, the NMR spectra of the compounds accordingto the invention were recorded in CD₃ OD solution. The notations inbrackets have the following meanings:

    ______________________________________                                        s = singlet        m = multiplet                                              d = doublet        AB = AB system                                             Le A 17 705                                                                   t = triplet                                                                   q = quartet                                                                   ______________________________________                                    

Unless otherwise indicated, the IR spectra of the compounds according tothe invention were recorded in liquid paraffin suspensions.

Explanation of the abbreviations used in the examples:

vol.=volume

pts by wt.=parts by weight

pts. by vol.=parts by volume

hrs.=hours

hr.=hour

THF=tetrahydrofurane

DMF=dimethylformamide

ether=diethyl ether

ethyl acetate=acetic acid ethyl ester

room temperature=about 20° C.

abs.=absolute

decomp. pt.=decomposition point

The % data for the yields denotes yields in % of theory.

EXAMPLE 1 ##STR84##

2-Oxo-imidazolidine (31.5 pts. by wt.) is dissolved in 2 N sulphuricacid (1,000 pts. by vol.), the solution is cooled to 3°-6° C., asolution of sodium nitrite (25.25 pts. by wt.) in water (50 pts. byvol.) is added dropwise in the course of 13 minutes, whilst stirring andcooling further, the mixture is then subsequently stirred for a further1.5 hrs. in an ice bath and purified zinc dust (55 pts. by wt.) is thenintroduced in the course of one hour. The mixture is stirred for afurther 0.5 hr., whilst cooling with ice, and then subsequently stirredfor a further 1 hr. at room temperature. The unreacted zinc is thenfiltered off and washed with a little water, benzaldehyde (35 pts. bywt.) is added to the combined filtrates and the mixture is stirredvigorously for 0.5 hr. The 1-benzalimino-2-oxo-imidazolidine which hasprecipitated is then filtered off and, after drying (49.2 pts. by wt.;melting point=194°-200° C.) is recrystallised from ethanol).

Yield 41.4 pts. by wt., melting point=202° C. IR spectrum: 1720 cm⁻¹(C═O).

Calculated: C, 63.5; H, 5.9; N, 22.2.

Found: C, 64.1; H, 5.7; N, 22.7. ##STR85##

A mixture of 1-benzalimino-2-oxo-imidazolidine (11.7 pts. by wt.) (see1.1.), benzene (120 pts. by vol.) and triethylamine (13.8 pts. by vol.)is heated to the boil and a solution of trimethylchlorosilane (10 pts.by wt.) in benzene (50 pts. by vol.) is then added dropwise in thecourse of 1 hr., whilst stirring. The mixture is then kept at the boilfor a further 5.5 hrs. and the triethylammonium hydrochloride which hasseparated out is filtered off hot and washed with hot benzene. Asolution of phosgene (6.2 pts. by wt.) in benzene (30 pts. by vol.) isadded to the cooled, combined benzene filtrates. The mixture is allowedto stand overnight well sealed at room temperature. The majority of theexcess phosgene present is then removed by means of a dry air stream.The 1-chlorocarbonyl-2-oxo-3-benzaliminoimidazolidine is filtered offand dried.

Yield 8.9 pts. by wt., melting point=250°-252° decomp. IR spectrum: 1800cm⁻¹ (-CO-Cl)

Calculated: C, 52.5; H, 4.0; Cl, 14.1; N, 16.7. Found: C, 51.8; H, 5.6;Cl, 14.6; N, 16.8. ##STR86##

Ampicillin (14 pts. by wt.) is suspended in 80% strength aqueoustetrahydrofurane (140 pts. by vol.) and dissolved by means of the amountof triethylamine which is just necessary (the pH is then 8.0),1-chlorocarbonyl-2-oxo-3-benzalimino-imidazolidine (7.8 pts. by wt.)(see 1.2.) is introduced slowly, whilst stirring, and the pH is kept at7.2-7.5 during this procedure by the appropriate addition oftriethylamine. The mixture is then further stirred until no furthertriethylammonium must be added in order to maintain the pH rangeindicated (about 1-2 hrs.). The mixture is diluted with water (200 pts.by vol.), the pH was adjusted to 6.5, the tetrahydrofurane issubstantially evaporated off in vacuo and the aqueous solution whichremains is washed once with ether in a separating funnel, then coveredwith a layer of ethyl acetate and acidified down to pH 2 by means ofdilute HCl, whilst stirring. The organic phase is then separated off,washed with saturated NaCl solution, dried over MgSO₄ and, afterdiluting with the same volume of ether, an about 1-molar sodium2-ethylhexanoate solution in methanol-containing ether is added untilprecipitation stops. The sodium6-{D-α-[(2-oxo-3-benzalimino-imidazolidin-1yl)-carbonylamino]phenylacetamido}-penicillanateis filtered off, washed with ether and then with a mixture of ether andmethanol (5-10%) and isopropanol and dried.

Yield 6.2 pts. by wt., β-lactam content 91%.

According to the NMR spectrum, the substance still contains 2.5 mols ofH₂ O, 0.1 of mol of isopropanol and 0.04 mol of sodium2-ethyl-hexanoate. This was taken into consideration in the calculatedanalysis values.

Calculated: C, 51.5; H, 5.3; N, 13.0; S, 5.0. Found: C, 50.9; H, 5.2; N,12.9; S, 5.1.

NMR signals at τ=2.1-2.8 (11H); 4.3-4.65 (3H); 5.8 (1H); (in CD₃ OD)6.1-6.35 (4H) and 8.3-8.6 ppm (6H).

IR spectrum (carbonyl range); 1770, 1730, 1665, 1610 and (in liquidparaffin) 1540 cm⁻¹. ##STR87##

This penicillin is prepared from amoxicillin trihydrate (6.0 pts. bywt.) and 1-chlorocarbonyl-2-oxo-3-benzaliminoimidazolidine (3.6 pts. bywt.) (see 1.2.) in the manner described under 1.3. On acidifying theaqueous reaction solution to pH 1.5 with dilute hydrochloric acid (about20% strength), some of the penicillic acid liberated is not taken up bythe ethyl acetate. This portion is filtered off, washed with water anddried (yield: 5.2 pts. by wt.). Further sodium salt of the penicillincan then be precipitated from the ethyl acetate phase with sodium2-ethyl-hexanoate (yield: 1.4 pts. by wt.).

6-{D-α-[(2-Oxo-3-benzalimino-imidazolidin-1-yl)-carbonylamino]-4-hydroxyphenylacetamino}-penicillanicacid

Yield: 5.2 pts. by wt.

β-Lactam content (iodometric); 81%

(from the NMR spectrum): 89%

According to the NMR spectrum, the substance contains 3.4 mols of H₂ Oand 0.5 mol of ether per mol of substance. If this is taken intoconsideration in the calculated analysis values, the following arefound:

Calculated: C, 51.2; H, 5.9; N, 12.4; S, 4.7. Found: C, 50.7; H, 5.5; N,12.8; S, 4.8.

NMR signals at τ=2.2-3.3 (10H); 4.3-4.65 (3H); 5.7 (1H); (in CD₃ OD)6.15-6.4 (4H) and 8.35-8.6 ppm (6H).

IR spectrum (carbonyl range): 1780, 1740 (shoulder), 1725, (in liquidparaffin) 1645 and 1520 cm⁻¹.

Sodium6-{D-α-[(2-oxo-3-benzalamino-imidazolidin-1-yl)-carbonylamino]-4-hydroxyphenylacetamido}-penicillanate

Yield: 1.4 pts. by wt.

β-Lactam content (iodometric): 96%

(from the NMR spectrum): 87%

According to the NMR spectrum, the substance contains 2.5 mols of H₂ Oand 0.25 mol of sodium 2-ethylhexanoate per mol of substance (and inaddition an unknown impurity, in an unknown amount, originating from theamoxil used). If the identified concomitant materials are taken intoconsideration in the calculated analysis values, there results:

Calculated: C, 50.6; H, 5.2; N, 12.2; S, 4.6. Found: C, 51.2; H, 6.0; N,11.7; S, 4.5.

NMR signals at τ=2.1-3.3 (10H); 4.4-4.7 (3H); 5.8 (1H); (in CD₃ OD)6.1-6.4 (4H) and 8.3-8.6 ppm (6H).

IR spectrum (carbonyl range): 1770, 1735, 1670, 1600 and (in liquidparaffin) 1560-1520 cm⁻¹. ##STR88##

This penicillin is prepared from epicillin (1.5 pts. by wt.) and1-chlorocarbonyl-2-oxo-3-benzalimino-imidazolidine (1.1 pts. by wt.) inthe manner described under 1.3. Yield: 1.7 pts. by wt. of sodium6-{D-α-[(2-oxo-3-benzalimino-imidazol-1-yl)-carbonylamino]-cyclohex-1,4-dien-1-yl-acetamido}-penicillanatewith a β-lactam content (iodometric) of 90%, (derived from the NMRspectrum: 91%).

According to the NMR spectrum, the substance contains 2.5 mols of H₂ Oand 0.072 mol of sodium 2-ethylhexanoate. This was taken intoconsideration in the following analysis values:

Calculated: C, 51.2; H, 5.4; N, 13.0; S, 4.9. Found: C, 50.9; H, 5.7; N,13.6; S, 4.6.

NMR signals at τ=2.0-2.65 (5H); 4.0 (1H); 4.25 (2H); (in CD₃ OD) 4.45(2H); 4.95 (1H); 5.75 (1H); 6.0-6.3 (4H); 7.1-7.4 (4H) and 8.25-8.5 ppm(6H).

IR spectrum (carbonyl range); 1765, 1730, 1660, 1600 and (in liquidparaffin) 1530 cm⁻¹. ##STR89##

2.25 pts. by wt. of cephaloglycine dihydrate are suspended in 50 ml of80 percent strength aqueous THF and reacted with 12.6 pts. by wt. of1-chlorocarbonyl-2-oxo-3-benzalimino-imidazolidine as in Example 1.3 andthe mixture is worked up. On acidifying with dilute hydrochloric acid(for example 2 N HCl)7-{D-α-[(2-oxo-3-benzalimino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylicacid precipitates (1.9 pts. by wt., corresponding to 61.4%). Theprecipitate is dissolved in 5 pts. by vol. of dimethylacetamide, 3 pts.by vol. of a methanolic 1 M sodium 2-ethyl-hexanoate solution are addedand the mixture is added to 30 pts. by vol. of a 10:1 mixture ofether/methanol, whilst stirring, whereupon 1.7 pts. by wt. of sodium7-{D-α-[(2-oxo-3-benzalimino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylateof decomp. pt. 180°-185° C. precipitate.

The ethyl acetate phase is worked up as in Example 1.3, whereupon afurther 0.9 pt. by vol. (corresponding to 28.0%) of the sodium salt isobtained.

C₂₉ H₂₇ N₆ NaO₈ S.H₂ O Calculated: C, 52.72; H, 4.42; N, 12.71; S, 4.85.Found: C, 52.5; H, 4.9; N, 12.2; S, 4.6.

IR (KBr): 1760, 1725, 1670, 1605 and 1520 cm⁻¹.

NMR (CD₃ OD/D₂ O): 7.75 and 7.40 (m, 11H), 5.75 (d, 1H), 5.57 (s, 1H),5.00 (d, 1H), 4.87 (overlaid by the signal of the replaceable protons),3.82 (m, 4H) and 2.08 (s, 3H) δ.

The signals of the C-2 protons are overlaid by the CD₃ OD solvent peak.

The β-lactam content is between 80 and 85%.

EXAMPLE 2 ##STR90##

15.8 wts. by st. of 2-oxo-imidazolidine, 12.6 pts. by wt. of sodiumnitrite and 27.5 pts. by wt. of zinc dust are processed as in Example1.1. and the mixture is stirred overnight with 23.2 pts. by wt. of4-chlorobenzaldehyde.

20.5 pts. by wt. of 1-(4-chloro)-benzalimino-2-oxo-imidazolidine ofmelting point 233°-235° C.

C₁₀ H₁₀ ClN₃ O Calculated: C, 53.70; H, 4.51; N, 18.79; Cl, 15.85.Found: C, 53.9; H, 4.5; N, 18.7; Cl, 16.0.

IR (KBr): 3250, 3130, 1735, 1705 and 1595 cm⁻¹.

NMR (d₆ -DMSO): 7.66 and 7.45 (AB, 4H), 7.60 (s, 1H), 7.15 (s, broad,1H), and m, centred at 3.6 (4H) δ. ##STR91##

A solution of 31.0 pts. by wt. of trimethylchlorosilane in 100 pts. byvol. of abs. dioxane is added dropwise to a boiling solution of 21.4pts. by wt. of 1-(4-chloro)-benzalimino-2-oxo-imidazolidine and 31.0pts. by wt. of triethylamine in 240 pts. by vol. of absolute dioxane inthe course of 1 hr., whilst stirring. The mixture is then heated underreflux overnight, the triethylammonium hydrochloride which has separatedout is filtered off hot and washed with hot dioxane and, after cooling,a solution of 9.9 pts. by wt. of phosgene is 60 pts. by vol. of abs.dioxane is added to the filtrate. After standing for 12 hrs. at roomtemperature, excess phosgene is blown out of the mixture by means of dryair. The precipitate is filtered off, the filtrate is concentrated andthe residue is recrystallised from abs. acetonitrile. 8.9 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-chloro)-benzalimino-imidazolidine of decomp.pt. 188°-192° C.

IR (liquid paraffin): 1800 and 1700 cm⁻¹. ##STR92##

7.9 pts. by wt. of ampicillin trihydrate in 80 pts. by vol. of 80%strength by volume aqueous THF are reacted with 2.8 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-chloro)-benzalimino-imidazolidine as inExample 1.3. This gives 1.4 pts. by wt. of sodium6-{D-α-[(2-oxo-3-{4-chloro}-benzalimino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-penicillanateof decomp. pt. 210°-5° C. with a β-lactam content of 87%.

IR (KBr): 1760, 1725, 1665 and 1595 cm⁻¹.

NMR (CD₃ OD): 7.6-7.2 (m, 10H), 5.60 (s, 1H), 5.45 (q, 2H), 4.15 (s,1H), 3.80 (broad s, 4H), 1.57 (s, 3H) and 1.48 (s, 3H) δ. ##STR93##

2.0 pts. by wt. of sodium epicillin in 40 pts. by vol. of 80% strengthby volume THF are reacted with 3.5 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-chloro)-benzalimino-imidazolidine as inExample 1.5. This gives 0.4 pt. by wt. of sodium6-{D-α-[(2-oxo-3-{4-chloro}-benzalimino-imidazolidin-1-yl)-carbonylamino]-cyclohex-1,4-dien-1-yl-acetamido}-penicillanatewith a β-lactam content of 92%.

IR (KBr): 1770, 1730, 1670 and 1605 cm⁻¹.

NMR (CD₃ OD): 7.78 (s, 1H), 7.76 and 7.36 (AB, 4H), 5.95 (m, 1H), 5.72(s, 2H), 5.50 (s, 2H), 5.00 (s, 1H), 4.20 (s, 1H), 3.95 (s, broad, 4H(,2.75 (s, broad, 4H), 1.65 (s, 3H) and 1.58 (s, 3H) δ. ##STR94##

2.25 pts. by wt. of cephaloglycine dihydrate in 40 pts. by vol. of 80%strength by volume THF are reacted with 3.5 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-chloro)-benzalimino-imidazolidine as inExample 1.6. This gives 0.6 pt. by wt. of sodium7-{D-α-[(2-oxo-3-{4-chloro}-benzalimino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylatewith a β-lactam content of 80-85%.

IR (KBr): 1760, 1720, 1660 and 1595 cm⁻¹.

NMR (CD₃ OD): 7.7 and 7.4 (m, 10H), 5.65 (d, 1H), 5.60 (s, 1H), 5.0-4.8m (overlaid by the signal of the replaceable protons) 3.88 and 3.70(overlaid multiplets) and 2.03 (s, 3H) δ.

C₂₉ H₂₆ ClN₆ NaO₈ S.11/2H₂ O.1/4 dimethylacetamide Calculated: C, 50.25;H, 4.22; N, 11.72; S, 4.48. Found: C, 50.1; H, 4.5; N, 11.1; S, 5.4.##STR95##

6.3 pts. by wt. of amoxicillin trihydrate in 80 pts. by vol. of 80percent strength aqueous THF are reacted with 2.9 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-chloro)-benzalimino-imidazolidine as inExample 1.4. This gives 4.6 pts. by wt. of sodium6-{D-α-[(2-oxo-3-{4-chloro}-benzalimino-imidazolidin-1-yl)-carbonylamino]-4-hydroxyphenyl-acetamido}-penicillanateof decomp. pt. 220°-4° C.

IR (KBr): 1775, 1730, 1670 and 1615 cm⁻¹.

NMR (CD₃ OD): 6.7-8.0 (9H), 5.4-5.6 (3H), 4.95 (3 replaceable H), 4.15(1 H), 3.80 (4H), 1.58 (3H) and 1.52 3H) δ.

C₂₇ H₂₆ ClN₆ NaO₇ S.2H₂ O Calculated: C, 48.18; H, 4.49; N, 12.49; S,4.77. Found: C, 48.7; H, 5.1; N, 12.6; S, 4.5.

EXAMPLE 3 ##STR96##

15.8 pts. by wt. of 2-oxo-imidazolidine 12.6 pts. by wt. of sodiumnitrite and 27.5 pts. by wt. of zinc dust are processed as in Example2.1. and the mixture is reacted with 22.4 pts. by wt. of4-methoxybenzaldehyde. This gives 15.8 pts. by wt. of1-(4-methoxy)-benzalimino-2-oxo-imidazolidine of melting point 179°-181°C.

IR (KBr); 3250, 3130, 1725, 1700 and 1605 cm⁻¹.

NMR (d₆ -DMSO): 7.56 and 6.92 (AB, 4H), 7.52 (s, 1H), 7.04 (s, 1H), 3.72(s, 3H) and m centred at 3.52 (4H) δ.

C₁₁ H₁₃ N₃ O₂ Calculated: C, 60.27; H, 5.97; N, 19.17. Found: C, 60.3;H, 5.9; N, 18.9. ##STR97##

A solution of 20.0 pts. by wt. of trimethylchlorosilane in 50 pts. byvol. of abs. benzene is added dropwise to a boiling solution of 13.6pts. by wt. of 1-(4-methoxy)-benzalimino-2-oxo-imidazolidine and 27.6pts. by vol. of triethylamine in 120 pts. by vol. of abs. benzene andthe mixture is reacted and worked up as in Example 1.2. This gives 6.2pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-methoxy-benzalimino-imidazolidine of meltingpoint 204°-208° C.

IR (liquid paraffin): 1800 cm⁻¹. ##STR98##

6.9 pts. by wt. of ampicillin trihydrate in 70 pts. by vol. of 80%strength by volume THF and 2.4 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-methoxy)-benzalimino-imidazolidine arereacted as in Example 1.3. This gives 4.5 pts. by wt. of sodium6-{D-α-[(2-oxo-3-{4-methoxy}-benzalimino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-penicillanateof decomp. pt. 213°-223° C. with a β-lactam content of 87%.

IR (KBr): 1770, 1730, 1675 and 1605 cm⁻¹.

NMR (CD₃ OD): 7.60 and 6.85 (AB, 4H), 7.4 (m, 5+1H), 5.60 (s, 1H), 5.45(q, 2H), 4.15 (s, 1H), 3.72 (s, 3H), 3.63 (broad s, 4H), 1.55 (s, 3H)and 1.50 (s, 3H) δ. ##STR99##

2.0 pts. by wt. of sodium epicillin in 40 pts. by vol. of 80% strengthby volume THF are reacted with 2.1 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-methoxy)-benzalimino-imidazolidine as inExample 1.5. This gives 3.5 pts. by wt. of sodium6-{D-α-[(2-oxo-3-{4-methoxy}-benzalimino-imidazolidin-1-yl)-carbonylamino]-cyclohex-1,4-dien-1-yl-acetamido}-penicillanatewith a β-lactam content of 68%.

IR (KBr): 1760, 1720, 1655 and 1600 cm⁻¹.

NMR (CD₃ OD): 7.60 and 6.85 (AB, 4H), 7.40 (s, overlaying the AB system,1H), 5.90 (broad s, 1H), 5.67 (s, 2H), 5.50 (s, 2H), 5.00 (s, 1H), 4.20(s, 1H), 3.77 (broad s, 4H), 2.72 (broad s, 4H), 1.65 (s, 3H) and 1.57(s, 3H) δ. ##STR100##

2.25 pts. by wt. of cephaloglycine dihydrate suspended in 40 pts. byvol. of 80% strength by volume THF are reacted with 1.41 pts. by wt. of1-chlorocarbonyl-2oxo-3-(4-methoxy)-benzalimino-imidazolidine as inExample 1.6. and the mixture is worked up. On acidifying,7-{D-α-[(2-oxo-3-{4-methoxy}-benzalimino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylicacid precipitates (1.2 pts. by wt.), which is reacted with 1.9 pts. byvol. of a 1 M sodium 2-ethyl-hexanoate solution as in Example 1.4. togive sodium7-{D-α-[(2-oxo-3-{4-methoxy}-benzalimino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylate(0.7 pt. by wt.).

The ethyl acetate phase is worked up as in Example 1.3., whereupon afurther 1.6 pts. by wt. of the sodium salt of decomp. pt. 220°-230° witha β-lactam content of 80% are obtained.

IR (KBr): 1770, 1730, 1660 and 1610 cm⁻¹.

NMR (CD₃ OD/D₂ O): 7.55 and 6.85 (AB, 4H), 7.40 (s, overlaying the ABsystem, 1H), 5.67 (d, 1H), 5.47 (s, 1H), 5.15-4.85 (m, overlaid by thesignal of the replaceable protons), 3.76 (broad s, 4H) and 2.05 (s, 3H)δ.

C₃₀ H₂₉ N₆ NaO₉ S.H₂ O 690.6 Calculated: C, 52.18; H, 4.52; N, 12.17; S,4.65. Found: C, 51.9; H, 4.4; N, 11.8; S, 5.1.

EXAMPLE 4 ##STR101##

15.8 pts. by wt. of 2-oxo-imidazolidine, 12.6 pts. by wt. of sodiumnitrite and 27.5 pts. by wt. of zinc dust as well as 24.9 pts. by wt. of4-nitrobenzaldehyde are reacted as in Example 2.1. The1-(4-nitro)-benzalimino-2-oxo-imdazolidine formed is freed fromimpurities by boiling with ethanol; 37.6 pts. by wt. of melting point265°-267° C.

IR (KBr): 3430, 3260, 1720, 1595 and 1570 cm⁻¹.

NMR (d₆ :DMSO): 8.20 and 7.88 (AB, 4H), 7.68 (s, 1H), 7.37 (broad s, 1H)and m, centred at 3.65 (4H) δ.

Calculated: C, 51.28; H, 4.31; N, 23.92. Found: C, 51.2; H, 4.3; N,23.9. ##STR102##

8.8 pts. by wt. of 1-(4-nitro)-benzalimino-2-oxo-imidazolidine, 12.1pts. by wt. of triethylamine, 12.0 pts. by wt. of trimethylchlorosilaneand 3.9 pts. by wt. of phosgene are reacted as in Example 2.2. The1-chlorocarbonyl-2-oxo-3-(4-nitro)-benzalimino-imidazolidine isrecrystallised from abs. acetonitrile; 2.6 pts. by wt. of decomp. pt.188°-192° C. result.

IR (liquid paraffin): 1800, 1760 and 1700 cm⁻¹. ##STR103##

6.8 pts. by wt. of ampicillin trihydrate in 70 pts. by vol. of 80%strength by volume aqueous THF are reacted with 2.5 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-nitro)benzalimino-imidazolidine as inExample 1.3. This gives 3.0 pts. by wt. of sodium6-{D-α-[(2-oxo-3-{4-nitro}-benzaliminoimidazolidin-1-yl)-carbonylamino]-phenylacetamido}-penicillanateof decomp. pt. 220°-5° C. with a β-lactam content of 98%.

IR (KBr): 1765, 1730, 1670 and 1600 cm⁻¹.

NMR (CD₃ OD): 8.30 and 7.96 (AB system, 4H), 7.81 (s, 1H), m centred at7.45 (5H), 5.64 (s, 1H), 5.57 (q, 2H), 4.20 (s, 1H), 3.88 (broad s, 4H),1.58 (s, 3H) and 1.50 (s, 3H) δ.

C₂₇ H₂₆ N₇ NaO₈ S.2.5 H₂ O Calculated: C, 47.93; H, 4.62; N, 14.50; S,4.74. Found: C, 47.7; H, 4.3; N, 14.4; S, 4.8. ##STR104##

6.5 pts. by wt. of cephaloglycine dihydrate in 80 pts. by vol. of 80percent strength aqueous THF are reacted with 4.4 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-nitro)-benzalimino-imidazolidine as inExample 3.5. This gives 9.3 pts. by wt. of sodium7-{D-α-[(2-oxo-3-{4-nitro}-benzaliminoimidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylateof decomp. pt. 220°-5° C.

IR (KBr): 1760, 1730, 1660 and 1605 cm⁻¹.

C₂₉ H₂₆ N₇ NaO₁₀ S.2 H₂ O Calculated: C, 48.13; H, 4.19; N, 13.56; S,4.42. Found C, 48.0; H, 4.1; N, 13.4; S, 4.4.

EXAMPLE 5 ##STR105##

12.6 pts. by wt. of 2-oxo-imidazolidine, 10.1 pts. by wt. of sodiumnitrite and 21.8 pts. by wt. of zinc dust are processed as in Example2.1. and reacted with 17.3 pts. by wt. of 4-cyanobenzaldehyde. Thisgives 26.2 pts. by wt. of 1-(4-cyano)-benzalimino-2-oxo-imidazolidine,which is freed from impurities by successive washing with water, ethanoland ether. Melting point 265°-267° C.

(IR (KBr): 3210, 3120, 2220, 1720 and 1590 cm⁻¹.

NMR (d₆ -DMSO): 7.88 (s, 4H), 7.66 (s, 1H), 7.30 (broad s, 1H), and mcentred at 3.7 (4H) δ.

Calculated: C, 61.68; H, 4.71; N, 26.15. Found: C, 59.8; H, 4.6; N,25.9. ##STR106##

7.5 pts. by wt. of 1-(4-cyano)-benzalimino-2-oxo-imidazolidine and 12.1pts. by wt. of triethylamine in 60 pts. by vol. of abs. dioxane as wellas 12.0 pts. by wt. of trimethylchlorosilane in 25 pts. by vol. of abs.dioxane and 3.9 pts. by wt. of phosgene are reacted as in Example 2.2.The 1-chlorocarbonyl-2-oxo-3-(4-cyano)-benzalimino-imidazolidine isrecrystallised from abs. acetonitrile; 4.7 pts. by wt. of melting point260°-264° C. result.

IR (liquid paraffin): 1800 cm⁻¹.

Calculated: C 52.09 H 3.28 N 20.25 Cl 12.82 Found: 52.0 3.3 20.3 12.5##STR107##

7.9 pts. by wt. of ampicillin trihydrate in 80 pts. by vol. of 80%strength by volume aqueous THF are reacted with 2.7 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-cyano)-benzalimino-imidazolidine as inExample 1.3. This gives 2.3 pts. by wt. of sodium6-{D-α-[(2-oxo-3-{4-cyano}-benzaliminoimidazolidin-1-yl)-carbonylamino]-phenylacetamido}-penicillanateof decomp. pt. 225°-230° C. with a β-lactam content of 88%.

IR (KBr): 2220, 1770, 1730, 1665 and 1600 cm⁻¹.

NMR (CD₃ OD): 7.95-7.20 (10H), 5.56 (s, 1H), 5.42 (q, 2H), 4.12 (s, 1H),3.87 (broad s, 4H), 1.57 (s, 3H) and 1.48 (s, 3H) δ.

C₂₈ H₂₆ N₇ NaO₆ S.2.5 H₂ O Calculated: C, 51.21; H, 4.76; N, 14.93.Found: C, 51.6; H, 4.9; N, 14.4.

EXAMPLE 6 ##STR108##

This substance is prepared from 15.8 pts. by wt. of imidazolidone and31.0 pts. by wt. of 4-methylsulphonylbenzaldehyde in the mannerdescribed in Example 1.1., but in a 1:1 (volume) water/dichloromethanemixture. The crude product is recrystallised from nitromethane.

Yield: 9.2 pts. by wt. of1-(4-methylsulphonyl)benzalimino-2-oxo-imidazolidine, melting point=264°C.

NMR signals at τ=2.0 (4H), 2.2 (1H), 5.9-6.65 (4H) and 6.7 ppm (3H).

Calculated: C, 49.4; H, 4.9; N, 15.7; O, 18.0; S, 12.0. Found: C, 48.6;H, 5.0; N, 15.7; O, 18.3; S, 12.1. ##STR109##

This substance is prepared from 9.2 pts. by wt. of1-(4-methylsulphonyl)-benzalimino-2-oxo-imidazolidine in the mannerdescribed in Example 1.2. The crude product is recrystallised fromnitromethane and acetonitrile. Yield 5.4 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-methylsulphonyl)benzalimino-imidazolidine.

Melting point=208°-213° C.

Calculated: C, 43.7; H, 3.6; Cl, 10.8; N, 12.8; S, 9.7. Found: C, 43.8;H, 4.9; Cl, 10.2; N, 12.5; S, 9.5. ##STR110##

This penicillin is prepared from ampicillin trihydrate (2.0 pts. by wt.)and1-chlorocarbonyl-2-oxo-3-(4-methylsulphonyl)-benzalimino-imidazolidine(1.6 pts. by wt.) in the manner described in Example 1.3. In thisprocedure, the penicillic acid separates out as a crystallineprecipitate (1.6 pts. by wt.) which is insoluble in water and ethylacetate. This penicillic acid is dissolved in a littledimethylformamide, the calculated amount of sodium 2-ethylhexanoatesolution (in methanol-containing ether) is added and the sodium salt ofthe penicillin is precipitated by pouring the mixture into a largeamount of ether.

Yield: 0.85 pt. by wt. of the sodium salt ofD-α-{[2-oxo-3-(4-methylsulphonyl)-benzalimino-imidazolidin-1-yl]carbonylamino}-benzylpenicillin.

β-Lactam content: 90%.

According to the NMR spectrum, the penicillin contains about 1.5 mols ofwater, 0.2 mol of ethyl acetate, 0.25 mol of dimethylformamide and 0.15mol of sodium 2-ethylhexanoate. This was taken into consideration in thecalculated analysis values:

Calculated: C, 49.1; H, 5.1; N, 11.6; S, 8.5. Found: C, 48.5; H, 4.8; N,11.8; S, 8.4.

NMR signals at τ=2.05 (4H), 2.2 (1H), 2.2-2.8 (5H), 4.3-4.65 (3H), 5.8(1H), 5.9-6.4 (4H), 6.85 (3H) and 8.2-8.7 ppm (6H). ##STR111##

This penicillin is obtained from amoxicillin (1.5 pts. by wt.) and1-chlorocarbonyl-2-oxo-3-(4-methylsulphonyl)benzalimino-imidazolidine(1.18 pts. by wt.) in the manner described in Example 1.3. and 6.3.,first as the crystalline penicillic acid (1.8 pts. by wt.) and then asthe sodium salt. Yield: 2.0 pts. by wt. of the sodium salt ofD-α-{[2-oxo-3-(4-methylsulphonyl)-benzalimino-imidazolidin-1-yl)]-carbonylamino}-p-hydroxybenzylpenicillin.

β-Lactam content: 85%.

According to the NMR spectrum, this penicillin contains about 0.2 molsof water, 0.25 mol of ethyl acetate, 0.7 mol of dimethylformamide and0.08 mol of sodium 2-ethylhexanoate. This was taken into considerationin the calculated analysis data.

Calculated: C, 47.4; H, 5.1; N, 11.7; S, 8.0. Found: C, 47.2; H, 5.0; N,11.1; S, 7.9.

NMR signals at τ=2.1 (4H), 2.2 (1H), 2.5-3.3 (4H), 4.35-4.65 (3H), 5.8(1H), 5.9-6.4 (4H), 6.85 (3H) and 8.2-8.7 ppm (6H). ##STR112##

This penicillin is obtained from epicillin (1.0 pt. by wt.) and1-chlorocarbonyl-2-oxo-3-(4-methylsulphonyl)benzalimino-imidazolidine(0.94 pt. by wt.) in the manner described in Example 1.3. and 6.3.,first as the crystalline penicillic acid (1.8 pts. by wt.) and then asthe sodium salt. Yield: 1.6 pts. by wt. of the sodium salt ofD-α-{[2-oxo-3-(4-methylsulphonyl)-benzalimino-imidazolidin-1-yl]-carbonylamino}-α-(1,4-cyclohexadien-1-yl)-methylpenicillin.

β-Lactam content: 81%.

According to the NMR spectrum, this penicillin contains about 3.0 molsof water, 0.3 mol of ethyl acetate, 0.4 mol of dimethylformamide and0.12 mol of sodium 2-ethylhexanoate. This was taken into considerationin the calculated analysis values:

Calculated: C, 47.3; H, 5.5; N, 11.3; S, 8.1. Found: C, 46.9; H, 5.5; N,11.3; S, 8.1.

NMR signals at τ=2.0 (4H), 2.15 (1H), 4.0 (1H), 4.25 (2H), 4.45 (2H),5.0 (1H), 5.8 (1H), 5.8-6.3 (4H), 6.8 (3H), 7.0-7.4 (4H) and 8.2-8.7 ppm(6H). ##STR113##

This cephalosporin is obtained from cephaloglycine (1.5 pts. by wt.) and1-chlorocarbonyl-2-oxo-3-(4-methylsulphonyl)-benzalimino imidazolidine(1.0 pt. by wt.) in the manner described in Example 1.3. and 6.3.,partially first as the crystalline acid (portion undissolved in ethylacetate and water) (1.0 pt. by wt.) and partially directly as the sodiumsalt (portion dissolved in ethyl acetate and precipitated from this asthe sodium salt) (0.75 pt. by wt.). Still further sodium salt is thenprepared from the penicillic acid as described in Example 6.3. Totalyield: 1.85 pts. by wt. of sodium 7D-α-[{[2-oxo-3-(4-methylsulphonyl)-benzaliminoimidazolidin-1-yl]-carbonylamino}-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylate.

β-Lactam content: 84%.

According to the NMR spectrum, this cephalosporin contains about 1.7mols of water, 0.4 mol of dimethylformamide, 0.4 mol of ethyl acetateand 0.16 mol of sodium 2-ethylhexanoate. This was taken intoconsideration in the calculated analysis figures:

Calculated: C, 47.4; H, 4.6; N, 10.5; S, 7.5. Found: C, 47.3; H, 4.2; N,10.8; S, 8.1.

NMR signals at τ=2.1 (4H), 2.25 (1H), 2.5-2.9 (5H), 4.3-4.6 (2H),5.05-5.3 (3H), 6.0-6.3 (4H), 6.7 (2H), 6.9 (3H) and 8.0 ppm (3H).

EXAMPLE 7 ##STR114##

15.8 pts. by wt. of 2-oxo-imidazolidine, 12.6 pts. by wt. of sodiumnitrite and 27.5 pts. by wt. of zinc dust as well as 18.5 pts. by wt. ofthiophene-2-aldehyde are reacted as in Example 1.1. The1-(thiophene-2-aldimino)-2-oxo-imidazolidine formed is freed fromimpurities by boiling with ethanol or is recrystallised fromdimethylformamide. 22.4 pts. by wt. of melting point 263°-265° C.

IR (KBr): 3240 and 1705 (broad) cm⁻¹.

NMR (d₆ -DMSO): 7.88 (s, 1H), 7.3-7.0 (hetero-aromatic protons, as wellas NH, 4H) and m, centred at 3.6 (4H).

Calculated: C, 49.22; H, 4.65; N, 21.52; S, 16.42. Found: C, 49.4; H,4.6; N, 21.4; S, 16.1. ##STR115##

9.8 pts. by wt. of 1-(thiophene-2-aldimino)-2-oxo-imidazolidine, 16.2pts. by wt. of triethylamine, 16.1 pts. by wt. of trimethylchlorosilaneand 5.1 pts. by wt. of phosgene are reacted as in Example 1.2. Thisgives 7.7 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(thiophene-2-aldimino)-imidazolidine of decomp.pt. 184°-188° C.

IR (liquid paraffin): 1830 and 1720 cm⁻¹.

The chlorocarbonyl compound still contains starting material, which wasnot removed since it does not interfere with the subsequent reactions.##STR116##

2.6 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(thiophene-2-aldimino)-imidazolidine and 4.1pts. by wt. of ampical in trihydrate in 40 pts. by vol. of 80% strengthby volume aqueous THF are reacted as in Example 1.3. This gives 0.4 pt.by wt. of sodium6-{D-α-[(2-oxo-3-{thiophene-2-aldimino}-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}penicillanateof decomp. pt. 210°-220° C. with a β-lactam content of 89%.

IR (KBr): 1760, 1720, 1660 and 1600 cm⁻¹.

NMR (CD₃ OD): 7.90 (s, 1H), 7.5-6.8 (aromatic and hetero-aromaticprotons, 8H), 5.51 (s, with overlaying m at about 5.4, together with3H), 4.12 (s, 1H), 3.79 (broad s, 4H), 1.57 (s, 3H) and 1.48 (s, 3H) δ.

C₂₅ H₂₅ N₆ NaO₆ S₂.2.5 H₂ O.0.25 ether; 656.1 Calculated: C, 47.60; H,5.00; N, 12.81; S, 9.79. Found: C, 47.6; H, 5.5; N, 12.4; S, 10.0.##STR117##

2.6 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(thiophene-2-aldimino)-imidazolidine and 2.0pts. by wt. of sodium epicillin in 40 pts. by vol. of 80% strength byvolume aqueous THF are reacted as in Example 1,5. This gives 0.8 pt. bywt. of sodium6-{D-α-[(2-oxo-3-{thiophene-2-aldimino}imidazolidin-1-yl)-carbonylamino]-cyclohex-1,4-dien-1-yl-acetamido}-penicillanateof decomp. pt. 205°-215° C. with a β-lactam content of 89%.

IR (KBr): 1770 1730, 1665 and 1605 cm⁻¹.

NMR (CD₃ OD): 8.00 (s, 1H), 7.5-7.0 (hetero-aromatic protons, 3H), 5.95(broad s, 1H), 5.70 (s, 2H), 5.50 (s, 2H), 5.00 (s, 1H), 4.20 (s, 1H),3.86 (broad s, 4H), 2.73 (broad s, 4H), 1.64 (s, 3H) and 1.57 (s, 3H) δ.

C₂₅ H₂₇ N₆ NaO₆ S₂.2 H₂ O, 530.6 Calculated: C, 47.61; H, 4.95; N,13.32; S, 10.16. Found: C, 47.6; H, 5.1; N, 13.0; S, 10.2. ##STR118##

1.50 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(thiophene-2-aldimino)-imidazolidine and 2.25pts. by wt. of cephaloglycine dihydrate in 40 pts. by vol. of 80%strength by volume THF are reacted as in Example 1.6. On acidifying,7-{D-α-[(2-oxo-3-{thiophene-2-aldimino}-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylicacid precipitates (0.6 pt. by wt.), which is reacted with 3 pts. by vol.of a 1 M sodium 2-ethyl-hexanoate solution as in Example 1.4. to givesodium7-{D-α-[(2-oxo-3-{thiophene-2-aldimino}-imidazolidin-1-yl)-carbonylamino]phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylate.The β-lactam content is 75-80%.

IR (KBr): 1755, 1720, 1660 and 1600 cm⁻¹.

NMR (CD₃ OD): 7.95 (s, 1H), 7.5-6.8 (aromatic and heteroaromaticprotons, 8H), 5.75-5.00 (m, 3H), 4.8 (overlaid by the signal of thereplaceable protons), 3.82 (broad s, 4H) and 2.00 (s, 3H) δ.

EXAMPLE 8 ##STR119##

15.8 pts. by wt. of 2-oxo-imidazolidine, 12.6 pts. by wt. of sodiumnitrite and 27.5 pts. by wt. of zinc dust as well as 15.8 pts. by wt. offurane-2-aldehyde are reacted as in Example 1.1. This gives 17.5 pts. bywt. of 1-furylideneamino-2-oxo-imidazolidine of melting point 218°-220°C.

IR (KBr): 3200, 3110, 1715 and 1585 cm⁻¹.

NMR (d₆ -DMSO): 7.70 (m, 1H), 7.50 (s, 1H), 7.15 (broad s, 1H),6.50-6.75 (m, 2H) and m, centred at 3.55 (4H) δ.

Calculated: C, 53.63; H, 5.06; N, 23.45. Found: C, 53.7; H, 5.0; N,23.2. ##STR120##

11.5 pts. by wt. of 1-furylideneamino-2-oxo-imidazolidine, 10.0 pts. bywt. of triethylamine, 13.2 pts. by wt. of trimethylchlorosilane and 6.2pts. by wt. of phosgene are reacted as in Example 1.2. This gives 3.8pts. by wt. of 1-chlorocarbonyl-2-oxo-3-furylideneamino-imidazolidine ofdecomp. pt. 130° C.

IR (liquid paraffin): 1800 and 1700 cm⁻¹.

The chlorocarbonyl compound still contains starting material, which wasnot removed since it does not interfere with the subsequent reactions.##STR121##

6.1 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(furane-2-aldimino)-imidazolidine and 20.4 pts.by wt. of ampicillin trihydrate in 200 pts. by vol. of 80% strength byvolume aqueous THF are reacted as in Example 1.3. This gives 2.3 pts. bywt. of sodium6-{D-α-[(2-oxo-3-furylideneaminoimidazolidin-1-yl)-carbonylamino]-phenylacetamido}-penicillanateof decomp. pt. 200°-207° C. with a β-lactam content of 81%.

IR (KBr): 1760, 1715, 1660 and 1600 cm⁻¹.

NMR (CD₃ OD): 7.60 (s, 1H), 7.50-6.35 (aromatic and heteroaromaticprotons, 8H), 5.55 (s, 1H), 5.40 (q 2H), 4.12 (s, 1H), m, centred at3.75 (4H), 1.55 (s, 3H) and 1.48 (s, 3H) δ.

C₂₄ H₂₅ N₆ NaO₇ S.1.5 H₂ O.0.25 ether Calculated: C, 49.22; H, 5.04; N,13.76; S, 5.26. Found: C, 49.5; H, 4.8; N, 13.5; S, 5.2. ##STR122##

10.0 pts. by wt. of cephaloglycine dihydrate in 100 pts. by vol. of 80percent strength aqueous THF and 6.1 pts. by wt. of1-chlorocarbonyl-2-oxo-3-furylideneamino-imidazolidine are reacted as inExample 1.6. and the mixture is worked up. On slowly acidifying with 0.1N HCL at 5°-10° C., 13.1 pts. by wt. of crystalline acid (Q=H)precipitate. This precipitate is dissolved in 500 pts. by vol. ofacetone, the small proportion of insoluble material is filtered off andthe filtrate is concentrated. The residue is suspended in 120 pts. byvol. of water and 1.5 N sodium hydroxide solution is added until thesolid dissolves, the pH being kept between 7.5 and 8.0. The mixture isfiltered, 940 pts. by vol. of acetone and then 190 pts. by vol. of ethylacetate are added to the filtrate and the sodium salt is thenprecipitated by adding 380 pts. by vol. of ether dropwise. This gives7.8 pts. by wt. of crystalline sodium7-{D-α-[(2-oxo-3-furylideneamino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylateof decomp. pt. 215°-220° C. with a β-lactam content of 95%.

IR (KBr): 1765, 1730, 1670, 1615, 1530, 1480, 1390, 1265, 1230, 1020,740 and 695 cm⁻¹.

NMR (D₂ O/CD₃ OD): 7.50 (s, 2H), 7.30 (s, 5H), 6.65 (1H), 6.45 (1H),5.56 (d, 1H), 5.38 (s, 1H), 4.91 (pseudo d, overlaid by the signal ofthe replaceable protons), 3.76 (6H) and 2.03 (s, 3H) δ.

C₂₇ H₂₅ N₆ NaO₉ S.H₂ O Calculated: C, 49.84; H, 4.18; N, 12.91; S, 4.92.Found: C, 49.4; H, 4.6; N, 12.9; S, 4.9. ##STR123##

9.4 pts. by wt. of amoxicillin trihydrate in 100 pts. by vol. of 80percent strength aqueous THF are reacted with 5.5 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(furane-2-aldimino)-imidazolidine as in Example1.4. This gives (0.1 pt. by wt. of sodium6-{D-α-[(2-oxo-3-furylideneaminoimidazolidin-1-yl)-carbonylamino]-4-hydroxyphenylacetamido}penicillanate.

IR (KBr): 1775, 1730, 1670 and 1615 cm⁻¹.

NMR (CD₃ OD): 7.7-6.6 (8H), 5.5 (3H), 4.18 (s, 1H), 3.90 (s, 4H), 1.58(s, 3H) and 1.50 (s, 3H) δ.

EXAMPLE 9 ##STR124##

18.9 pts. by wt. of 2-oxo-imidazolidine, 15.2 pts. by wt. of sodiumnitrite and 33.2 pts. by wt. of zinc dust are processed as in Example2.1. and reacted with 29.1 pts. by wt. of 2-chlorothiophene-5-aldehyde.This gives 36.0 pts. by wt. of1-(2-chlorothiophene-5-aldimino)-2-oxo-imidazolidine, which was purifiedby successive washing with water, ethanol and ether. Melting point194°-197° C.

IR (KBr): 3260, 1700 (broad) and 1580 cm⁻¹.

NMR (d₆ -DMSO): 7.92 and 7.78 (s, together 1H, syn-form and anti-form),7.16 and 7.10 (AB with overlaid NH, 3H) and m, centred at 3.6 (4H) δ.

Calculated: C, 41.84; H, 3.51; N, 18.28; S, 13.96. Found: C, 41.9; H,3.8; N, 18.0; S, 14.3. ##STR125##

8.6 pts. by wt. of 1-(2-chlorothiophene-5-aldimino)-2-oxo-imidazolidineand 12.1 pts. by wt. of triethylamine in 60 pts. by vol. of abs. dioxaneas well as 12.0 pts. by wt. of trimethylchlorosilane in 25 pts. by vol.of abs. dioxane and 3.9 pts. by wt. of phosgene are reacted as inExample 2.2. The precipitate which separates out after driving offexcess phosgene is filtered off and dried. This gives 5.1 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(2-chlorothiophene-5-aldimino)-imidazolidine ofdecomp. pt. 215°-220° C.

IR (liquid paraffin): 1800 cm⁻¹. ##STR126##

13.9 pts. by wt. of ampicillin trihydrate in 140 pts. by vol. of 80%strength by volume aqueous THF are reacted with 5.0 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(2-chlorothiophene-5-aldimino)-imidazolidine asin Example 1.3. This gives 7.5 pts. by wt. of sodium6-{D-α-[(2-oxo-3-{2-chlorothiophene-5-aldimino}-imidazolidin-1-yl)-carbonylamino]phenylacetamido}-penicillanateof decomp. pt. 215°-225° C. with a β-lactam content of 90%.

IR (KBr): 1765, 1730, 1670 and 1605 cm⁻¹.

NMR (CD₃ OD): 7.77 (s, 1H), m, centred at 7.32 (5H), 7.06 and 6.83 (AB,2H), 5.55 (s, IH), 5.42 (q, 2H), 4.13 (s, 1H), 3.77 (broad s, 4H), 1.56(s, 3H) and 1.48 (s, 3H) δ.

C₂₅ H₂₄ ClN₆ NaO₆ S₂.1 H₂ O. 1/4 ether Calculated: C, 47.10; H, 4.33; N,12.68; S, 9.68; Cl, 5.35. Found: C, 47.0; H, 4.2; N, 12.5; S, 9.5; Cl,4.9. ##STR127##

2.5 pts. by wt. of cephaloglycine dihydrate in 50 pts. by vol. of 80percent strength THF are reacted with 1.7 pts. by wt. of1-chlorocarbonyl-2-oxo-(2-chlorothiophene-5-aldimino)imidazolidine as inExample 1.6. and the mixture is worked up. This gives 2.5 pts. by wt. ofsodium7-{D-α-[(2-oxo-3-{2-chlorothiophene-5-aldimino}-imidazolidin-1-yl)-carbonylamino]phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylate.

IR (KBr): 1760, 1730, 1670 and 1600 cm⁻¹.

NMR (CD₃ OD/D₂ O): 7.87 (s, 1H), 7.50 (s, 5H), 7.18 (d, 1H), 6.93 (d,1H), 5.65 (d, 1H), 5.53 (s, 1H), 5.05 (overlaid by the signal of thereplaceable protons), 3.83 (6H) and 2.10 (s, 3H) δ.

C₂₇ H₂₄ ClN₆ O₈ S₂.H₂ O Calculated: C, 46.26; H, 3.74; N, 11.99; S,9.14; Cl, 5.07. Found: C, 46.3; H, 3.9; N, 11.9; S 9.5; Cl, 5.0.

EXAMPLE 10 ##STR128##

15.8 pts. by wt. of 2-oxo-imidazolidine, 12.6 pts. by wt. of sodiumnitrite and 27.5 pts. by wt. of zinc dust are processed as in Example2.1. and the mixture is reacted with 31.5 pts. by wt. of3-bromothiophene-5-aldehyde. This gives 41.2 pts. by wt. of1-(3-bromothiophene-5-aldimino)-2-oxo-imidazolidine, which is purifiedby successive washing with water, ethanol and ether and recrystallisedfrom DMF. Melting point 253°-255° C.

IR (KBr): 3230 and 1710 cm⁻¹.

NMR (d₆ -DMSO): 7.77 (s, 1H), 7.60 (s, 1H), 7.28 (s, 1H), 7.24 (s, 1H)and m, centred at 3.6 (4H).

Calculated: C, 35.04; H, 2.93; N, 15.33; S, 11.70; Br, 29.15. Found: C,34.7; H, 2.9; N, 15.5; S, 11.8; Br, 29.1. ##STR129##

12.2 pts. by wt. of 1-(3-bromothiophene-5-aldimino)-2-oxo-imidazolidineand 14.1 pts. by wt. of triethylamine in 120 pts. by vol. of abs.dioxane as well as 14.0 pts. by wt. of trimethylchlorosilane in 50 pts.by vol. of abs. dioxane and 4.6 pts. by wt. of phosgene are reacted asin Example 2.2. The precipitate which separates out after driving offexcess phosgene is filtered off, the filtrate is concentrated and theresidue is triturated with abs. ether and filtered off. This gives 7.5pts. by wt. of1-chlorocarbonyl-2-oxo-3-(3-bromothiophene-5-aldimino)-imidazolidine ofmelting point 165-170, which still contains a proportion of startingmaterial.

IR (liquid paraffin): 1780 and 1690 cm⁻¹. ##STR130##

6.5 pts. by wt. of ampicillin trihydrate in 70 pts. by vol. of 80%strength by volume aqueous THF and 2.7 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(3-bromothiophene-5-aldimino)imidazolidine arereacted as in Example 1.3. This gives 2.2 pts. by wt. of sodium6-{D-α-[(2-oxo-3-{3-bromothiophene-5-aldimino}-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-penicillanateof decomp. pt. 210°-220° C., with a β-lactam content of 85%.

IR (KBr): 1765, 1730 1675 and 1610 cm⁻¹.

NMR (CD₃ OD): 7.83-7.20 (8H), 5.53 (s, 1H), 5.42 (q, 2H), 4.12 (s, 1H),3.78 (broad s, 4H), 1.55 (s, 3H) and 1.48 (s, 3H) δ. ##STR131##

6.5 pts. by wt. of cephaloglycine dihydrate in 80 pts. by vol. of 80percent strength aqueous THF are reacted with 5.0 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(3-bromothiophene-5-aldimino)-imidazolidine asin Example 1.6. and the mixture is worked up. This gives 4.2 pts. by wt.of sodium7-{D-α-[(2-oxo-3-{3-bromothiophene-5-aldimino}-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylateof decomp. pt. 190°-5° C.

IR (KBr): 1760, 1725, 1670 and 1605 cm⁻¹.

C₂₇ H₂₄ BrN₆ NaO₈ S₂.H₂ O Calculated: C, 43.50; H, 3.52; N, 11.28; S,8.59. Found: C, 43.8; H, 3.8; N, 10.8; S, 8.1. ##STR132##

7.5 pts. by wt. of amoxicillin trihydrate in 100 pts. by vol. of 80percent strength aqueous THF are reacted with 6.0 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(3-bromothiophene-5-aldimino)-imidazolidine asin Example 1.4. This gives 4.3 pts. by wt. of sodium6-{D-α-[(2-oxo-3-{3-bromothiophene-5-aldimino}-imidazolidin-1-yl)-carbonylamino]-4-hydroxyphenylacetamido}-penicillanate.

IR (KBr): 1760, 1720, 1670 and 1605 cm⁻¹.

NMR (CD₃ OD): 7.80 (s, 1H), 6.6-7.4 (6H), 5.5 (m, 3H), 4.12 (s, 1H),3.78 (s, broad, 4H), 1.54 (s, 3H) and 1.48 (s, 3H) δ.

C₂₅ H₂₄ BrN₆ NaO₇ S₂.H₂ O Calculated: C, 41.50; H, 3.91; S, 8.84. Found:C, 41.7; H, 4.3; S, 8.3.

EXAMPLE 11 ##STR133##

Cinnamaldehyde (18.5 pts. by wt.) are added to a solution of1-amino-2-oxo-imidazolidine hydrochloride (21 pts. by wt.) in 1 N sodiumhydroxide solution (150 pts. by vol.) at 20° C., whilst stirring, andthe mixture is subsequently stirred for a further 90 minutes at the sametemperature and then left to stand for 16 hrs. The precipitate whichseparates out is filtered off, washed thoroughly with water and driedover P₄ O₁₀ in a desiccator.

Yield: 29.9 pts. by wt.

Melting point=209°-210° C. (Kofler stage)

The substance still contains 0.28 molar equivalents of water. This istaken into consideration in the following calculated analysis values:

Calculated: C, 65.4; H, 6.1; N, 19.1. Found: C, 65.5; H, 6.1; N, 19.1.##STR134##

A solution of phosgene (4.3 pts. by vol.) in benzonitrile (15 pts. byvol.) is added dropwise to a mixture of1-(cinnamylidene-amino)-2-oxo-imidazolidine (10 pts. by wt.),benzonitrile (50 pts. by vol.) and triethylamine (7.7 pts. by vol.),whilst stirring and cooling with ice/water. The mixture is thensubsequently stirred for 4.5 hrs., with further cooling. The precipitatewhich has formed is then filtered off, stirred in about 30 pts. by vol.of dichloromethane for 2 hrs. at 20° C., filtered off again and thendried over P₄ O₁₀ in a desiccator.

Yield: 8.2 pts. by wt.

Melting point=227°-230° C. (Kofler stage)

The substance still contains triethylamine hydrochloride, which,however, is not troublesome during the further reaction.

IR spectrum (--CO--Cl): 1800 cm⁻¹ (in liquid paraffin). ##STR135##

This penicillin is prepared from ampicillin trihydrate (2.0 pts. by wt.)and 1-chlorocarbonyl-2-oxo-3-(cinnamylideneamino)-imidazolidine (2.06pts. by wt.; in excess because of the triethylamine still present in thesubstance) in the manner described in Example 1.3.

Yield: 2.1 pts. by wt. of sodiumD-α-[(2-oxo-3-cinnamylideneamino-imidazolidin-1-yl)-carbonylamino]-benzylpenicillin.

β-Lactam content: 82%.

According to the NMR spectrum, the substance contains about 2.6 molarequivalents of H₂ O and 0.56 molar equivalent of sodium2-ethylhexanoate. This was taken into consideration in the followingcalculated analysis data:

Calculated: C, 53.6; H, 5.6; N, 11.2; S, 4.3. Found: C, 53.6; H, 5.6; N,10.8; S, 4.3.

NMR signals at τ=2.3-3.2 (13H), 4.45 (1H), 4.45-4.75 (AB, 2H), 5.9 (1H),6.1-6.4 (4H), 8.5 (3H) and 8.55 ppm (3H).

IR spectrum (carbonyl range): 1770, 1730, 1670, 1610 and (in liquidparaffin) 1525 cm⁻¹ ##STR136##

This penicillin is prepared from amoxicillin trihydrate (1.5 pts. bywt.) and 1-chlorocarbonyl-2-oxo-3-(cinnamylidene amino)-imidazolidine(1.49 pts. by wt.) in the manner described in Example 1.3.

Yield: 1.3 pts. by wt. of sodiumD-α-[(2-oxo-3-cinnamylideneamino-imidazolidin-1-yl)-carbonylamino]-p-hydroxybenzylpenicillin.

β-Lactam content: 88%.

The penicillin contains 1.5 molar equivalents of H₂ O and 0.36 molarequivalent of sodium 2-ethylhexanoate (according to the NMR spectrum).This was taken into consideration in the following calculated analysisfigures:

Calculated: C, 53.6; H, 5.2; N, 11.8; S, 4.5. Found: C, 53.6; H, 5.7; N,11.7; S, 4.6.

IR spectrum (carbonyl range): 1770, 1740, 1670, 1615 and (in liquidparaffin) 1555-1520 cm⁻¹. ##STR137##

This penicillin is prepared from epicillin (1.5 pts. by wt.) and1-chlorocarbonyl-2-oxo-3-(cinnamylidene-amino)-imidazolidine (1.77 pts.by wt.; in excess since it still contained triethylamine hydrochloride)in the manner described in Example 1.3.

Yield: 1.6 pts. by wt. of sodiumD-α-[(2-oxo-3-cinnamylideneamino-imidazolidin-1-yl)-carbonylamino]-.alpha.-(1,4-cyclohexadien-1-yl)-methylpenicillin.

β-Lactam content: 82%.

According to the NMR, the penicillin contained about 2 molar equivalentsof water and 0.36 molar equivalent of sodium 2-ethylhexanoate. This wastaken into consideration in the calculated analysis figures:

Calculated: C, 54.0; H, 5.6; N, 11.8; S, 4.5. Found: C, 54.0; H, 5.7; N,11.7; S, 4.5.

IR spectrum (carbonyl range): 1772, 1730, 1670, 1610 and (in liquidparaffin) 1530 cm⁻¹.

NMR signals at τ=2.25-3.15 (8H), 4.05 (1H), 4.3 (2H), 4.5 (2H), 5.0(1H), 5.8 (1H), 6.05-6.4 (4H), 7.15-7.45 (4H), 8.4 (3H) and 8.46 ppm(3H). ##STR138##

This cephalosporin is prepared from cephaloglycine dihydrate (1.5 pts.by wt.) and 1-chlorocarbonyl-2-oxo-3-(cinnamylidene-amino)-imidazolidine(1.08 pts. by wt.; in excess since the substance still containstriethylamine hydrochloride) in a manner corresponding to that describedfor the penicillins in Examples 1.3. and 1.6. In this procedure, afterremoving the tetrahydrofurane at pH 7.0, a precipitate which isinsoluble in water and ethyl acetate is filtered off and is stirred witha mixture of ethyl acetate and water at pH 2.0. After filtering off, theprecipitate is stirred with 10 pts. by vol. of dimethylformamide, theundissolved material is filtered off and, after diluting the filtratewith 150 pts. by vol. of ether, the sodium salt is precipitated.

Yield: 0.5 pt. by wt. of sodium7-{D-α-[(2-oxo-3-cinnamylideneamino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylate.

β-Lactam content: 80%.

According to the NMR, this cephalosporin contains about 3 molarequivalents of water and 0.65 molar equivalent of sodium2-ethylhexanoate. This was taken into consideration in the followingcalculated analysis values:

Calculated: C, 52.3; H, 5.4; N, 10.1; S, 3.9. Found: C, 52.4; H, 5.6; N,10.3; S, 3.8.

IR spectrum (carbonyl range): 1770, 1730, 1668, 1612 and (in liquidparaffin) 1540 cm⁻¹.

NMR signals at τ=2.1-2.9 (13H), 3.9-4.3 (2H), 4.75-5.1 (in deuteratedDMF) (3H), 4.0 (4H), 6.6 (2H) and 7.9 ppm (3H).

EXAMPLE 12 ##STR139##

Pyridine-3-aldehyde (10.7 pts. by wt.) is added to a solution of1-amino-2-oxo-imidazolidine (10.1 pts. by wt.) in a mixture of methanoland water (50 pts. by vol. each) and the mixture is then stirred forabout 20 hrs. at 20° C. The precipitate which has formed is thenfiltered off, washed with water and a little methanol and dried at 60°C. over P₄ O₁₀ in vacuo.

Yield: 16.5 pts. by wt.

Melting point=195° C. (Kofler stage)

Calculated: C, 56.9; H, 5.3; N, 29.5; O, 8.4. Found: C, 56.9; H, 5.2; N,30.0; O, 8.0. ##STR140##

A solution of phosgene (1.35 pts. by vol.) in tetrahydrofurane (10 pts.by vol.) is added to a suspension of1-(3-pyridyl-methylideneamino)-2-oxo-imidazolidine (3.0 pts. by wt.) ina mixture of benzonitrile (30 pts. by vol.) and triethylamine (2.6 pts.by vol.), whilst cooling with ice-water. After 20 minutes, the mixtureis allowed to come to 20° C. and is then stirred at this temperatureovernight. The precipitate present is then filtered off, washed withether and then with dichloromethane and dried.

Yield: 4.2 pts. by wt. IR spectrum (CO.Cl): 1800 cm⁻¹ (in liquidparaffin)

Melting point=252° C. (Kofler stage). ##STR141##

This penicillin is prepared from ampicillin trihydrate (1.0 pt. by wt.)and 1-chlorocarbonyl-2-oxo-3-(3-pyridylmethylideneamino)-imidazolidine(0.63 pt. by wt.) in the manner described in Example 1.3. In thisprocedure, on acidifying the reaction solution, which has been freedfrom tetrahydrofurane and covered with a layer of ethyl acetate, some ofthe penicillin is obtained as the free acid (0.20 pt. by wt.; IRspectrum [carbonyl range]: 1775, 1725, 1670 and 1520 cm⁻¹ in liquidparaffin), dissolved in ethyl acetate. The sodium salt is obtained fromthe organic phase by precipitation with sodium 2-ethylhexanoatesolution.

Yield: 0.70 pt. by wt. of sodiumD-α-{[(2-oxo-3-(3-pyridyl-methylideneamino)-imidazolidin-1-yl]-carbonylamino}-benzylpenicillin.

β-Lactam content: 90%.

According to the NMR spectrum, the penicillin contains about 3.3 molarequivalents of water and 0.13 molar equivalent of sodium3-ethylhexanoate. This was taken into consideration in the followingcalculated analysis data:

Calculated: C, 48.6; H, 5.3; N, 14.7; S, 4.8. Found: C, 48.5; H, 5.8; N,14.5; S, 4.8.

IR spectrum (carbonyl range): 1768, 1722, 1667, 1625, 1600 (in liquidparaffin) 1550 and 1525 cm⁻¹.

NMR signals at τ=1.0-1.2 (1H), 1.35-1.55 (1H), 1.6-1.85 (1H), 2.15 (1H),2.3-2.8 (6H), 4.3 (1H), 4.3-4.6 (AB; 2H), 5.8 (1H), 5.9-6.2 (4H), 8.4(3H) and 8.45 ppm (3H).

EXAMPLE 13 ##STR142##

3-Methylbenzaldehyde is added to a mixture of1-amino-2-oxo-imidazolidine hydrochloride (14.0 pts. by wt.) and 1 Nsodium hydroxide solution (100 pts. by vol.) and the mixture is thensubsequently stirred for 5 hrs. at 20° C. The precipitate formed is thenfiltered off, washed with water and dried.

Yield: 20.3 pts. by wt. Melting point=205°-207° C. (Kofler stage).##STR143##

A solution of trimethylchlorosilane (9.65 pts. by wt.) in benzene (50pts. by vol.) is added dropwise to a weakly boiling mixture of1-(3-methyl-benzylidene-amino)-2-oxo-imidazolidine (12.1 pts. by wt.),benzene (150 pts. by vol.) and triethylamine (13.4 pts. by vol.) in thecourse of one hour. The mixture is then boiled under reflux for 20 hrs.and the triethylamine hydrochloride is filtered off hot and rinsed withhot benzene. A solution of phosgene (4.7 pts. by vol.) in benzene (30pts. by vol.) is added to the combined filtrates, which have been cooledto 10° C., and the mixture is then left to stand at 20° C. for 48 hrs.The precipitate which has formed is then filtered off, washed withbenzene, subsequently triturated with dichloromethane (40 pts. by vol.)and then dried.

Yield: 3.2 pts. by wt. Melting point=209°-210° C. (Kofler stage).

Calculated: C, 54.3; H, 4.5; Cl, 13.4; N, 15.8. Found: C, 54.5; H, 4.6;Cl, 13.5; N, 15.4.

IR spectrum (CO.Cl): 1810 cm⁻¹ (in liquid paraffin). ##STR144##

This penicillin is obtained when ampicillin trihydrate (2.0 pts. by wt.)and 1- chlorocarbonyl-2-oxo-3-(3-methylbenzylidene-amino)-imidazolidine(1.6 pts. by wt.) are reacted in the manner described in Example 1.3.

Yield: 2.55 pts. by wt. of sodiumD-α-{[(2-oxo-3-(3-methylbenzylidene-amino)-imidazolidin-1-yl]-carbonylamino}-benzylpenicillin.

β-Lactam content: 90%.

According to the NMR spectrum, the penicillin contains some sodium2-ethylhexanoate (about 0.06 molar equivalent) and water (3 molarequivalents). This was taken into consideration in the calculatedanalysis data:

Calculated: C, 52.1; H, 5.4; N, 12.6; S, 4.8. Found: C, 51.9; H, 6.3; N,12.4; S, 4.9.

IR spectrum (carbonyl range): 1770, 1730, 1675, 1612 and (in liquidparaffin) 1530 cm⁻¹.

NMR signals at τ=2.25-2.9 (10H), 4.35 (1H), 4.35-4.65 (AB, (CD₃ OD) 2H),5.85 (1H), 6.1-6.4 (4H), 7.7 (3H), 8.4 (3H) and 8.5 ppm (3H). ##STR145##

This penicillin is obtained when amoxicillin trihydrate (1.0 pt. by wt.)and 1-chlorocarbonyl-2-oxo-3-(3-methylbenzylidene-amino)-imidazolidine(0.73 pt. by wt.) are reacted with one another according to Example 1.3.

Yield: 1.1 pts. by wt. of crystalline sodiumD-α-{[(2-oxo-3-(3-methylbenzylidene-amino)-imidazolidin-1-yl]-carbonylamino}-p-hydroxybenzylpenicillin.

β-Lactam content: 90%.

According to the NMR spectrum, the penicillin contains some sodium2-ethylhexanoate (0.16 molar equivalent) and water (2.9 molarequivalents). This was taken into consideration in the followingcalculated analysis data:

Calculated: C, 50.5; H, 5.3; N, 12.1; S, 4.6. Found: C, 50.5; H, 5.4; N,11.9; S, 4.6.

IR spectrum (carbonyl range): 1790, 1765, 1720, 1690, 1660, (in liquidparaffin) 1612, 1590, 1550 and 1510 cm⁻¹.

NMR signals at τ=2.2-3.3 (9H), 4.4-4.65 (3H), 5.85 (1H), (in CD₃ OD)6.0-6.3 (4H), 7.65 (3H), 8.4 (3H) and 8.5 ppm (3H). ##STR146##

This penicillin is obtained when epicillin (1.0 pt. by wt.) is reactedwith 1-chlorocarbonyl-2-oxo-3-(3-methylbenzylidene-amino)-imidazolidine(0.91 pt. by wt.) in the manner described in Example 1.3. During theprecipitation of the sodium salt, 0.8 pt. by wt. of the amorphouspenicillin salt was first obtained, and 0.9 pt. by wt. of crystallinesodiumD-α-{[(2-oxo-3-(3-methylbenzylidene-amino)-imidazolidin-1-yl]-carbonylamino}-α-(1,4-cylohexadien-1-yl)methylpenicillinwas obtained by further precipitation from its mother liquor.

IR spectrum of the amorphous salt (carbonyl range): 1770, (in liquidparaffin) 1730, 1670, 1610 and 1525 cm⁻¹.

IR spectrum of the crystalline salt (carbonyl range): 1790, (in liquidparaffin) (1775), 1740, 1712, 1660, 1600, 1575 and 1520 cm⁻¹.

NMR signals at τ=2.1-2.8 (5H), 4.05 (1H), 4.3 (2H), 4.5 (2H), (in CD₃OD) 5.0 (1H), 5.8 (1H), 6.1 (4H), 7.25 (4H), 7.65 (3H), 8.35 (3H) and8.45 ppm (3H). ##STR147##

This cephalosporin is obtained when cephaloglycine dihydrate (1.0 pt. bywt.) is reacted with1-chlorocarbonyl-2-oxo-3-(3-methylbenzylideneamino)-imidazolidine (0.69pt. by wt.) in the manner described for the penicillins in Examples 1.3.and 1.6. The sodium salt separated out as a gel-like precipitate whichcould not be filtered off. All the volatile constituents were thereforestripped off and the residue was treated with dry ether. Thecephalosporin salt was thereby obtained as a loose white powder.

Yield: 1.2 pts. by wt. of sodium7-{D-α-[(2-oxo-3-{3-methylbenzylideneamino}-imidazolidin-1-yl)-carbonylamino]phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylate.

β-Lactam content: 90%.

The cephalosporin salt contains about 2.9 molar equivalents of water.This was taken into consideration in the calculated analysis data:

Calculated: C, 51.2; H, 4.9; N, 11.9; S, 4.6. Found: C, 51.4; H, 5.5; N,11.7; S, 4.7.

IR spectrum (carbonyl range): 1765 (shoulder), 1740, 1660, (in liquidparaffin) 1610 and 1535 cm⁻¹.

NMR signals at τ=1.85-2.8 (10H), 3.9-4.3 (2H), 4.7-5.0 (3H), (in d₇-DMF) 5.8-6.1 (4H), 6.4-6.7 (2H), 7.5 (3H) and 7.8 ppm (3H).

EXAMPLE 14 ##STR148##

This substance is obtained from 1-amino-2-oxo-imidazolidinehydrochloride (14.0 pts. by wt.) and 4-fluorobenzaldehyde (12.8 pts. bywt.) in the manner described in Example 13.1.

Yield: 20.4 pts. by wt. Melting point=229°-230° C. (Kofler stage).##STR149##

A solution of phosgene (4.2 pts. by vol.) in benzonitrile (10 pts. byvol.) is added dropwise to a mixture of1-(4-fluorobenzylidene-amino)-2-oxo-imidazolidine (6.0 pts. by wt.),benzonitrile (50 pts. by vol.) and triethylamine (8 pts. by vol.),whilst cooling with ice/water and stirring, and the mixture is thensubsequently stirred for a further 3 hrs. at 20° C. The precipitate isthen filtered off, suspended in dichloromethane (240 pts. by vol.),filtered off again and dried.

Yield: 0.9 pt. by wt. (still more of this substance is in the motherliquor).

The substance is not completely free from triethylamine hydrochloride,which, however, was not troublesome in the further reaction.

IR spectrum (CO.Cl): 1820/1810 cm⁻¹ (in liquid paraffin)

Melting point=240°-247° C. decomp. (Kofler stage). ##STR150##

This penicillin is obtained when ampicillin trihydrate (1.0 pt. by wt.)and 1-chlorocarbonyl-2-oxo-3-(4-fluorobenzylidene-amino)-imidazolidine(0.8 pt. by wt.) are reacted with one another in the manner described inExample 1.3.

Yield: 1.2 pts. by wt. of crystalline sodiumD-α-{[(2-oxo-3-(4-fluorobenzylidene-amino)-imidazolidin-1-yl]-carbonylamino}-benzylpenicillin.

β-Lactam content: 93%.

According to the NMR spectrum, the penicillin contains about 1.7 molarequivalents of water. This was taken into consideration in thecalculated analysis values:

Calculated: C, 51.1; H, 4.6; N, 13.2; S, 5.0. Found: C, 51.1; H, 5.4; N,13.2; S, 5.1.

IR spectrum (carbonyl range): 1790, (1767), 1730, 1702, 1670 (in liquidparaffin) (shoulder), 1660 and 1602 cm⁻¹.

NMR signals at τ=2.1-3.1 (10H), 4.4 (1H), 4.4-4.65 (AB, 2H), (in CD₃ OD)5.85 (1H), 6.0-6.3 (4H), 8.45 (3H) and 8.55 ppm (3H). ##STR151##

This cephalosporin is obtained when cephloglycine dihydrate (1.0 pt. bywt.) is reacted with1-chlorocarbonyl-2-oxo-3-(4-fluorobenzylidene-amino)-imidazolidine (0.7pt. by wt.) in the manner described for the penicillins in Examples 1.3.and 1.6. Since the sodium salt separated out as a gel and was difficultto filter off in this form, all the volatile constituents were removedin vacuo and the residue was treated with a mixture of ether/methanol(10/1).

During this procedure, the sodium salt was converted into a loose, whitepowder.

Yield: 0.5 pt. by wt. of sodium7-{D-α-[(2-oxo-3-p-fluorobenzylideneamino-imidazolidin-1-yl)-carbonylamino]phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylate.

β-Lactam content: 91%.

According to the NMR spectrum, the cephalosporin contains about 0.13molar equivalent of sodium 2-ethylhexanoate and 1.7 molar equivalents ofwater. This was taken into consideration in the calculated analysisdata:

Calculated: C, 50.7; H, 4.4; N, 11.8; S, 4.5. Found: C, 50.7; H, 4.4; N,11.8; S, 4.6.

IR spectrum (carbonyl range): 1775 (shoulder), 1760 (shoulder), (inliquid paraffin) 1735, 1680, 1610 and 1550-1520 cm⁻¹.

NMR signals at τ=2.1-2.9 (10), 4.2-4.35 (1H), 4.4 (1H), (in CD₃ OD)5.0-5.2 (3H), 6.1 (4H), 6.5-6.7 (2H) and 8.0 ppm (3H).

EXAMPLE 15 ##STR152##

This substance is obtained from 1-amino-2-oxoimidazolidine hydrochloride(14.0 pts. by wt.) and 2-fluorobenzaldehyde (12.7 pts. by wt.), as inExample 13.1., in a yield of 17.6 pts. by wt.

Melting point 214°-216° C. (Kofler stage). ##STR153##

A solution of phosgene (4.2 pts. by vol.) in benzonitrile (10 pts. byvol.) is added dropwise to a mixture of1-(2-fluorobenzylidene-amino)-2-oxo-imidazolidine (6.0 pts. by wt.),benzonitrile (50 pts. by vol.) and triethylamine (8 pts. by vol.),whilst stirring and cooling with ice/water. The mixture is subsequentlystirred for a further 3 hrs. at 20° C. The precipitate is then filteredoff, washed with ether, suspended in about 120 pts. by vol. ofdichloromethane, filtered off again and dried.

Yield: 5.6 pts. by wt.

Melting point=230° C. (Kofler stage)

IR spectrum (CO.Cl): 1800 (with shoulder at about 1815) cm⁻¹.

The substance contains some triethylamine hydrochloride, which, however,was not troublesome in the further reaction. ##STR154##

This penicillin is obtained from ampicillin trihydrate (1.0 pt. by wt.)and 1-chlorocarbonyl-2-oxo-3-(2-fluorobenzylidene-amino)-imidazolidine(0.8 pt. by wt.) when they are reacted with one another using theprocedure described in Example 1.3.

Yield: 0.55 pt. by wt. of crystalline sodiumD-α-{[2-oxo-3-(2-fluorobenzylidene-amino)-imidazolidin-1-yl]carbonylamino}-benzylpenicillin.

β-Lactam content: 90%.

According to the NMR spectrum, the penicillin contains about 2.9 molarequivalents of water. This was taken into consideration in the followingcalculated analysis figures:

Calculated: C, 49.4; H, 4.9; N, 12.8; S, 4.9. Found: C, 49.4; H, 4.9; N,12.6; S, 5.3.

IR spectrum (carbonyl range): 1793, (1775), 1740, (1700 and (in liquidparaffin) 1680, both shoulders), 1660, 1610, 1560 and 1520 cm⁻¹.

NMR signals at τ=1.8-3.1 (10), 4.4 (1H), 4.4-4.65 (2H), 5.8 (in CD₃ OD)(1H), 6.0-6.3 (4H), 8.45 (3H) and 8.55 ppm (3H). ##STR155##

This cephalosporin is obtained from cephaloglycine dihydrate (1.5 pts.by wt.) and1-chlorocarbonyl-2-oxo-3-(2-fluorobenzylidene-amino)-imidazolidine (1.07pts. by wt.) according to the preparation process described for thepenicillins in Examples 1.3. and 1.6. During the working up, onacidifying the mixture to pH 2, some of the cephalosporin is obtained asthe free acid (0.2 pt. by wt.; IR spectrum [carbonyl range]: 1780, 1745,1670 and 1540 cm⁻¹ in liquid paraffin), which is insoluble in water andethyl acetate. If the cephalosporin formed is dissolved in the organicphase, it is obtained from this in a yield of 0.8 pt. by wt. as sodium7-{D-α-[(2-oxo-3-{2-fluorobenzylidene-amino}-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylate.

The following data relate to the sodium salt.

β-Lactam content: 91%.

According to the NMR spectrum, the cephalosporin contains about 2.8molar equivalents of water and 0.05 molar equivalent of sodium2-ethylhexanoate. This was taken into consideration in the calculatedanalysis data:

Calculated: C, 49.2; H, 4.5; N, 11.7; S, 4.5. Found: C, 49.1; H, 4.3; N,11.7; S, 4.9.

IR spectrum (carbonyl range): 1780, 1730, 1670, 1610 and (in liquidparaffin) 1530 cm⁻¹.

NMR signals at τ=1.8-2.9 (10H), 4.0-4.4 (2H), 4.8-5.1 (3H), (in d₇ -DMF)5.8-6.2 (4H), 6.5-6.75 (2H) and 7.95 ppm (3H).

EXAMPLE 16 ##STR156##

47.5 pts. by wt. of 2-oxo-imidazolidine, 38.0 pts. by wt. of sodiumnitrite and 82.5 pts. by wt. of zinc dust are processed as in Example2.1. and the mixture is reacted with 64.0 pts. by wt. of2-chlorobenzaldehyde. This gives 65.0 pts. by wt. of1-(2-chloro)-benzalimino-2-oxo-imidazolidine, which is recrystallisedfrom ethanol. Melting point 216°-17° C. ##STR157##

50.0 pts. by wt. of 1-(2-chloro)-benzalimino-2-oxo-imidazolidine and73.0 pts. by wt. of triethylamine in 400 pts. by vol. of abs. dioxane aswell as 72.7 pts. by wt. of trimethylchlorosilane in 150 pts. by vol. ofabs. dioxane and 44.5 pts. by wt. of phosgene are reacted as in Example2.2. This gives 37.2 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(2-chloro)-benzalimino-imidazolidine, which isrecrystallised from acetonitrile. Melting point: 233°-7° C.

IR (liquid paraffin): 1800 cm⁻¹.

Calculated: C, 46.18; H, 3.17; N, 14.68; Cl, 24.78. Found: C, 46.1; H,3.2; N, 14.6; Cl, 24.7. ##STR158##

14.1 pts. by wt. of ampicillin trihydrate in 150 pts. by vol. of 80percent strength aqueous THF are reacted with 5.0 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(2-chloro)-benzalimino-imidazolidine as inExample 1.3. This gives 11.3 pts. by wt. of sodium6-{D-α-[(2-oxo-3-{2-chloro}-benzalimino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-penicillanateof decomp. pt. 215°-220° C.

β-Lactam content: 83%.

IR (KBr): 1765, 1730, 1675 and 1605 cm⁻¹.

NMR (CD₃ OD): 7.92 (s with overlaid m, 2H), m centred at 7.3 (8H), 5.55(s, 1H), 5.42 (AB system, 2H), 4.12 (s, 1H), 3.83 (s, broad, 4H), 1.58(s, 3H) and 1.50 (s, 3H) δ.

C₂₇ H₂₆ ClN₆ NaO₆ S.2H₂ O Calculated: C, 49.36; H, 4.60; N, 12.79.Found: C, 49.4; H, 4.6; N, 12.7. ##STR159##

6.3 pts. by wt. of amoxicillin trihydrate in 80 pts. by vol. of 80percent strength aqueous THF are reacted with 2.9 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(2-chloro)-benzalmino-imidazolidine as inExample 1.4.

This gives 8.5 pts. by wt. of sodium6-{D-α-[(2-oxo-3-{2-chloro}-benzalimino-imidazolidin-1-yl)-carbonylamino]-4-hydroxyphenylacetamido}-penicillanate.

IR (KBr): 1760, 1720, 1655 and 1600 cm⁻¹.

NMR (CD₃ OD): 7.95 s (1H), 7.5-6.8 (8H), 5.5 (m,3H), 4.20 (s,1H), 3.92(s, broad, 4H), 1.60 (s, 3H) and 1.50 (s, 3H) δ. ##STR160##

10.5 pts. by wt. of cephradin in 100 pts. by vol. of 80 percent strengthaqueous THF are reacted with 5.7 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(2-chloro)-benzalimino-imidazolidine as inExample 1.3. This gives 10.9 pts. by wt. of sodium7-{D-α-[(2-oxo-3-{2-chloro}-benzalimino-imidazolidin-1-yl)-carbonylamino]-cyclohex-1,4-dien-1-yl-acetamido}-3-methyl-ceph-3-em-4-carboxylateof decomp. pt. 222° C. IR (KBr): 1770, 1735, 1665 and 1590 cm⁻¹.

C₂₇ H₂₆ ClN₆ NaO₆ S.2H₂ O Calculated: C, 49.36; H, 4.66; N, 12.79; S,4.88; Cl, 5.39. Found: C, 48.9; H, 4.5; N, 12.4; S, 4.4; Cl, 5.3.##STR161##

5.0 pts. by wt. of cephaloglycine dihydrate in 100 pts. by vol. of 80percent strength aqueous THF are reacted with 3.3 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(2-chloro)-benzalimino-imidazolidine as inExample 1.6. This gives 6.7 pts. by wt. of sodium7-{D-α-[(2-oxo-3-{2-chloro}-benzalimino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylateof decomp. pt. 195°-200° C.

IR (KBr): 1760, 1725, 1670 and 1600 cm⁻¹.

NMR (CD₃ OD/D₂ O): 7.2-8.0 (aromatic protons and --CH═N--), 5.65 (d,1H), 5.50 (s, 1H), 5.05 (d, overlaid by the signal of the replaceableprotons), 3.8 (6H) and 2.10 (s, 3H) δ.

C₂₉ H₂₆ ClN₆ NaO₈ S.H₂ O Calculated: C, 50.11; H, 4.21; N, 12.09; S,4.63. Found: C, 50.1; H, 4.1; N, 12.1; S, 4.8.

EXAMPLE 17 ##STR162##

47.6 pts. by wt. of 2-oxo-imidazolidine, 34.5 pts. by wt. of sodiumnitrite and 78.4 pts. by wt. of zinc dust are processed as in Example1.1. and the mixture is stirred overnight with 77.0 pts. by wt. of3-chlorobenzaldehyde. This gives 65.7 pts. by wt. of1-(3-chloro)-benzalimino-2-oxoimidazoidine of melting point 210°-212° C.

IR (KBr): 3230, 3120, 1715, 1475 and 1405 cm⁻¹.

NMR (d₆ -DMSO): m, centred at 7.5 (aromatic protons, --CH═N-- and NH:6H), and 3.65 (m, 4H) δ.

Calculated: C, 53.70; H, 4.51; N, 18.79; Cl, 15.85. Found: C, 54.0; H,4.7; N, 18.4; Cl, 16.2. ##STR163##

A solution of 43.3 pts. by wt. of trimethylchlorosilane in 80 pts. byvol. of abs. dioxane is added dropwise to a boiling solution of 30.0pts. by wt. of 1-(3-chloro)-benzalimino-2-oxo-imidazolidine and 43.4pts. by wt. of triethylamine in 250 pts. by vol. of abs. dioxane and themixture is reacted with 26.4 pts. by wt. of phosgene as in Example 2.2.This gives 16.2 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(3-chloro)-benzalimino-imidazolidine ofdecomp.pt. 190° C., which still contains a small amount of startingmaterial.

IR (liquid paraffin): 1800 cm⁻¹. ##STR164##

9.3 pts. by wt. of ampicillin trihydrate in 100 pts. by vol. of 80percent strength aqueous THF are reacted with 8.7 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(3-chloro)-benzalimino-imidazolidine as inExample 1.3. This gives 5.0 pts. by wt. of sodium6-{D-α-[(2-oxo-3-{3-chloro}-benzaliminoimidazolidin-1-yl)-carbonylamino]-phenylacetamido}-penicillanate.

IR(KBr): 1760, 1720, 1660 and 1600 cm⁻¹. ##STR165##

3.3 pts. by wt. of cephaloglycine dihydrate in 100 pts. by vol. of 80percent strength aqueous THF are reacted with 2.5 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(3-chloro)-benzalimino-imidazolidine as inExample 1.6. This gives 2.1. pts. by wt. of sodium7-{D-α-[(2-oxo-3-{3-chloro}-benzaliminoimidazolidin-1-yl)-carbonylamino]-phenyacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylateof melting point 212°-218° C. (decomp.).

IR (KBr): 1765, 1735, 1665 and 1610 cm⁻¹.

C₂₉ H₂₆ ClN₆ NaO₈ S.3H₂ O Calculated: C, 47.65; H, 4.42; N, 11.49.Found: C, 47.6; H, 4.8; N, 11.5.

EXAMPLE 18 ##STR166##

47.6 pts. by wt. of 2-oxo-imidazolidine, 34.5 pts. by wt. of sodiumnitrite and 78.4 pts. by wt. of zinc dust as well as 87.5 pts. by wt. of3,4-dichlorobenzaldehyde are reacted as in Example 1.1. This gives 50.4pts. by wt. of 1-(3,4-dichloro)-benzalimino-2-oxo-imidazolidine ofmelting point 178°-181° C.

IR (KBr): 3240, 1710 (broad), 1470, 1400 and 1260 cm⁻¹.

NMR (d₆ -DMSO): 7.95 (s, 1H), 7.7 (m, 3H), 7.37 (s, broad, 1H), and mcentred at 3.7 (4H).

Calculated: C, 46.46; H, 3.52; N, 16.28; Cl, 27.47. Found: C, 46.4; H,3.6; N, 16.1; Cl, 27.4. ##STR167##

30.0 pts. by wt. of 1-(3,4-dichloro)-benzalimino-2-oxoimidazolidine and37.8 pts. by wt. of triethylamine in 250 pts. by vol. of abs. dioxane aswell as 37.7 pts. by wt. of trimethylchlorosilane in 80 pts. by vol. ofabs. dioxane and 23.1 pts. by wt. of phosgene are reacted as in Example2.2. This gives 11.2 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(3,4-dichloro)-benzalimino-imidazolidine ofdecomp. pt. 224°-230° C.

IR (liquid paraffin): 1800 cm⁻¹.

Calculated: C, 41.80; H, 2.82; N, 13.07; Cl, 33.07. Found: C, 41.9; H,2.8; N, 12.9; Cl, 32.8. ##STR168##

9.4 pts. by wt. of ampicillin trihydrate in 100 pts. by vol. of 80percent strength aqueous THF are reacted with 5.0 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(3,4-dichloro)benzalimino-imidazolidine as inExample 1.3. This gives 5.3 pts. by wt. of sodium6-{D-α-[(2-oxo-3-{3,4-dichloro}benzalimino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}penicillanate.

IR (KBr): 1765, 1725, 1660 and 1605 cm⁻¹.

NMR (CD₃ OD): 7.3-7.7 (aromatic protons and --CH═N--), 5.61 (s, 1H),5.50 (q, 2H), 4.18 (s, 1H), 3.85 (s, broad, 4H), 1.58 (s, 3H) and 1.50(s, 3H) δ. ##STR169##

7.0 pts. by wt. of cephaloglycine dihydrate in 100 pts. by vol. of 80percent strength aqueous THF are reacted with 5.0 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(3,4-dichloro)benzalimino-imidazolidine as inExample 1.6. This gives 7.7 pts. by wt. of sodium7-{D-α-[(2-oxo-3-{3,4-dichloro}benzalimino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylateof decomp. pt. 190°-5° C.

IR (KBr): 1765, 1740, 1665 and 1615 cm⁻¹.

Calculated: C, 48.95; N, 11.80; O, 17.99. Found: C, 49.0; N, 11.7; O,18.1.

EXAMPLE 19 ##STR170##

27.8 pts. by wt. of 2-oxo-imidazolidine, 20.0 pts. by wt. of sodiumnitrite and 38.0 pts. by wt. of zinc dust as well as 54.0 pts. by wt. of4-bromobenzaldehyde are reacted as in Example 1.1. This gives 22.4 pts.by wt. of 1-(4-bromo)-benzalimino-2-oxo-imidazolidine of melting point250°-2° C.

IR (KBr): 3240, 3120, 1740, 1705, 1595, 1475, 1415 and 1270 cm⁻¹.

NMR (d₆ -DMSO): 7.67 (aromatic protons and --CH═N--), 7.30 (s, broad,1H) and m, centred at 3.6 (4H) δ.

Calculated: C, 44.80; H, 3.76; N, 15.67. Found: C, 44.9; H, 3.7; N,15.3. ##STR171##

21.7 pts. by wt. of 1-(4-bromo-(benzalimino-2-oxo-imidazolidine and 26.3pts. by wt. of triethylamine in 250 pts. by vol. of abs. dioxane as wellas 26.2 pts. by wt. of chlorotrimethylsilane in 80 pts. by vol. of abs.dioxane and 16.0 pts. by wt. of phosgene are reacted as in Example 2.2.

This gives 4.2 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-bromo)-benzalimino-imidazolidine of meltingpoint 177°-180° C. IR (liquid paraffin): 1800 cm⁻¹. ##STR172##

5.7 pts. by wt. of cephaloglycine dihydrate and 4.2 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-bromo)-benzalimino-imidazolidine are reactedas in Example 18.3. This gives 3.5 pts. by wt. of sodium7-{D-α-[(2-oxo-3-{4-bromo}benzalimino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylateof decomp. pt. 190°-3° C.

IR (KBr): 1760, 1725, 1655 and 1600 cm⁻¹.

EXAMPLE 20 ##STR173##

47.6 pts. by wt. of 2-oxo-imidazolidine, 34.5 pts. by wt. of sodiumnitrite and 78.4 pts. by wt. of zinc dust as well as 60.1 pts. by wt. of4-methylbenzaldehyde are reacted as in Example 1.1. This gives 52.2 pts.by wt. of 1-(4-methyl)-benzalimino-2-oxo-imidazolidine of melting point235°-6° C.

IR (KBr): 3230, 3110, 1710 (broad), 1475, 1410 and 1270 (broad) cm⁻¹.

NMR (d₆ -DMSO): 7.2-7.8 (aromatic protons, --CH═N-- and NH; 6H), m,centred at 3.7 (4H) and 2.40 (s, 3H) δ.

Calculated: C, 65.00; H, 6.45; N, 20.68. Found: C, 65.0; H, 6.3; N,20.8. ##STR174##

20.3 pts. by wt. of 1-(4-methyl)-benzalimino-2-oxo-imidazolidine, 33.3pts. by wt. of triethylamine, 32.1 pts. by wt. of chlorotrimethylsilaneand 19.8 pts. by wt. of phosgene are reacted as in Example 19.2. Thisgives 19.6 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-methyl)-benzaliminoimidazolidine of meltingpoint 265°-8° C.

IR (liquid paraffin): 1800 cm⁻¹.

Calculated: C, 54.24; H, 4.55; N, 15.82; Cl, 13.34. Found: C, 54.2; H,4.5; N, 15.8; Cl, 13.6. ##STR175##

8.1 pts. by wt. of ampicillin trihydrate and 2.7 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-methyl)-benzaliminoimidazolidine are reactedas in Example 2.3. This gives 5.0 pts. by wt. of sodium6-{D-α-[(2-oxo-3-{4-chloro}-benzalimino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-penicillanateof decomp. pt. 220°-225° C.

IR (KBr): 1760, 1725, 1660 and 1600 cm⁻¹.

NMR (CD₃ OD): 7.1-7.8 (aromatic protons and --CH═N--), 5.60 (s, 1H),5.45 (q, 2H), 4.17 (s, 1H), 3.60 (s, broad, 4H), 2.18 (s, 3H), 1.58 (s,3H) and 1.50 (s, 3H) δ.

C₂₈ H₂₉ N₆ NaO₆ S.2H₂ O Calculated: C, 52.82; H, 5.22; N, 13.20; S,5.03. Found: C, 52.6; H, 5.3; N, 12.8; S, 5.2. ##STR176##

5.0 pts. by wt. of amoxicillin trihydrate and 3.2 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-methyl)-benzaliminoimidazolidine are reactedas in Example 10.5. This gives 6.8 pts. by wt. of sodium6-{D-α-[(2-oxo-3-{4-methyl}-benzalimino-imidazolidin-1-yl)-carbonylamino]-4-hydroxyphenylacetamido}-penicillanateof decomp. pt. 230°-5° C.

IR (KBr): 1765, 1730, 1665 and 1610 cm⁻¹.

NMR (CD₃ OD): 7.6-6.7 (aromatic protons and --CH═N--), 5.5 (m, 3H), 4.18(s, 1H), 3.6 (m, 4H), 3.25 (s, 3H), 1.55 (s, 3H) and 1.50 (s, 3H) δ.

C₂₈ H₂₉ N₆ NaO₇ S.2H₂ O Calculated: C, 51.53; H, 5.09; N, 12.87; S,4.91. Found: C, 51.2; H, 5.2; N, 12.7; S, 5.1. ##STR177##

5.0 pts. by wt. of cephaloglycine dihydrate in 50 pts. by vol. of 80percent strength aqueous THF are reacted with 3.0 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-methyl)benzalimino-imidazolidine as inExample 1.6. This gives 5.5 pts. by wt. of sodium7-{D-α-[(2-oxo-3-{4-methyl}-benzalimino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylateof decomp. pt. 178°-80° C.

IR (KBr): 1760, 1725, 1660 and 1615 cm⁻¹.

C₃₀ H₂₉ N₆ NaO₈ S.H₂ O Calculated: C, 53.41; N, 12.47. Found: C, 53.4;N, 12.5.

EXAMPLE 21 ##STR178##

47.6 pts. by wt. of 2-oxo-imidazolidone, 34.5 pts. by wt. of sodiumnitrite and 78.4 pts. by wt. of zinc dust as well as 77.1 pts. by wt. of4-carboxy-benzaldehyde are reacted as in Example 1.1. This gives 82.8pts. by wt. of 1-(4-carboxy)-benzalimino-2-oxo-imidazolidine, which issuspended in 200 pts. by vol. of methanol, and ethereal diazomethanesolution is added until the yellow coloration remains. Shortly after aclear solution has formed,1-(4-methoxycarbonyl)-benzalimino-2-oxo-imidazolidine of melting point245°-6° C. crystallises out.

IR (KBr): 2240 and 1700 with a shoulder at 1720 cm⁻¹.

NMR (d₆ -DMSO): 7.6-8.1 (AB system and s at 7.63; 5H), 7.20 (s, broad,1H), 3.88 (s, 3H) and m centred at 3.7 (4H) δ.

Calculated: C, 58.29; H, 5.30; N, 17.00; O, 19.41. Found: C, 58.7; H,5.2; N, 17.3; O, 19.6. ##STR179##

17.4 pts. by wt. of1-(4-methoxycarbonyl)-benzalimino-2-oxo-imidazolidine, 22.8 pts. by wt.of triethylamine, 22.7 pts. by wt. of chlorotrimethylsilane and 13.9pts. by wt. of phosgene are reacted as in Example 19.2. This gives 21.0pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-methoxycarbonyl)-benzalimino-imidazolidineof decomp. pt. 210°-15° C. IR (liquid paraffin): 1800 cm⁻¹. ##STR180##

6.2 pts. by wt. of ampicillin trihydrate and 4.6 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-methoxycarbonyl)-benzalimino-imidazolidineare reacted as in Example 2.3. This gives 5.4 pts. by wt. of sodium6-{D-α-[(2-oxo-3-{4-methoxycarbonyl}-benzalimino-imidazolidin-1-yl)-carbonylamino]phenylacetamido}-penicillanateof decomp. pt. 215°-20° C.

IR (KBr): 1760, 1720, 1665 and 1595 cm⁻¹.

NMR (CD₃ OD): 8.0-7.1 (aromatic protons and --CH═N--, 10H), 5.58 (s,1H), 5.45 (q, 2H), 4.15 (s, 1H), m at about 3.8 (4H), 2.30 (s, 3H), 1.57(s, 3H) and 1.50 (s, 3H) δ.

C₂₉ H₂₉ N₆ NaO₈ S.3H₂ O Calculated: C, 49.86; H, 5.05; N, 12.02; S,4.58. Found: C, 49.7; H, 5.2; N, 11.9; S, 4.4. ##STR181##

2.3 pts. by wt. of cephaloglycine dihydrate in 40 pts. by vol. of 80percent strength aqueous THF are reacted with 2.2 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(4-methoxycarbonyl)benzalimino-imidazolidine asin Example 1.6. This gives 1.0 pts. by wt. of sodium7-{D-α-[(2-oxo-3-{4-methoxycarbonyl}benzalimino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-carboxylate.

IR (KBr): 1755, 1725, 1665 and 1600 cm⁻¹.

C₃₁ H₂₉ N₆ NaO₁₀ S.3H₂ O Calculated: C, 49.34; H, 4.67; N, 11.14; S,4.25. Found: C, 49.1; H, 4.5; N, 11.1; S, 4.4.

EXAMPLE 22 ##STR182##

A solution of 1-amino-2-oxo-imidazolidine (3.0 pts. by wt.) in water (30pts. by vol.) is added to a suspension of5-acetoxymethyl-furane-2-aldehyde (5.0 pts. by wt.) in water (50 pts. byvol.) in the course of 30 minutes, whilst stirring and cooling withice/water. The mixture is subsequently stirred for a further 20 hrs. at20° C. and the precipitate is then filtered off and washed withisopropanol. The substance was dried at 70° C. over P₄ O₁₀ in vacuo.

Yield: 6.6 pts. by wt. Melting point=146° C.

Calculated: C, 52.6; H, 5.2; N, 16.7; O, 25.5. Found: C, 52.6; H, 5.3;N, 16.8; O, 25.8. ##STR183##

A solution of trimethylchlorosilane (3.2 pts. by wt.) in benzene isadded dropwise to a mixture, boiling under reflux, of1-(5-acetoxymethyl-furfurylideneamino)-2-oxo-imidazolidine (6.6 pts. bywt.), benzene (60 pts. by vol.) and triethylamine (4.1 pts. by vol.) andthe mixture is then boiled for a further 20 hrs. The triethylaminehydrochloride is then filtered off while still hot and rinsed withbenzene and a solution of phosgene (1.6 pts. by vol.) in benzene (10pts. by vol.) is added to the combined filtrates, whilst cooling. Themixture is left to stand for 20 hrs. at 20° C. and the precipitate isthen filtered off.

Yield: 4.3 pts. by wt. Melting point=184°-85° C.

IR spectrum (carbonyl range): 1810 and 1745 cm⁻¹. (in liquid paraffin)

Calculated: C, 45.9; H, 3.8; Cl, 11.3; N, 13.4; O, 25.5. Found: C, 46.4;H, 3.9; Cl, 11.1; N, 13.4; O, 25.3. ##STR184##

This penicillin is formed when ampicillin trihydrate (2.0 pts. by wt.)and1-chlorocarbonyl-2-oxo-3-(5-acetoxymethyl-furfurylidene-amino)-imidazolidine(1.75 pts. by wt.) are reacted with one another in the manner describedin Example 1.3.

Yield: 2.8 pts. by wt. of sodiumD-α-{[2-oxo-3-(5-acetoxymethylfurfurylideneamino)-imidazolidin-1-yl]-carbonylamino}-benzylpenicillin.

Melting point=agglutination from about 190° C., then increasingdecomposition.

NMR signals at τ=2.37 (1H), 2.5-2.85 (5H), 3.15-3.30 (d, 1H), 3.40-3.55(d, 1H), 4.43 (1H), 4.43-4.70 (AB, 2H), 4.93 (2H), 5.87 (1H), 5.98-6.30(4H), 7.94 (3H), 8.45 (3H) and 8.52 ppm (3H).

IR spectrum (carbonyl range): 1767 (shoulder), 1734, 1660, (in liquidparaffin) 1600 and 1530°-1510 cm⁻¹ β-Lactam content: 92%. ##STR185##

This cephalosporin is obtained when cephaloglycine dihydrate (2.0 pts.by wt.) and1-chlorocarbonyl-2-oxo-3-(5-acetoxymethyl-furfurylidene-amino)-imidazolidine(1.5 pts. by wt.) are reacted with one another in the manner such as isdescribed for penicillins in Examples 1.3. and 1.6. On acidifying, thisgives one part of the cephalosporin as a precipitate which is insolublein water and in the organic phase (ethyl acetate): (yield: 0.1 pt. bywt.; melting point=tacky at 205° C., increasing decomposition up to 260°C., but no clear melt; IR spectrum, carbonyl range: 1770, 1726, 1678,1600 and 1528 cm⁻¹ in liquid paraffin). The cephalosporin can then beprecipitated from the organic phase as described.

Yield: 2.7 pts. by wt. of sodium7-D-α-[{[2-oxo-3-(5-acetoxymethyl-furfurylidene-amino)-imidazolidin-1-yl]-carbonylamino}-phenylacetamido]-3-acetoxymethyl-ceph-3-em-4-carboxylate.

β-Lactam content: 86%.

IR spectrum (carbonyl range): 1770 (shoulder), 1760 (shoulder), 1730,1668, 1610, 1550 (shoulder) and 1530 cm⁻¹.

NMR signals at τ=2.33 (1H), 2.45-2.85 (5H), 3.15-3.25 (1H), 3.4-3.52(1H), 4.24-4.48 (2H), 4.92 (2H), 5.0-5.22 (3H), 6.0-6.27 (4H), 6.55-6.75(2H), 7.96 (3H) and 8.02 ppm (3H).

Melting point=from 220° C. falling and decomp.

EXAMPLE 23 ##STR186##

2-Chlorofurane-5-aldehyde is reacted with 1-amino-2-oxo-imidazolidine asin Example 1.1. This gives1-(5-chlorofurylideneamino)-2-oxo-imidazolidine of melting point173°-175° C.

NMR (d₆ -DMSO): 7.45 (s, 1H), 7.26 (s, broad, 1H), 6.77 (d, 1H), 6.60(d, 1H) and 3.55 (m, 4H)δ.

Calculated: C, 45.0; H, 3.7; N, 19.7; Cl, 16.6. Found: C, 45.5; H, 3.8;N, 20.0; Cl, 16.2. ##STR187##

20.0 pts. by wt. of 1-(5-chlorofurylideneamino)-2-oxoimidazolidine, 31.8pts. by wt. of triethylamine, 31.8 pts. by wt. of chlorotrimethylsilaneand 18.6 pts. by wt. of phosgene are reacted as in Example 1.2.

This gives, after recrystallisation from acetonitrile, 16.5 pts. by wt.of 1-chlorocarbonyl-2-oxo-3-(5-chlorofurylideneamino)-imidazolidine ofdecomp. pt. 193°-196° C.

Calculated: Cl 25.68 Found: Cl 25.7. ##STR188##

3.9 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(5-chlorofurylideneamino)-imidazolidine and 5.0pts. by wt. of ampicillin trihydrate in 100 pts. by vol. of 80 percentstrength aqueous THF are reacted as in Example 1.3. This gives 4.7 pts.by wt. of sodium6-{D-α-[(2-oxo-3-{5-chloroflurylideneamino}-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-penicillanateof decomp. pt. 210°-220° C.

IR (KBr): 1760, 1720, 1660, 1525, 1470, 1405, 1270 and 1225 cm⁻¹.

NMR (CD₃ OD): 7.55 (s, 1H), 7.3 (m, 5H), 6.82 (d, 1H), 6.35 (d, 1H),5.56 (s, 1H), 5.43 (pseudo q, 2H), 4.12 (s, 1H), 3.82 (s, broad, 4H),1.55 (s, 3H) and 1.48 (s, 3H)δ.

C₂₅ H₂₄ ClN₆ NaO₇ S.11/2H₂ O Calculated: C, 47.06; H, 4.27; N, 13.18; S,5.04. Found: C, 47.1; H, 4.7; N, 13.2; S, 5.2. ##STR189##

5.0 pts. by wt. of cephaloglycine dihydrate in 100 pts. by vol. of 80percent strength aqueous THF and 3.5 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(5-chlorofurylideneamino)-imidazolidine arereacted as in Example 1.6. This gives 4.3 pts. by wt. of sodium7-{D-α-[(2-oxo-3-{5-chlorofurylideneamino}-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylateof decomp. pt. 185°-190° C.

IR (KBr): 1765, 1720, 1660, 1595, 1520, 1405 and 1225 cm⁻¹.

NMR (CD₃ OD/D₂ O): 7.48 (s) and 7.37 (m, a total of 6H), 6.78 (1H), 6.34(1H), 5.65 (1H), 5.43 (1H), 4.95 (overlaid by the signal of thereplaceable protons), 3.8 (s, broad, 4H), 3.6 (overlaid by the solventpeak) and 2.06 (s, 3H)δ.

EXAMPLE 24 ##STR190##

33.5 pts. by wt. of 2-bromofurane-5-aldehyde, dissolved in 100 pts. byvol. of THF, are added to a solution of 1-amino-2-oxo-imidazolidinehydrochloride in 350 pts. by vol. of water, adjusted to pH 5 with sodiumhydroxide solution, and the mixture is stirred overnight. Theprecipitate is filtered off, washed with water and recrystallised frommethanol. This gives 30.0 pts. by wt. of1-(5-bromofurylideneamino)-2-oxo-imidazolidine of decomp. pt. 153°-158°C.

IR (KBr): 1720, 1580, 1410, 1265 and 1245 cm⁻¹.

NMR (d₆ -DMSO): 7.55 (s, 1H), 7.31 (s, 1H), 6.80 (AB, 2H) and m at about3.6 (4H)δ. ##STR191##

30.0 pts. by wt. of 1-(5-bromofurylideneamino)-2-oxo-imidazolidine, 37.8pts. by wt. of triethylamine, 36.8 pts. by wt. of chlorotrimethylsilaneas well as 23.0 pts. by wt. of phosgene are reacted as in Example 1.2.

This gives, after recrystallisation from acetonitrile, 21.6 pts. by wt.of 1-chlorocarbonyl-2-oxo-3-(5-bromofurylideneamino)-imidazolidine ofdecomp. pt. 190°-194° C.

IR (liquid paraffin): 1815 cm⁻¹. ##STR192##

6.1 pts. by wt. of ampicillin trihydrate and 3.2 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(5-bromofurylideneamino)-imidazolidine in 80pts. by vol. of 80 percent strength aqueous THF are reacted as inExample 1.3. This gives 3.7 pts. by wt. of sodium6-{D-α-[(2-oxo-3-{5-bromofurylideneamino}-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-penicillanateof decomp. pt. 220°-228° C.

IR (KBr): 1760, 1725, 1660, 1600, 1400 and 1225 cm⁻¹.

NMR (CD₃ OD): 7.60 (s, 1H), 7.46 (s, 5H), 6.83 (d, 1H), 6.52 (d, 1H),5.58 (s, 1H), 5.50 (AB, 2H), 4.18 (s, 1H), 3.85 (s, broad, 4H), 1.57 (s,3H) and 1.50 (s, 3H)δ. ##STR193##

4.5 pts. by wt. of cephaloglycine dihydrate and 3.3 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(5-bromofurylideneamino)-imidazolidine in 100pts. by vol. of 80 percent strength aqueous THF are reacted as inExample 1.6. This gives 3.3 pts. by wt. of sodium7-{D-α-[(2-oxo-3-{5-bromofurylideneamino}-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylateof decomp. pt. 187°-196° C.

IR (KBr): 1775, 1715, 1655, 1450 and 1275 cm⁻¹.

NMR (CD₃ OD/D₂ O): 7.55 (s, 1H), 7.4 (m, 5H), 6.80 (d, 1H), 6.50 (d,1H), 5.68 (d, 1H), 5.50 (s, 1H), 4.96 (d, 1H), 4.92 (overlaid by thesignal of the replaceable protons), 3.80 (s, broad, 4H), 3.4 (overlaidby the solvent peak) and 2.08 (s, 3H)δ.

EXAMPLE 25 ##STR194##

98.3 pts. by wt. of 2-methylfurane-5-aldehyde are added to a solution of1-amino-2-oxo-imidazolidine hydrochlorde in 1,000 pts. by vol. of water,brought to pH 4.5 with sodium hydroxide solution, and the mixture isstirred overnight. The precipitate is filtered off, washed with waterand recrystallised from ethanol. This gives 126 pts. by wt. of1-(5-methylfurylideneamino)-2-oxo-imidazolidine of melting point 194°-6°C.

IR (KBr): 3320, 1735, 1710, 1480, 1420, 1395 and 1245 cm⁻¹.

NMR (d₆ -DMSO): 7.57 (s, 1H), 7.22 (s, broad, 1H), 6.67 and 6.25 (ABsystem, 2H), 3.65 (m, 4H) and 2.38 (s, 3H)δ.

Calculated: C, 55.95; H, 5.74; N, 21.75. Found: C, 56.0; H, 5.8; N,21.3. ##STR195##

50.0 pts. by wt. of 1-(5-methylfurylideneamino)-2-oxo-imidazolidine,84.3 pts. by wt. of triethylamine, 84.0 pts. by wt. ofchlorotrimethylsilane and 51.4 pts. by wt. of phosgene are reacted as inExample 1.2. This gives, after recrystallisation from acetonitrile, 50.7pts. by wt. of1-chlorocarbonyl-2-oxo-3-(5-methylfurylideneamino)-imidazolidine ofdecomp. pt. 180°-186° C.

IR (liquid paraffin): 1815 cm⁻¹. ##STR196##

6.1 pts. by wt. of ampicillin trihydrate and 2.6 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(5-methylfurylideneamino)-imidazolidine in 80pts. by vol. of 80 percent strength aqueous THF are reacted as inExample 1.3. This gives 4.2 pts. by wt. of sodium6-{D-α-[(2-oxo-3-{5-methylfurylideneamino}-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-penicillanateof decomp. pt. 210°-220° C.

IR (KBr): 1760, 1720, 1660, 1600, 1525 and 1410 cm⁻¹.

NMR (CD₃ OD): 7.62 (s, 1H), 7.35 (m, 5H), 6.75 (d, 1H), 6.13 (d, 1H),5.60 (s, 1H), 5.45 (AB, 2H), 4.18 (s, 1H) 3.83 (s, broad, 4H), 2.35 (s,3H), 1.56 (s, 3H) and 1.49 (s, 3H). ##STR197##

4.4 pts. by wt. of cephaloglycine dihydrate and 2.6 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(5-methylfurylideneamino)-imidazolidine in 80pts. by vol. of 80 percent strength aqueous THF are reacted as inExample 1.6. This gives 4.4 pts. by wt. of sodium7-{D-α-[(2-oxo-3-{5-methylfurylideneamino}-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylate.

IR (KBr): 1760, 1725, 1660, 1600, 1525, 1405 and 1225 cm⁻¹.

NMR (CD₃ OD): 7.70 (s, 1H), 7.40 (m, 5H), 6.80 (d, 1H), 6.20 (d, 1H),5.75 (d, 1H), 5.68 (s, 1H), 4.95 (m, overlaid by the signal of thereplaceable protons), 3.88 (s, broad, 4H), 3.45 (overlaid by the solventpeak), 2.35 (s, 3H) and 2.04 (s, 3H)δ.

EXAMPLE 26 ##STR198##

14.0 pts. by wt. of 5-methyl-3-formyl-isoxazole are reacted with 25.6pts. by wt. of 1-amino-2-oxo-imidazolidine hydrochloride in 100 pts. byvol. of water as in Example 25.1. After 90 minutes, the precipitate isfiltered off, washed with water, dried and recrystallised from absoluteacetonitrile. This gives 12.5 pts. by wt. of1-(5-methyl-isoxazol-3-yl-methyleneamino)-2-oxo-imidazolidine of meltingpoint 195°-7° C.

IR (liquid paraffin): 3220, 1695 and 1610 cm⁻¹.

NMR (CD₃ OD): 7.65 (s, 1H), 7.47 (s, broad, 1H), 6.53 (s, 1H), 3.7 (m,4H) and 2.50 (s, 3H)δ.

Calculated: C, 49.48; H, 5.19; N, 28.85. Found: C, 49.6; H, 5.2; N,29.2. ##STR199##

12.0 pts. by wt. of1-(5-methyl-isoxazol-3-yl-methyleneamino)-2-oxo-imidazolidine, 21.0 pts.by wt. of triethylamine, 20.8 pts. by wt. of chlorotrimethylsilane and12.3 pts. by wt. of phosgene are reacted as in Example 1.2.

This gives 19.8 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(5-methyl-isoxazol-3-yl-methyleneamino)-imidazolidineof melting point 199°-203° C. The compound still contains small amountsof triethylamine hydrochloride, which do not need to be removed sincethey are not troublesome in the subsequent reaction.

IR (liquid paraffin): 1790 cm⁻¹. ##STR200##

16.5 pts. by wt. of ampicillin trihydrate and 9.5 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(5-methylisoxazol-3-yl-methyleneamino)-imidazolidinein 100 pts. by vol. of 80 percent strength aqueous THF are reacted as inExample 1.6. This gives 1.0 pt. by wt. of sodium6-{D-α-[(2-oxo-3-{5-methylisoxazol-3-yl-methyleneamino}-imidazolidin-3-yl)-carbonylamino]-phenylacetamido}-penicillanate.

IR (KBr): 1760, 1730, 1660, 1600, 1525, 1395 and 1225 cm⁻¹.

NMR (CD₃ OD/D₂ O): 7.72 (s, 1H), 7.38 (s, 5H), 6.62 (s, 1H), 5.53 (s,1H), 5.43 (m, 2H), 4.13 (s, 1H), 3.90 (m, 4H), 2.45 (s, 3H), 1.53 (s,3H) and 1.48 (s, 3H)δ. ##STR201##

18.1 pts. by wt. of cephaloglycine dihydrate and 9.5 pts. by wt. of1-chlorocarbonyl-2-oxo-3-(methylisoxazol-3-yl-methyleneamino)-imidazolidinein 150 pts. by vol. of 80 percent strength aqueous THF are reacted as inExample 1.6.

This gives 2.2 pts. by wt. of sodium7-{D-α-[(2-oxo-3-{5-methyl-isoxazol-3-yl-methyleneamino}-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylate.Decomp. pt. 215°-220° C.

IR (KBr): 1760, 1730 (shoulder), 1670, 1595 and 1395 cm⁻¹.

NMR (CD₃ OD/D₂ O): 7.74 (s, 1H), 7.38 (s, 5H), 6.63 (s, 1H), 5.65 (d,1H), 5.50 (s, 1H), 4.95 (overlaid by the signal of the replaceableprotons), 3.90 (s, broad, 4H), 3.4 (overlaid by the solvent peak), 2.45(s, 3H) and 2.05 (3, 3H)δ.

EXAMPLE 27 ##STR202##

2-(Diacetoxymethyl)-5-nitro-furane (48.6 pts. by wt.) are boiled in amixture of water (216 pts. by vol.) and concentrated H₂ SO₄ (108 pts. bywt.) for 15 minutes under N₂, the mixture is then cooled and the5-nitro-furfurol formed is taken up in ether and, after removing theether, dissolved in 100 pts. by vol. of methanol. A solution of1-amino-2-oxo-imidazolidine hydrochloride (27.5 pts. by wt.) in water(100 pts. by vol.) is added to this solution. After 4.5 hrs., theproduct which has separated out is filtered off, washed with water anddried.

Yield: 42.1 pts. by wt.

Melting point=259°-260° C. (Kofler heated stage)

Calculated: C, 42.9; H, 3.6; N, 25.0; O, 28.6. Found: C, 42.8; H, 3.7;N, 25.2; O, 29.1. ##STR203##

8.0 pts. by wt. of the product described above (27.1.) are silylated inthe manner described in Example 1.2. and then reacted with phosgene (2.6pts. by vol.).

Yield: 5.2 pts. by wt.

Melting point=188°-190° C. (Kofler stage)

The substance still contains some triethylamine hydrochloride (themajority is removed by washing with dichloromethane) which, however, isnot troublesome in the further reaction. ##STR204##

This penicillin is obtained when ampicillin trihydrate (1.5 pts. by wt.)is reacted with1-chlorocarbonyl-2-oxo-3-(5-nitro-furylideneamino)-imidazolidine (1.1pts. by wt.) in the manner described in Example 1.3. This gives, afterworking up, 0.7 pt. by wt. of the crude sodium salt. For purification,this is suspended in a little water and the undissolved material isfiltered off and dried (1st yield: 0.3 pt. by wt.). The aqueous filtrateis covered with a layer of ethyl acetate and acidified down to pH 1.5and the sodium salt is precipitated from this mixture in the manneralready described (2nd yield: 0.2 pt. by wt.).

Total yield: 0.5 pt. by wt. of sodiumD-α-{[2-oxo-3-(5-nitrofurylideneamino)-imidazolidin-1-yl]-carbonylamino}-benzylpenicillin.

β-Lactam content (according to the NMR spectrum and elementaryanalysis): 44%. The substance also contains 44% of the product with anopen β-lactam ring (the reaction mixture had stood at 20° C. for arelatively long time after the acidification).

According to the NMR spectrum and the analysis, the substance contains(including that consumed in the opening of the β-lactam ring) 4.8 molarequivalents of water. This was taken into consideration in the followingcalculated analysis data:

Calculated: C, 42.4; H, 4.8; N, 13.8; S, 4.5. Found: C, 42.1; H, 4.8; N,13.8; S, 4.3.

Melting point=decomposition from about 260° C.

IR spectrum (carbonyl range): 1775 (shoulder), 1745, 1665, 1590 and 1515cm⁻¹ (in Nujol). ##STR205##

This cephalosporin is obtained when cephaloglycine dihydrate (4.0 pts.by wt.) is reacted with1-chlorocarbonyl-2-oxo-3-(5-nitro-furylidene-amino)-imidazolidine (2.5pts. by wt.) with one another in the manner described in Example 1.3.and 1.6. On acidifying the reaction mixture, freed fromtetrahydrofurane, only some of the cephalosporic acid formed dissolvesin the ethyl acetate. The rest precipitates. The sodium salt is thenobtained from the two fractions in the manner already described.

Yield: 2.8 pts. by wt. of sodium7-{D-α-[(2-oxo-3-{5-nitro-furylideneamino}-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylate.

Melting point=decomposition from about 230° C.--up to 260° C., but noclear melt (Kofler heated stage)

β-Lactam content (determined iodometrically) 84%.

NMR signals at τ=1.95-2.9 (8H), 4.1-4.5 (2H), 4.9-5.2 (3H), (in d₆ -DMF)6.0 (4H), 6.6-6.85 (2H and 8.0 ppm/3H).

IR spectrum (carbonyl range): 1765 (shoulder), 1725, 1670, 1600 and 1510cm⁻¹ (in Nujol).

EXAMPLE 28 ##STR206##

This substance is obtained from 1-amino-2-oxoimidazolidine (1.2 pts. bywt.) and 5-methoxycarbonyl-furfural (1.8 pts. by wt.) in aqueousmethanol (1:1; 12 pts. by vol.) at 20° C. in 60 minutes.

Yield: 2.7 pts. by wt.

Melting point=sticky from 88° C. (Kofler stage). ##STR207##

2.6 pts. by wt. of the product described above (29.1.) are silylated inthe manner described in Example 1.2. and then reacted with phosgene (0.8pt. by vol.).

Yield: 1.5 pts. by wt.

Melting point=(crude product, still contains some triethylaminehydrochloride)=about 220° C., decomposition (Kofler stage). ##STR208##

This penicillin is obtained from 0.87 pt. by wt. of ampicillintrihydrate when this compound is reacted with 0.65 pt. by wt. of1-chlorocarbonyl-2-oxo-3-(5-methoxycarbonylfurylidene-amino)-imidazolidine,in the manner described in Example 1.3.

Yield: 0.5 pt. by wt. of sodiumD-α-{[2-oxo-3-(5-methoxycarbonyl-furylidene-amino)-imidazolidin-1-yl]-carbonylamino}-benzylpenicillin.

β-Lactam content (determined iodometrically): 80%.

Melting point=185°-210° C., decomposition (Kofler stage).

IR spectrum (carbonyl range): 1770, 1730, 1670, 1605 and 1530 cm⁻¹ (inNujol).

EXAMPLE 29 ##STR209##

This substance is obtained from 1-amino-2-oxo-imidazolidine (1.3 pts. bywt.) and 5-ethoxycarbonyl-furfural (2.6 pts. by wt.) in aqueousmethanol.

Yield: 3.1 pts. by wt.

Melting point (crude product)=135°-138° C. (Kofler stage). ##STR210##

2.85 pts. by wt. of th product described above (30.1.) are silylated inthe manner described in Example 1.2. (but using dioxane as the solvent)and then reacted with phosgene (0.9 pt. by vol.)

Yield: 1.1 pts. by wt.

Melting point=230°-33° C. (Kofler stage) (crude product). ##STR211##

This penicillin is obtained when ampicillin trihydrate (1.3 pts. by wt.)is reacted with1-chlorocarbonyl-2-oxo-3-(5-ethoxycarbonyl-furylidene-amino)-imidazolidine(1.0 pt. by wt.) with one another in the manner described in Example1.3.

Yield: 0.8 pt. by wt. of sodiumD-α-{[2-oxo-3-(5-ethoxycarbonyl-furylidene-amino)-imidazolidin-1-yl]-carbonylamino}-benzylpenicillin.

β-Lactam content (determined iodometrically): 92% (the substancecontains about 6% of the product with an open β-lactam ring).

Melting point=about 220° C., decomposition (Kofler stage).

IR spectrum (carbonyl range): 1775-1790, 1740, 1675, 1610 and 1520-1540cm⁻¹ (in Nujol).

According to the analysis and the NMR data, the penicillin containsabout 4.3 molar equivalents of water and 0.16 molar equivalent of sodium2-ethylhexanoate.

This was taken into consideration in the following calculated analysisfigures:

Calculated: C, 46.7; H, 5.3; N, 11.2; S, 4.3. Found: C, 46.7; H, 5.6; N,11.2; S, 4.5.

EXAMPLE 30 ##STR212##

This precursor is obtained when 1-amino-2-oxo-imidazolidinehydrochloride (6.9 pts. by wt.) is dissolved in 1 N sodium hydroxidesolution (50 pts. by vol.), 4-tertiarybutyl-benzaldehyde (8.0 pts. bywt.) is added and the mixture is stirred for 24 hrs. at 20° C. Theproduct which has precipitated is recrystallised from acetonitrile.

Yield: 5.9 pts. by wt.

Melting point=208° C. (Kofler stage). ##STR213##

This substance is obtained, using the procedure described in Example1.2., from the product (5.5 pts. by wt.) described above (31.1.), aftersilylation with triethylchlorosilane (4.4 pts. by wt.) and subsequentreaction with phosgene (2.1 pts. by vol.), using dioxane as the solvent.

The substance still contained some triethylamine hydrochloride.

IR spectrum (COCl): 1808 cm⁻¹ (in Nujol). ##STR214##

This penicillin is obtained when ampicillin trihydrate (2.2 pts. by wt.)is reacted with 1-chlorocarbonyl-2-oxo-3-(4-tertiarybutyl-benzalimino)-imidazolidine (see above; 2.0 pts. by wt.) using theprocedure described in Example 1.3.

Yield: 2.7 pts. by wt. of sodium 6-{D-α-[(2-oxo-3-{4-tertiarybutyl-benzalimino}-imidazolidin-1-yl)-carbonylamino]phenylacetamido}-penicillanate.

β-Lactam content (iodometrically): 83% (the penicillin contained about10% of the product with an open β-lactam ring).

Melting point=tacky from about 240° C., a dark melt at about 259° C.,which rapidly solidified again as a result of decomposition.

NMR signals at τ=2.15-2.8 (10H), 4.4 (1H), 4.4-4.65 (2H), (in CD₃ OD)5.85 (1H), 6.3 (broad, 4H), 8.45 (3H), 8.52 (3H) and 8.75 ppm (9H).

The NMR spectrum shows that the substance contains about 1.8 molarequivalents of water. This was taken into consideration in thecalculated analysis figures:

Calculated: C, 55.1; H, 5.8; N, 12.4; S, 4.7. Found: C, 55.1; H, 5.9; N,12.4; S, 4.8.

IR spectrum (carbonyl range): 1772, 1730, 1672, 1610 and 1515-1530 cm⁻¹(in Nujol).

EXAMPLE 31 ##STR215##

To prepare this cephalosporin, cephaloglycine dihydrate (1.5 pts. bywt.) and1-chlorocarbonyl-2-oxo-3-(3-pyridylmethylidene-amino)-imidazolidine (0.8pt. by wt.) are reacted in the manner described in Examples 1.3. and1.6. After removing the tetrahydrofurane and acidifying the mixture topH 1.5, the free cephalogsporic acid separates out as a precipitate (0.8pt. by wt.; melting point: decomposition from about 200° C.-to 260° C.,no clear melt [Kofler heated stage]; IR bands at 1770, 1745, 1675 and1520-1550 cm⁻¹ [Nujol]), which is insoluble in water and ethyl acetate.This acid is dissolved in a little dimethylformamide, 1.3 pts. by vol.of an approximately 1 molar sodium 2-ethylhexanoate solution inmethanol-containing ether are added and the sodium salt of thecephalosporin is precipitated with ether.

Yield: 0.6 pt. by wt. of sodium7-{D-α-[(2-oxo-3-{3-pyridyl-methylidene-amino}-imidazolidin-1-yl)-carbonylamino]phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylate.

Melting point=on sprinkling the finely powdered substance onto theKofler heated stage, it melts briefly to give a clear melt from 242° C.and then decomposes and solidifies immediately--no further melting up to260° C.

IR spectrum (carbonyl range): 1770 (shoulder), 1760, 1730, 1670, 1605and 1530-50 cm⁻¹ (in Nujol).

According to the NMR spectrum, the substance contains about 5.5 molarequivalents of water and 0.26 molar equivalent of sodium2-ethylhexanoate. This was taken into consideration in the followingcalculated analysis figures:

Calculated: C, 45.9; H, 5.2; N, 12.5. Found: C, 45.9; H, 5.3; N, 12.4.

β-Lactam content: (determined iodometrically) 82%.

EXAMPLE 32 ##STR216##

11.0 pts. by wt. of7-(D-α-amino-phenylacetamido)-3-hydroxymethyl-ceph-3-em-4-carboxylicacid in 100 pts. by vol. of 80 percent strength aqueous THF and 6.1 pts.by wt. of 1-chlorocarbonyl-2-oxo-3-furylideneamino-imidazolidine arereacted as in Example 1.6. and the mixture is worked up. This gives 6.9pts. by wt. of sodium7-{D-α-[(2-oxo-3-furylideneamino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-hydroxymethyl-ceph-3-em-4-carboxylateof decomp. pt. 215°-220° C.

NMR (CD₃ OD): 7.80 (s, 1H), 7.70 (s, 1H), 6.97 (q, 1H), 5.75 (d, 1H),5.63 (s, 1H), 5.37 (overlaid by the replaceable protons), 4.40 (s, 2H),3.95 (s, broad, 4H), the C-2 protons are overlaid by the solvent peak(in δ).

EXAMPLE 33 ##STR217##

7.5 pts. by wt. of7-(D-α-amino-phenylacetamido)-3-[(3-methyl-thiadiazol-5-yl)-thiomethyl]-ceph-3-em-4-carboxylicacid in 100 pts. by vol. of 80 percent strength aqueous THF and 6.1 pts.by wt. of 1-chlorocarbonyl-2-oxo-3-furylideneamino-imidazolidine arereacted as in Example 1.6. and the mixture is worked up.

This gives 5.2 pts. by wt. of sodium7-{D-α-[(2-oxo-3-furylideneamino-imidazolidin-1-yl)-carbonylamino]phenylacetamido}-3-[(3-methyl-thiadiazol-5-yl)-thiomethyl]-ceph-3-em-4-carboxylateof decomp. pt. 210°-215° C.

IR (KBr): 1760, 1720, 1660, 1595, 1525, 1475, 1410, 1275 and 1230 cm⁻¹.

NMR (CD₃ OD): 7.70 (s, 1H), 7.64 (d, 1H), 7.33 (m, 5H), 6.86 (d, 1H),6.50 (dd, 1H), 5.65 (d, 1H), 5.55 (s, 1H), 4.90 (d, 1H), 4.02 (pseudo q,2H), 3.85 (s, broad, 4H), 3.4 (overlaid by the solvent peak) and 2.52(s, 3H) δ.

EXAMPLE 34 ##STR218##

5.0 pts. by wt. of7-(D-α-amino-phenylacetamido)-3-[(1-methyltetrazol-5-yl9-thiomethyl]-ceph-3-em-4-carboxylicacid in 100 pts. by vol. of 80 percent strength aqueous THF and 6.1 pts.by wt. of 1-chlorocarbonyl-2-oxo-3-furylideneaminoimidazolidine arereacted as in Example 1.6. and the mixture is worked up. This gives 3.2pts. by wt. of sodium7-{D-α-[(2-oxo-3-furylideneamino-imidazolidin-1-yl)-carbonylamino]phenylacetamido}-3-[(1-methyl-tetrazol-5-yl)-thiomethyl]ceph-3-em-4-carboxylateof decomp. pt. 210°-220° C.

IR (KBr): 1760, 1720, 1660, 1610, 1520, 1475, 1410 and 1230 cm⁻¹.

NMR (CD₃ OD): 7.73 (s, 1H), 7.63 (d, 1H), 7.38 (m, 5H), 6.88 (d, 1H),6.54 (q, 1H), 5.67 (d, 1H), 5.56 (s, 1H), 4.9 (overlaid by thereplaceable protons), 4.32 (s, 2H), 3.95 (s, 3H), 3.85 (s, broad, 4H)and 3.45 (overlaid by the solvent peak) δ.

EXAMPLE 34a ##STR219##

8.0 pts. by wt. of7-(D-α-amino-phenylacetamido)-3-[(5-trifluoromethyl-1,3,4-thiadiazol-2-yl)-thiomethyl]-ceph-3-em-4-carboxylicacid in 100 pts. by vol. of 80 percent strength aqueous THF and 6.1 pts.by wt. of 1-chlorocarbonyl-2-oxo-3-furylideneamino-imidazolidine arereacted as in Example 1.6. and the mixture is worked up.

This gives 7.8 pts. by wt. of sodium7-{D-α-[(2-oxo-3-furylideneamino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-[(5-trifluoromethyl-1,3,4-thiadiazol-2-yl)-thiomethyl]-ceph-3-em-4-carboxylateof decomp. pt. 220° C. with a β-lactam content of 76%.

IR (liquid paraffin): carbonyl range: 1765, 1720, 1660, 1600 and 1530cm⁻¹.

EXAMPLE 35 (35.1.) Preparation of the1-alkylideneamino-imidazolidin-2-ones

0.10 mol of 1-aminoimidazolidin-2-one and 50 mg of p-toluenesulphonicacid as well as 15 g of a molecular sieve (4 A) are added to a solutionof 0.12 mole of the freshly distilled aliphatic aldehyde in 100 ml ofabs. acetonitrile. After standing for 3 days at room temperature (thereaction product partially crystallises out during this period) themolecular sieve is separated off, the reaction mixture is concentratedand the residue is recrystallised (Table 35.1.).

    __________________________________________________________________________    TABLE for Example 35.1                                                        __________________________________________________________________________     ##STR220##                                          (B)                                     Melting point,                                                 Example        recrystallised                                                                           IR (KBr)                                                                            NMR in   calculated:                          No.   R        from   Yield                                                                             in cm.sup.-1                                                                        ppm (δ)                                                                          found:                                                                              C  H  N                        __________________________________________________________________________    35.1.1                                                                             CH.sub.3  174-7°                                                                        19.4%                                                                             3300, 1730,                                                                         CD.sub.3 OD:   47.23                                                                            7.13                                                                             33.05                                   Acetone    1690, 1490,                                                                         q 6.99 (1H),   47.2                                                                             7.1                                                                              32.7                                               1420, 1270,                                                                         m 3.62 (4H)                                                             1220  d 2.00 (3H)                                   35.1.2                                                                             CH.sub.3CH.sub.2                                                                        116-7°                                                                        35.3%                                                                             3300, 1740,                                                                         CD.sub.3 OD:   51.06                                                                            7.86                                                                             29.77                                   Ethyl acetate                                                                            1695, 1480,                                                                         t 7.00 (1H),   51.7                                                                             7.9                                                                              29.7                                               1415, 1265                                                                          m 2.40 (2H),                                                                  pseudo t 1.17                                                                 (3H)                                          35.1.3                                                                              ##STR221##                                                                             152-8° Acetonitrile                                                           45.8%                                                                             3290, 1740, 1700, 1460, 1410,                                                       CD.sub.3 OD: d 6.86 (1H), m 3.60 (4H),                                        sep 2.55 (1H), s 1.16 (3H), s 1.05                                                           54.18 54.3                                                                       8.44 8.3                                                                         27.08 27.9               35.1.4                                                                              ##STR222##                                                                             186-8° Isopropanol                                                            51.9%                                                                             3340, 1740-1690, 1470, 1410, 1250,                                                  CD.sub.3 OD: s 6.90 (1H), m 3.59 (4H), s                                      1.17 (9H)      56.78 56.7                                                                       8.93 9.0                                                                         24.83 24.6               35.1.5                                                                             CH.sub.3CHCH                                                                            209-13°                                                                       83.1%                                                                             3290, 1730,                                                                         CD.sub.3 OD:   54.89                                                                            7.24                                                                             27.43                                              1700, 1480,                                                                         d 7.33 (1H),   54.5                                                                             7.1                                                                              27.2                                               1405, 1255                                                                          m 6.25 (2H),                                                                  m 3.63 (4H),                                                                  d 1.87 (3H)                                   35.1.6                                                                              ##STR223##                                                                             243-7°                                                                        81.3%                                                                             3200, 3100,  1705, 1405, 1265,                                                      d.sub.6 -DMSO: d 7.53 (1H), s (broad)                                         7.20 (NH), d 6.05 (1H), m at about 3.6                                        (4H), s 1.90 (6H)                                                                            57.46 57.4                                                                       7.84 7.8                                                                         25.13 25.1               35.1.7                                                                              ##STR224##                                                                             145-8°                                                                        61.6%                                                                             3280, 1740-1710, 1405, 1255, 1220                                                   d.sub.6 -acetone: d 7.05 (1H), s 5.69                                         (2H), m 3.6-3.3 (5H), m at about 2.05 (+                                      solvent peak)  62.15 61.5                                                                       7.82 6.9                                                                         21.75 21.8               35.1.8                                                                              ##STR225##                                                                             133-4° Acetone                                                                64.0%                                                                             3400, 3260, 1690, 1440, 1280,                                                       CD.sub.3 OD: s 6.83 (1H), m 3.59 (4H), s                                      3.49 (3H), s 1.10 (6H)                                                                       51.87 51.6                                                                       8.16 8.1                                                                         22.69 22.6               __________________________________________________________________________

(35.2.) Preparation of the1-alkylideneamino-3-chlorocarbonylimidazolidin-2-ones

First 60 mmols of phosgene and then 60 mmols of tributylamine are addedto a suspension of 60 mmols of the 1-alkylideneamino-imidazolidinonecompound in 100 ml of abs. ethyl acetate at 0°-5°. The mixture isstirred overnight at room temperature and thereafter dry nitrogen isbubbled through for 1 hour. The sparingly soluble acid chlorides arefiltered off and further reacted directly. In the case of the morereadily soluble acid chlorides (R═CH₃ --, CH₃ --CH₂ or (CH₃)₂ CH--), thereaction mixture is concentrated and the residue is used for the furtherreactions.

The acid chlorides are characterised by the appearance of the COCl bandat about 1800 cm⁻¹ (Table 35.2.).

    ______________________________________                                        TABLE for Example 35.2                                                        ______________________________________                                         ##STR226##                                                                   Example                                                                       No.       R              IR (Nujol) in cm.sup.-1                              ______________________________________                                        35.2.1    CH.sub.3       1820                                                 35.2.2    CH.sub.3CH.sub.2                                                                             1800                                                 35.2.3                                                                                   ##STR227##    1820                                                 35.2.4                                                                                   ##STR228##    1800                                                 35.2.5    CH.sub.3CHCH   1810                                                 35.2.6                                                                                   ##STR229##    1810                                                 35.2.7                                                                                   ##STR230##    1820                                                 ______________________________________                                    

(35.3) Preparation of the acylated ampicillins, amoxicillins,dephaloglycines and 7-methoxy-cephaloglycines

15-50 mmols of ampicillin trihydrate, amoxicillin trihydrate,cephaloglycine dihydrate or 7-methoxycephaloglycine trifluoroacetate aresuspended in 100-150 ml of 80% strength aqueous THF and 4% strengthsodium hydroxide solution is added at 5° until the pH remains constantat 8.1. The equivalent amount of acid chloride is then added and 2%strength sodium hydroxide solution is added dropwise until the pHremains constant at 7.5. The small amount of undissolved material isfiltered off, 100 ml of water are added to the filtrate and the THF isstripped off. The aqueous phase is extracted with 100 ml of ethylacetate and the extract is cooled to 5°, covered with a layer of 100 mlof ethyl acetate and brought to pH 1.8 by adding dropwise 0.1 Nhydrochloric acid. During this procedure, some of the acid precipitates(A) and some dissolves in the ethyl acetate (B). (The particularquantitative proportion depends on the solubility of the correspondingderivative).

(A) is dissolved in methanol, the equivalent amount of sodium caprylatesolution is added and (A) is precipitated as the sodium salt by pouringthe mixture into abs. ether containing 5% of methanol.

(B) is dried over magnesium sulphate, sucked up and reacted with sodiumcaprylate solution in the same manner as (A).

The sodium salts are freed from ether under a high vacuum and then driedin ethyl acetate over P₂ O₅.

The β-lactam content was determined from the NMR spectra (Table 35.5).

    __________________________________________________________________________    TABLE for Example 35.3                                                        __________________________________________________________________________     ##STR231##                                                                   Example                   β-Lactam                                                                      IR (KBr)                                       No.  R          R'    Yield                                                                             content                                                                            in cm.sup.-1                                                                            NMR (CD.sub.3 OD) in ppm                                                      (δ)                            __________________________________________________________________________    35.3.1                                                                             CH.sub.3                                                                 ampi                  44.0%                                                                             85%  3420, 1760, 1720,                                                                       m 7.6 (5H), s 5.58 (1H), AB                                                   5.45                                                                1630, 1600, 1520                                                                        (2H), s 4.15 (1H), m 3.8 (4H),                                                d                                                                             2.02 (3H), s 1.57 (3H), s 1.49                                                (3H)                                 35.3.2                                                                             CH.sub.3                                                                 amoxi                                                                              76.6%      60%   3320, 1760, 1665,                                                                 A.sub.2 B.sub.2 + q 7.20 and 6.72 (5H), m 5.4                                      1600, 1510, 1260                                                                        (3H), s 4.13 (1H), m at about                                                 3.5                                                                           (4H), d 2.00 (3H), s 1.50 (3H)       35.3.3                                                                             CH.sub.3                                                                 cephgly                                                                            74.6%      80%   3420, 3380, 1760,                                                                 m at about 7.25 (5H), q 7.20 (1H),                                                 1720, 1665, 1600,                                                                       s 5.58 (1H), d 4.9 (1H), AB                                                   ˜ 4.85                                                        1410, 1380, 1220                                                                        (2H), m 3.75 (4H), AB 3.3 (2H),                                               s                                                                             2.00 (3H), d 8.01 (3H)               35.3.4                                                                             CH.sub.3CH.sub.2                                                         ampi 29.7%      75%   3380, 1765, 1730,                                                                 m 7.3 (5 + 1H), m 5.5 (3H), s 4.1                                                  1670, 1600, 1520,                                                                       (1H), m 3.7 (4H), m 2.4 (2H), s                                     1410      1.55 (3H), S 1.50 (3H)               35.3.5                                                                             CH.sub.3CH.sub.2                                                         chephygly                                                                          44.0%      80%   3310, 1765, 1725,                                                                 m 7.35 (5H), t 7.15 (1H), d 5.67                                                   1605, 1530, 1410,                                                                       (1H), s 5.58 (1H), d 4.92 (1H),                                               AB                                                                  1220      4.86 (2H), m 3.8 (4H), AB                                                     ˜ 3.3, m                                                                2.4 (2H), s 2.00 (3H)                35.3.6                                                                              ##STR232##                                                              ampi 80.1%      90%   3400, 1760, 1720, 1660, 1600, 1520, 1410,                                         m 7.4 (5H), d 7.03 (1H), s 5.60 (1H), AB 5.45                                 (2H), s 4.15 (1H), m 3.77 (4H), septet 2.59                                   (1H), s 1.56  (3H), s 1.50 (3H), d 1.12 (6H)        35.3.7                                                                              ##STR233##                                                              ampi 93.3%      90%   3300-3500, 1760, 1725, 1665, 1600, 1520,                                          m at about 7.35 (5H), s 7.08 (1H), s 5.58 (1H),                               AB 5.45 (2H), s 4.15 (1H), m 3.76 (4H), s 1.58                                (3H), s 1.50 (3H), s 1.15 (9H)                      35.3.8                                                                              ##STR234##                                                              amoxi                                                                              97.1%      90%   3310, 1760, 1730, 1670, 1610, 1410                                                A.sub.2 B.sub.2 7.25 and 6.75 (4H), s 7.04                                    (1H), m 5.42 (3H), s 4.12 (1H), m 3.75 (4H), s                                1.55 (3H), s 1.48 (3H), s 1.12 (9H)                 35.3.9                                                                              ##STR235##                                                              cephygly                                                                           90.9%      80%   3300, 1760, 1720, 1660, 1600, 1400, 1260                                          m at about 7.35 (5H), s 7.06 (1H), d 5.56 (1H),                               s 5.58 (1H), d 4.90 (1H), AB 4.85 (2H), m 3.75                                (4H), AB ˜ 3.3, s 2.00 (3H), s 1.14 (9H)      35.3.10                                                                            CH.sub.3CHCH                                                             ampi 81.5%      85%   3320, 1765, 1715,                                                                 m 7.35 (5 + 1H), m 6.27 (2H), s 5.55                                               1670, 1600, 1515,                                                                       (1H), AB 5.42 (2H), s 4.22 (1H),                                              m                                                                   1410, 1265, 1215                                                                        3.75 (4H), m 1.84 (3H), s 1.54                                                (3H),                                                                         s 1.46 (3H)                          35.3.11                                                                            CH.sub.3CHCH                                                             amoxi                                                                              57.3%      90%   3400, 1760, 1720,                                                                 pseudo d 7.43 (1H), A.sub.2 B.sub.2 7.22 and                                  6.77                                                                               1660, 1600, 1410,                                                                       (4H), d 6.28 (2H), AB + s                                                     5.50-5.33 (3H),                                                     1260, 1210                                                                              s 4.12 (1H), m 3.78 (4H), m 1.87                                              (3H),                                                                         s 1.54 (3H), s 1.48 (3H)             35.3.12                                                                            CH.sub.3CHCH                                                             cephgly                                                                            88.2%      80%   3440, 1760, 1720,                                                                 m at about 7.35 (5 + 1H), dd 6.26 (2H),                                            1665, 1600, 1425,                                                                       d 5.63 (1H), s 5.52 (1H), m at                                                about                                                               1410, 1265, 1220                                                                        4.85 (3H), m 3.8 (4H), AB                                                     ˜ 3.3, s                                                                1.98 (3H)                            35.3.13                                                                             ##STR236##                                                              ampi 87.2%      90%   3400, 1760, 1720, 1660, 1600, 1515, 1410, 1260,                               1220                                                                              d 7.63 (1H), m 7.3 (5H), d 6.05 (1H), s 5.58                                  (1H), AB 5.38 (2H), s 4.08 (1H), s 1.88 (6H), s                               1.55 (3H), s 1.46 (3H)                              35.3.14                                                                             ##STR237##                                                              cephgly                                                                            75.9%      80%   3420, 1755, 1720, 1665, 1605, 1920, 1410, 1370,                               1270, 1220                                                                        d 7.65 (1H), m 7.3 (5H), d 6.05 (1H), d + s 5.5                               (2H), m 4.85 (3H), m 3.8 (4H), AB ˜ 3.3                                 (covered), s 1.98 (3H), s 1.88 (6H)                 35.3.15                                                                             ##STR238##                                                              ampi 92.3%      90%   3400, 3300, 1799, 1720, 1600, 1919, 1405, 1270,                               1219                                                                              m 7.3 (5H), d 7.02 (1H), s (broad), 5.67 (2H),                                s 5.58 (1H), AB 5.45 (2H), s 4.13 (1H), m 3.8                                 (5H), m 2.6 (2H?), m 2.15 (4H), s 1.58 (3H), s                                1.50 (3H)                                           35.3.16                                                                             ##STR239##                                                              cephgly                                                                            79.3%      85%   3280, 1760, 1715, 1660, 1600, 1920, 1410, 1270,                               1220                                                                               m 7.35 (5H), d 7.08 (1H), m 5.75-5.55 (4H), d                                4.9 (1H), AB 4.88 (2H), m 3.75 (5H), AB ˜                               3.3 (covered), m + s 2.15 and 2.00 (5H?)            35.3.17                                                                            CH.sub.3   7-methoxy-                                                                          61.2%                                                                             85%  3430, 3380, 2850,                                                                       m at about 7.25 (5H), d 7.20                                                  (1H), s                                              cephgly.       1760, 1720, 1665,                                                                       5.58 (1H), s 9.9 (1H), a,b                                                    ˜ 4.84 (2H),                                                  1600, 1430, 1385                                                                        s 9.45 (3H), m 3.75 (4H), a,b                                                 3.3 (2H),                                                                     s 2.05 (3H), d 2.00 (3H)             35.3.18                                                                             ##STR240##                                                                              7-methoxy- cephgly.                                                                 60.8%                                                                             80%  3425, 2855, 1765, 1720, 1660, 1600, 1510,                                     1410, 1385                                                                              d 7.65 (1H), m 7.3 (5H), d 6.05                                               (1H), s 5.6 (1H), m 4.9 (3H), m                                               3.85 (4H), s 3.45 (3H), a,b                                                   ˜ 3.3 (2H) (covered), s                                                 2.00 (3H), s 1.9                     __________________________________________________________________________                                             (6H)                             

EXAMPLE 36 ##STR241##

1.65 pts. by wt. of7-methoxy-7-(D-α-aminophenylacetamido)-3-acetoxymethyl-ceph-3-em-carboxylicacid trifluoroacetate are dissolved in 120 parts by vol. of 80% strengthaqueous THF and the solution is adjusted to a pH value of 7.5 withdilute NaOH, whilst cooling with ice. 0.65 part by wt. of1-chlorocarbonyl-2-oxo-3-but-2-enylideneamino-imidazolidine in 150 partsby wt. of THF are added to this solution at 0° C., whilst stirring; atthe same time, enough dilute NaOH to keep the pH value at ˜7.5 and afurther 40 parts by vol. of water are added.

After one hour, the clear solution is concentrated to ˜100 parts by vol.and extracted twice with acetic acid ethyl ester and the aqueous phaseis then acidified to pH 2.0 with dilute HCl (cooling with ice) andextracted several times with ethyl acetate/acetone.

The organic phases are dried over MgSO₄ and slowly concentrated; duringthis procedure, 1.2 parts by wt. of7-methoxy-7-{D-α-[(2-oxo-3-but-2-enylideneamino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylicacid crystallise out; β-lactam content >85%.

IR spectrum (KBr) 3396, 2913, 2720, 1780, 1675, 1459, 1378, 1267, 973,875 and 720;

NMR spectrum (acetone+10% H₂ O) m 7.5 (1), s 7.3 (5H), m 6.2 (2H), s 5.5(1H), s 5.0 (1H), A,B 4.8 (2H), m 3.7 (4H) (covered), s 3.45 (3H), A,B3.35 (2H), s 1.95 (3H), m 1.85 (3H).

EXAMPLE 37 ##STR242##

(A) 1.1 parts by wt. of7-methoxy-7-(D-α-aminophenylacetamido)-3-acetoxymethyl-ceph-3-em-carboxylicacid trifluoroacetate are dissolved in 60 parts by vol. of 80% strengthaqueous THF, the solution is brought to pH=7.5 with dilute NaOH, whilstcooling with ice, and 0.5 part by wt. of solid1-chlorocarbonyl-2-oxo-3-furfurylideneamino-imidazolidine is added at 0°C., whilst stirring. The pH value is kept at 7.5 with dilute NaOH. Afterhalf an hour, the reaction has ended and the mixture is worked up asdescribed under Example 1.3 or 6.4.

This gives 0.8 part by wt. of crystalline7-methoxy-7-{D-α[(2-oxo-3-furfurylideneamino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylicacid; β-lactam content 85%.

100 MHz--1H--NMR spectrum (acetone (D₂ O)

s 2.0 3H, A,B 3.3 2H, s 3.45 3H, s 3.8 2H, A, B 4.8 2H, s 4.9 1H, s 5.71H, q 6.5 1H, d 6.8 1H, s 7.4 5H, d 7.55 1H and s 7.7 1H.

(B) Alternatively, this compound can also be obtained in the followingmanner:

1. 30.5 parts by wt. of the acid prepared according to Example 6.4 areesterified on the carboxylic group with 15.5 parts by wt. ofbiphenyldazomethane.

600 parts by vol. of THF are used as the solvent. After 12 hours, thesolution is concentrated and washed with n-pentane until a colourlesssubstance remains. This procedure gives 37.2 parts by wt. ofbiphenylmethyl-7-methoxy-7-{D-2-[(2-oxo-3-furfurylideneamino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylate.

2. 500 parts by vol. of absolute THF are added to 34.1 parts by wt. ofthis compound under nitrogen; this mixture is cooled to -65° C. and asolution of 1.35 parts by wt. of LiH in 200 parts by vol. of methanol isfirst added dropwise, and immediately thereafter 7.16 parts by wt. oftert.-butyl hypochlorite are added dropwise.

The mixture is subsequently stirred for a further 20 minutes, it beingallowed to come to -40° C. 72 parts by vol. of glacial acetic acid and7.2 parts by wt. of triethyl phosphite are then added and the mixture issubsequently allowed to warm to room temperature.

The solution is added to 4 l of acetic acid ethyl ester and this mixtureis washed successively with one liter each of 5% strength NaCl solution,10% strength Na₂ S₂ O₃ solution, saturated NaHCO₃ solution, citric acidsolution, water and saturated NaCl solution.

After drying over MgSO₄, the solution is concentrated and the product isreprecipitated from CH₂ Cl₂ (n-pentane). This product is chromatographedon 600 parts by wt. of silica gel with CH₂ Cl₂ /ethyl acetate.

This gives, finally, 25.3 parts by wt. of the corresponding 7-methoxycompound.

3. The removal of the ester protective group is effected withtrifluoroacetic acid/anisole, as is described, for example, in DOS(German Published Specification) No. 2,555,159.

The acid is finally obtained in a purity comparable to that under 37 A.

(C) Furthermore, this compound can also be prepared in the followingmanner:

48.8 parts by wt. of7-[D-α-[(2-oxo-3-fufurylideneamino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido]-3-acetoxymethyl-ceph-3-em-4-carboxylicacid in anhydrous tetrahydrofurane are added to a solution, cooled to-70° C., of 1,000 parts by volume of anhydrous tetrahydrofurane, 2.54parts by wt. of lithium hydride and 1,000 parts by volume of abs.methanol.

8.68 parts by wt. of t-butyl hypochlorite are then added immediately tothe clear solution and the mixture is subsequently stirred for 20minutes at -70° C.

The reaction solution is then added to water, whilst simultaneouslyadding half-concentrated hydrochloric acid, so that the pH value isabout 7.

After clarifying with active charcoal, the solution is concentrated invacuo and covered with a layer of ethyl acetate, the pH value isadjusted to 7.5 and the aqueous phase is separated off and extractedagain with ethyl acetate.

The aqueous phase is then covered with a layer of ethyl acetate and thepH value is adjusted to 1.8, whilst stirring. After separating off theorganic phase and extracting it a further two times with ethyl acetate,the organic phases are dried over MgSO₄ and concentrated in vacuo. Thewhite precipitate which has separated out is filtered off, washedthoroughly with ether and dried in vacuo in a desiccator. Yield: 39parts by wt. (76%).

In the thin layer chromatogram, the compound appears uniform, withvirtually the same Rf value as the corresponding compound without amethoxy group. (Running agent: 200 ml of n-butyl acetate, 36 ml ofn-butanol and 100 ml of acetic acid (treated with phosphate buffer of pH6))

100 MHz-¹ H-NMR spectrum (acetone D₂ O)

s 2.0 3H, a,b 3.3 2H, s 3.45 3H, s 3.8 2H, a,b 4.8 2H, s 4.9 1H, s 5.71H, g 6.5 1H, d 6.8 1H m 7.4 5H d 7.55 1H and 5 7.7 1H.

The compounds which follow can be prepared by the procedure of Example37(A), (B) or, advantageously, also (c). If the procedure of Example37(B) is followed, the protective group introduced is removed withhydrogen in the presence of a platinum catalyst.

EXAMPLES 38-45 ##STR243## EXAMPLE 46 ##STR244##

8.1 parts by wt. of sodium6-{D-α-[2-oxo-3-(furfurylideneamino)-imidazolidin-1-yl)-carbonylamino}-p-hydroxyphenylacetamido]-penicillanate,dissolved in abs. methanol, are added to a solution, cooled out of -70°C., of 150 parts by vol. of THF/100 parts by vol. of methanol (bothanhydrous) and 0.52 part by wt. of LiH in the course of 5 minutes. 3.1parts by wt. of t-butyl hypochlorite are then added at the sametemperature and the mixture is subsequently stirred for 2 hrs. at -70°to -60° C.

The working up is initially as described in Example 1.

The 6-methoxy-penicillic acid then contained in the ethyl acetate, byacid extraction at pH 1.8, is now converted into the sodium salt in thefollowing manner:

A layer of water is introduced below the ethyl acetate solution, the pHvalue is adjusted to 7.2 with dilute sodium hydroxide solution, theaqueous phase is separated off and the procedure is repeated.

The combined aqueous phases are extracted with ether and the aqueousphase is finally subjected to freeze-drying.

Yield: 6.2 parts by wt. (73%)

In the thin layer chromatogram, the white salt is uniform and has aslightly higher Rf value than the corresponding non-methoxylatedstarting material.

100 MHz--¹ H--NMR spectrum (d-acetone/D₂ O)

s 1.1 3H, s 1.4 3H, s 3.5 3H, s 3.95 4H, s 4.1 1H, s 5.5 1H, S 5.55 1H,m 6.5 1H, d 6.85 1H, m 6.7-7.05 3H, m 7.25-7.55 2H, d 7.7 1H and s 7.81H.

IR spectrum, bands [cm⁻¹ ]: 3418, 1762, 1721, 1667, 1608, 1526, 1476,1415, 1272, 1234, 1096, 1015, 931, 882 and 741.

EXAMPLE 47 ##STR245##

4 parts by wt. of6-{D-α-[(2-oxo-3-furfurylideneaminoimidazolidin-1-yl)-carbonylamino]-phenylacetamido}-penicillanicacid, 0.23 part by wt. of LiH, 0.78 part by wt. of t-butyl hypochloriteand 50 parts by volume each of methanol and tetrahydrofurane are reactedin the manner described in Example 1. The reaction time is 2 hrs.

Yield: 3.7 parts by wt. (80%)

60 MHz ¹ H-NMR sectrum (d-acetone/D₂ O)

s 0.95 3H, s 1.35 3H, s 3.53 3H, s 3.95 4H, s 4.1 1H, s 5.6 1H, s 5.651H, g 6.6 1H, d 6.9 1H and multiplet 7.3-7.8 7H.

The compound is uniform in the thin layer chromatogram.

EXAMPLE 48 ##STR246##

9.1 parts by wt. of6-{D-α-[(2-oxo-3-{5-chlorofurylideneamino}-imidazolidin-1-yl)-carbonylamino]-p-hydroxyphenylacetamido}-penicillanicacid, 0.5 part by wt. of LiH and 3.3 parts by wt. of t-butylhypochlorite in methanol and THF are reacted as in Example 1.

Yield: 6.7 parts by wt. (68%). A uniform compound according to thinlayer chromatography.

NMR spectrum (in d-acetone/D₂ O)

s 1.0 3H, s 1.35 3H, s 3.5 3H, s 3.95 4H, s 4.05 1H, s 5.5 1H, s 5.531H, d 6.5 1H, m 6.8-7.0 3H, m 7.2-7.55 2H and s 7.8 1H.

EXAMPLE 49 ##STR247##

This compound is obtained when

(a) the compound from Example 37 is treated with an equimolar amount of1-methyltetrazole-5-thiol in an aqueous solution at a pH value of 6.5for 3 hrs. at 70° C., or

(b) the compound from Example 8.4 is methoxylated directly according toExample 37 C.

NMR spectrum: (d-acetone/D₂ O)

s 3.4 3H, s 3.55 2H, broad s 3.85 4H, s 3.95 3H, s 4.4 2H, s 4.9 1H, s5.7 1H, g 6.5 1H, d 6.8 1H, m 7.4 5H, d 7.55 1H and s 7.7 1H.

EXAMPLE 50 ##STR248##

The above compound is prepared from the following amounts of substancesin the manner described in Example 46: 7 parts by wt. of7-{D-α-[(2-oxo-3-furylideneamino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxy-methyl-ceph-3-em-4-carboxylicacid and 0.36 part by wt. of LiH in 150 parts by vol. of abs. ethanol,1.25 parts by wt. of t-butyl hypochlorite and 100 parts by vol. of THF.

The reaction time is 2 hrs. at -50° to -65° C.

Yield: 4.8 parts by wt. (70%)

According to thin layer chromatography, the compound is uniform and hasa higher R_(f) (more lipophilic) than the starting material and alsothan the compound from Example 37.

The NMR spectrum is as for the compound from Example 37, except thatthere is an additional triplet (3H) at δ=1.3 and instead of the singletat δ=3.5 there is now a quartet (2H) which, however, is indistinct dueto overlaying.

EXAMPLE 51 ##STR249##

9.15 parts by wt. of7-{D-α-[(2-oxo-3-furylideneaminoimidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylicacid and 0.5 part by wt. of LiH, dissolved in 250 parts by vol. ofn-propanol, whilst warming, 1.6 parts by wt. of t-butyl hypochlorite and150 parts by vol. of THF are reacted for 2 hrs. at -60° C. according toExample 46.

Yield: 8 parts by wt. (77%).

Thin layer chromatography: uniform, significantly higher R_(f) valuethan the starting material.

NMR: similar change as in the transition from the compound from Example37→the compound from Example 50.

EXAMPLE 52 ##STR250##

The preparation is as in Example 51, except that the alcoholate solutionis prepared beforehand from i-propanol and BuLi.

The reaction time is about 3 hrs. at -55° C.

EXAMPLE 53 ##STR251##

The preparation is analogous to Example 52, except that i-butanol isused instead of i-propanol.

The reaction time is 4 hrs. at -55° C.

EXAMPLE 54 ##STR252##

200 parts by vol. of abs. THF and 150 parts by vol. of freshly distilled2-dimethylaminoethanol are initially introduced, under nitrogen, and 39parts by vol. of a 15% strength solution of n-butyllithium in n-hexaneare added dropwise (together with 20 parts by vol. of THF). 9.8 parts bywt. of7-{D-α-[(2-oxo-3-furylideneamino-imidazolidin-1-yl)-carbonylamino]-phenylacetamido}-3-acetoxymethyl-ceph-3-em-4-carboxylicacid, dissolved in 100 parts by vol. of THF are added to this solution,cooled to -70° C. Finally, 1.9 parts by vol. of t-butyl hypochlorite areslowly added dropwise and the mixture is subsequently stirred for 3 hrs.at -60° C.

The reaction solution is then poured into 200 ml of water, the organicimpurities are extracted several times with ethyl acetate at pH 7-7.5,the aqueous phase is then slowly acidified to pH 4.5-4.7 and theprecipitate is filtered off and washed thoroughly with acetone/H₂ O.

After drying, 5.7 g (51%) of the desired compound are obtained.

What is claimed is:
 1. A β-lactam compound of the formula ##STR253## inwhich R is hydrogen or a group --UR',in which U is oxygen or sulphur andR' is alkenyl, alkinyl, aralkyl, aryl or cycloalkyl, or alkyl optionallysubstituted by halogen, amino, monoalkylamino, dialkylamino or alkoxy, Zis a group of the formula ##STR254## wherein R¹ and R² and the same ordifferent and each is hydrogen; optionally substituted alkyl, alkenyl,cycloalkyl, cycloalkenyl, cycloalkadienyl, aralkyl or aryl, the optionalsubstituents being selected from the group consisting of amino,mono-lower alkylamino, di-lower alkylamino, pyrrolidyl, piperidyl,HCO--NH--, lower alkyl--CO--NH--, lower alkyl --CO--N--(lower alkyl)--,(lower alkyl)₂ C═N--, lower alkyl--SO₂ --NH--, lower alkyl --SO₂--N(lower alkyl)--HO--, SO₂ --NH--, HO--SO₂ --N(lower alkyl)--, amidino,(lower alkyl)₂ --N--CH═N--, ##STR255## guanido, nitro, azido, hydroxyl,lower alkyl-oxy-, H--CO--O--, lower alkyl --CO--O--, lower alkyl--O--CO--O--, H₂ N--CO--O--, lower alkyl--NH--CO--O, (lower alkyl)₂N--CO--O--, ##STR256## H₂ N--SO₂ --O--, lower alkyl --NH--SO₂ --O--,(lower alkyl)₂ N--SO₂ --O--, HOOC--, H₂ N--CO--, (lower alkyl)₂--N--CO--, OHC--, HO--SO₂ --O--, HS--, lower alkyl--S--, ##STR257## HO₃S--, lower alkyl--SO₂ --, H₂ N--SO₂ --, lower alkyl --NH--SO₂ --, (loweralkyl)₂ N--SO₂ --, ##STR258## HO--SO₂ --S--, alkyl having 1 to 6 carbonatoms, phenyl and phenoxy; heterocyclyl optionally substituted by loweralkyl, trifluoromethyl, halogen, amino, lower alkylamino, di-loweralkylamino, formylamino, acetylamino, CH₃ --O--CO--NH--, C₂ H₅O--CO--NH--, CH₃ --SO₂ --NH--, hydroxyl, methoxy, ethoxy, methylthio,ethylthio, CH₃ --SO₂ --, CH₃ --SO--, HOOC--, HO₃ S--, HCO--, loweralkyl--CO--, lower alkyl--O--CO--, or --CN; carboxyl, methoxycarbonyl,ethoxycarbonyl, cyano, nitro, lower alkylcarbonyl, --CONH₂, --CONHCH₃,--CON(CH₃)₂, --SO₂ NH₂, --SO₂ --NHCH₃ or --SO₂ N(CH₃)₂, or R¹ and R²,together with the carbon atom to which they are bonded, represent anoptionally substituted 3-membered to 7-membered saturated or unsaturatedcarbocyclic or heterocyclic ring optionally substituted as washeterocyclyl; A is --CH₂ --CH₂ --, --CH₂ --CH₂ --CH₂ -- or ##STR259## Bis phenyl, hydroxyphenyl, cyclohexenyl or cyclohexadienyl; X representsS, O, SO, SO₂ or --CH₂ --; and E is hydrogen, a radical forming with thecarboxyl group to which it is attached a carboxyl ester group, a cationof a pharmaceutically acceptable salt, or a protective group;or ahydrate thereof.
 2. A compound as claimed in claim 1, wherein R ishydrogen, alkoxy having from 1 to 4 C atoms or --OCH₂ CH₂ N(CH₃)₂,R¹ ishydrogen; and R² is phenyl optionally substituted by halogen, alkylhaving 1 to 4 carbon atoms, alkoxy having 1 to 4 carbon atoms, nitro,cyano, alkylsulphonyl having 1 to 4 carbon atoms or CH₃ OOC--, or furylor thienyl optionally substituted by halogen NO₂, alkyl oralkoxycarbonyl having 1 to 4 carbon atoms or CH₃ COOCH₂ --; or pyridylor is optionally substituted, cyclic alkyl or alkenyl having up to 7carbon atoms, or alkyl or alkenyl having up to 4 carbon atoms, saidalkyl and alkenyl being optionally substituted, and A is --CH₂ --CH₂ --;and B is phenyl, hydroxyphenyl or cyclohexadienyl; and T is hydrogen,O--CO--CH₃, hydroxyl or thiadiazolylthio or tetrazolylthio optionallysubstituted by alkyl having 1 to 4 carbon atoms or CF₃ ; the compoundbeing in the D- =R-configuration with respect to the chirality centerC;or a sodium salt thereof.
 3. A compound as claimed in claim 1, inwhich R is hydrogen or methoxy.
 4. A compound as claimed in claim 2, inthe form of the free acid.
 5. A compound as claimed in claim 4, in whichR is methoxy.
 6. A compound as claimed in claim 1 in which R² is phenyloptionally substituted by fluorine, chlorine, bromine, methyl, methoxy,nitro, cyano or methylsulphonyl; furyl or thienyl substituted in the 4-or 5-position by chlorine, bromine, NO₂, alkyl or alkoxycarbonyl having1 to 4 carbon atoms or CH₃ COOCH₂ --; the furyl and thienyl ring beingbonded in the 2- or 3-position; pyridyl-3; cyclohexenyl; or alkyl oralkenyl having up to 4 carbon atoms and being optionally substituted byhalogen or alkoxy having 1 to 4 carbon atoms; and B is phenyl,p-hydroxyphenyl or cyclohexa-1,4-dien-1-yl.
 7. A compound as claimed inclaim 6, wherein R² is alkyl or alkenyl having up to 4 carbon atomssubstituted by methoxy.
 8. A compound according to claim 1 of theformula ##STR260## or a pharmaceutically acceptable salt or hydratethereof.
 9. A compound according to claim 1 of the formula ##STR261## ora pharmaceutically acceptable salt or hydrate thereof.
 10. A compoundaccording to claim 1 of the formula ##STR262## or a pharmaceuticallyacceptable salt or hydrate thereof.
 11. A compound according to claim 1of the formula ##STR263## or a pharmaceutically acceptable salt orhydrate thereof.
 12. A compound according to claim 1 of the formula##STR264## or a pharmaceutically acceptable salt or hydrate thereof. 13.A compound according to claim 1 of the formula ##STR265## or apharmaceutically acceptable salt or hydrate thereof.
 14. A compoundaccording to claim 1 of the formula ##STR266## or a pharmaceuticallyacceptable salt or hydrate thereof.
 15. An antibacterial and growthpromoting composition containing as an active ingredient anantibacterial or growth promoting effective amount of a compound orpharmaceutically acceptable salt according to claim 1 in admixture witha diluent.
 16. An antibacterial composition in dosage unit formcomprising a compound or pharmaceutically acceptable salt according toclaim
 1. 17. A method of combating bacterial diseases in human andnon-human animals which comprises administering to the animals anantibacterially effective amount of a compound or pharmaceuticallyacceptable salt according to claim
 1. 18. A medicament animal foddercomprising an effective amount of a compound or pharmaceuticallyacceptable salt according to claim 1 in admixture with a nutritiousmaterial.
 19. A method of promoting the growth of animals whichcomprises feeding said animals a growth promoting amount of a compoundor pharmaceutically acceptable salt according to claim 1.